metronidazole has been researched along with Recrudescence in 509 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This pilot study examines whether single-dose intravenous metronidazole preoperatively is at least as effective as a broad-spectrum multi-drug regimen in preventing infection-related wound complications following excision of pilonidal sinuses with primary closure." | 9.10 | Single-dose metronidazole versus 5-day multi-drug antibiotic regimen in excision of pilonidal sinuses with primary closure: a prospective randomised controlled double-blinded study. ( Bekdash, BA; Chaudhuri, A, 2002) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 9.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 9.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| "We conducted a prospective, randomized study to compare the efficacy of oral fusidic acid, oral metronidazole, oral vancomycin, and oral teicoplanin for the treatment of Clostridium difficile-associated diarrhea." | 9.08 | Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. ( Graninger, W; Hasenhündl, M; Hirschl, AM; Parschalk, B; Wenisch, C, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 9.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 9.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| "To determine if the use of topical metronidazole gel (Metrogel) could prevent relapse of moderate to severe rosacea." | 9.08 | Topical metronidazole maintains remissions of rosacea. ( Aly, R; Baker, MO; Bayles, C; Coleman, E; Czernielewski, JM; Dahl, MV; Herndon, JH; Katz, HI; Krueger, GG; Millikan, LE; Odom, RB; Parker, F; Patrignelli, R; Reusser, B; Tuley, MR; Weidner, M; Wolf, JE, 1998) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 9.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| "88 Patients who had previously been in a prospective random control trial of two regimens of antibiotic treatment (ampicillin and metronidazole for one compared with four days) before incision, curettage, and primary closure of perianal abscess or pilonidal sinus." | 9.07 | Outcome at three to five years of primary closure of perianal and pilonidal abscess. A randomised, double-blind clinical trial with a complete three-year followup of one compared with four days' treatment with ampicillin and metronidazole. ( Gottrup, F; Lundhus, E, 1993) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 9.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| "110 patients suffering from laparoscopical verified salpingitis and desire for a baby, were treated with tetracycline (oxytetracycline or doxycycline; TC)/metronidazole (n = 67), augmentan (n = 22) or cipropfloxacin/metronidazole (n = 21)." | 9.07 | [Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study]. ( Barten, G; Gerber, B; Splitt, G; Wilken, H; Zacharias, K, 1992) |
| "The efficacy of metronidazole and doxycycline in preventing recurrent periodontitis was studied in 23 patients." | 9.07 | Serial doxycycline and metronidazole in prevention of recurrent periodontitis in high-risk patients. ( Aitken, S; Birek, P; Kulkarni, GV; Lee, WL; McCulloch, CA, 1992) |
| "In a double-blind placebo-controlled trial using triple tetracycline (Deteclo, Lederle) 300 mg twice daily for two weeks in conjunction with metronidazole (Flagyl, May & Baker) 400 mg or matching placebo twice daily for seven days, it was shown that the addition of anti-anaerobic therapy did not significantly affect the number of cases of persistent urethritis or the relapse of patients with non-gonococcal urethritis (NGU)." | 9.06 | Efficacy of combined metronidazole and triple tetracycline therapy in the treatment of non-gonococcal urethritis. ( Duerden, BI; Kinghorn, GR; Talbot, MD; Woolley, PD, 1990) |
| "Vaginitis associated with the presence of Gardnerella vaginalis (confirmed by culture) was treated either with metronidazole or with one of the two nitroimidazole derivatives; nimorazole or tinidazole, as a single oral 2 g dose." | 9.06 | Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis. ( Deighton, R; Mohanty, KC, 1987) |
| "In a clinical trial of metronidazole for dracunculiasis (75 cases), the drug was effective in giving symptomatic relief but had no preventive or vermicidal action." | 9.04 | Efficacy of metronidazole in dracunculiasis. A clinical trial. ( Rathore, HS; Sharma, MM; Sharma, VP, 1979) |
| "Sixty patients with parasitologically confirmed giardiasis were treated with metronidazole using four different regimens administered to four groups of 15 patients each." | 9.04 | Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. ( Jokipii, AM; Jokipii, L, 1978) |
| "At present, vancomycin (VCM) and metronidazole (MNZ) are used for the first-line standard treatment of Clostridioides difficile infection (CDI)." | 8.98 | Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. ( Enoki, Y; Igarashi, Y; Kunishima, H; Matsumoto, K; Mikamo, H; Mori, N; Morinaga, Y; Nakamura, A; Ohge, H; Suzuki, H; Taguchi, K; Tashiro, S; Yamagishi, Y; Yanagihara, K; Yoshizawa, S, 2018) |
| "Pancreatitis is a very rare adverse effect of metronidazole with only six cases of metronidazole-induced pancreatitis reported in the English literature so far." | 8.82 | Metronidazole-induced pancreatitis. A case report and review of literature. ( Casey, KJ; Nigwekar, SU, 2004) |
| "We sought to assess the effectiveness of oral vancomycin compared to metronidazole on recurrence and mortality among hospitalized patients with non-severe Clostridioides difficile infection (CDI)." | 8.12 | Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study. ( Bazazhina, A; Najjar-Debbiny, R; Saliba, W; Schwartz, N; Shaked, P; Weber, G, 2022) |
| "The shift away from metronidazole as a preferred option in initial non-severe Clostridioides difficile infection did not improve the composite of treatment failure or recurrence." | 8.02 | Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study. ( Campbell, DL; Gentry, CA; Williams, RJ, 2021) |
| "Current guidelines recommend oral vancomycin or fidaxomicin for the treatment of mild-to-moderate Clostridium difficile associated diarrhea (CDAD), while metronidazole is recommended as an alternative when oral vancomycin and fidaxomicin are unavailable." | 7.88 | Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study. ( Anders, S; Garcia-Diaz, J; Hand, J; Li, J; Nguyen, CT; Staffeld-Coit, C, 2018) |
| "We present the first case of metronidazole-related acute pancreatitis during a relapse of ulcerative colitis." | 7.74 | Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. ( Ekonomou, IA; Giannoulis, EK; Giannoulis, KE; Savopoulos, CG; Tsesmeli, NE; Vretou, EE, 2007) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 7.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| "We report on the microbiological and clinical effects of mechanical debridement in combination with metronidazole plus amoxicillin therapy in 118 patients with Actinobacillus actinomycetemcomitans-associated periodontitis." | 7.68 | Microbiological and clinical results of metronidazole plus amoxicillin therapy in Actinobacillus actinomycetemcomitans-associated periodontitis. ( de Graaff, J; Tijhof, CJ; van Winkelhoff, AJ, 1992) |
| "60 patients with recurrent duodenal ulcers were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 7.68 | [Treatment of stomach ulcer with bismuth subnitrate, oxytetracycline and metronidazole]. ( Berstad, A; Berstad, K; Hundal, O; Wilhelmsen, I, 1992) |
| "Twenty-two patients suffering from rosacea papulosa or rosacea papulo-pustulosa were treated with Metronidazole at a low dosage (125 or 250 mg/d) for 2 to 6 months." | 7.67 | [Treatment of rosacea with metronidazole internally and externally]. ( Prinz, L, 1984) |
| "Six men with nongonococcal urethritis (NGU) who remained symptomatic after specific therapy with different antibiotic regimens were empirically treated with either of two regimens of oral metronidazole: 500 mg." | 7.66 | Use of oral metronidazole HCl (Flagyl) for posturethritis syndrome. ( Toth, A, 1982) |
| "pylori on the recurrence of duodenal ulcer, we treated 104 patients with H." | 6.67 | Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Nemec, H; Schütze, K; Taufer, M; Wurzer, H, 1993) |
| " A dosage of 15-25 mg/kg a day for 5 days is recommended." | 6.65 | Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine) and metronidazole (Flagyl). ( Kavousi, S, 1979) |
| "difficile colitis has become more challenging with the increasing failure of therapeutic response to metronidazole and oral vancomycin." | 6.48 | Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. ( Baban, TA; El-Herte, RI; Kanj, SS, 2012) |
| "Women with a spontaneous preterm birth < 34 weeks' gestational age were randomized at 4 months' postpartum to receive oral azithromycin 1 g twice (4 days apart) plus sustained-release metronidazole 750 mg daily for 7 days, or identical-appearing placebos." | 5.12 | Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial. ( Andrews, WW; Cliver, SP; Conner, M; Copper, R; Goldenberg, RL; Hauth, JC, 2006) |
| " Significant reduction of malodorous vaginal discharge (whiff test) and lowest recurrence of BV were noted in the metronidazole plus lactic acid gel arm." | 5.12 | Metronidazole with Lactacyd vaginal gel in bacterial vaginosis. ( Co, JT; Dancel, LA; Decena, DC; Lelis, MA; Manalastas, RM; Padolina, CS; Palaypayon, EP; Sison, JM, 2006) |
| "Our objective was to document how intake of Lactobacillus plantarum 299v affects the concentrations of fecal organic acids during and after metronidazole treatment in 19 patients with recurrent Clostridium difficile-associated diarrhea." | 5.12 | Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea. ( Berggren, A; Johansson Hagslätt, ML; Odenholt, I; Wullt, M, 2007) |
| "Patients with pouchitis at least twice in the previous year or requiring continuous antibiotics, associated with a pouchitis disease activity index (PDAI) > or =7 (0 = perfect; 18 = worst), in whom remission was induced by four weeks of combined metronidazole and ciprofloxacin, were randomised to receive VSL#3 6 g or placebo once daily for one year or until relapse." | 5.11 | Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. ( Campieri, M; Gionchetti, P; Helwig, U; Kamm, MA; Mimura, T; Nicholls, RJ; Poggioli, G; Rizzello, F; Schreiber, S; Talbot, IC, 2004) |
| "248 patients with Hp-associated active duodenal ulcer confirmed by endoscopy, 193 males and 55 females, were randomized to receive OAC(250): omeprazole (0." | 5.11 | [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. ( , 2004) |
| "This pilot study examines whether single-dose intravenous metronidazole preoperatively is at least as effective as a broad-spectrum multi-drug regimen in preventing infection-related wound complications following excision of pilonidal sinuses with primary closure." | 5.10 | Single-dose metronidazole versus 5-day multi-drug antibiotic regimen in excision of pilonidal sinuses with primary closure: a prospective randomised controlled double-blinded study. ( Bekdash, BA; Chaudhuri, A, 2002) |
| "To evaluate, in a prospective, open-label study, the influence of antibiotics and azathioprine on the clinical outcome of perianal fistulas in patients with Crohn's disease." | 5.10 | Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. ( Dejaco, C; Harrer, M; Miehsler, W; Reinisch, W; Vogelsang, H; Waldhoer, T, 2003) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 5.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence." | 5.08 | Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. ( Cheng, AF; Chung, SC; Leung, VK; Li, AK; Li, MK; Ling, TK; Ng, EK; Sung, JJ; Yung, MY, 1995) |
| ") in eradicating Helicobacter pylori in patients with duodenal ulcer successfully healed with omeprazole or ranitidine; second, to examine the influence of the eradication on duodenal ulcer recurrence rate after 12 months." | 5.08 | Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. ( Archimandritis, A; Balatsos, V; Delis, V; Kastanas, K; Mentis, A; Scandalis, N, 1995) |
| "The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence." | 5.08 | Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996) |
| "We conducted a prospective, randomized study to compare the efficacy of oral fusidic acid, oral metronidazole, oral vancomycin, and oral teicoplanin for the treatment of Clostridium difficile-associated diarrhea." | 5.08 | Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. ( Graninger, W; Hasenhündl, M; Hirschl, AM; Parschalk, B; Wenisch, C, 1996) |
| "To investigate differences between omeprazole and Helicobacter pylori eradication in patients with duodenal ulcers refractory to H2-receptor antagonists and to compare the recurrence rates after the two treatments." | 5.08 | Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication. ( Avsar, E; Gültekin, O; Kalayci, C; Kiziltas, S; Lawrence, R; Tözün, N; Ulusoy, NB, 1996) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 5.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| "Recurrent Clostridium difficile diarrhea (RCDD) occurs in 20% of patients after they have received standard antibiotic treatment with vancomycin or metronidazole, but the reasons for the recurrences are largely unknown." | 5.08 | Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. ( Elmer, GW; Fekety, R; Greenberg, RN; McFarland, LV; Mulligan, ME; Surawicz, CM, 1997) |
| "To determine if the use of topical metronidazole gel (Metrogel) could prevent relapse of moderate to severe rosacea." | 5.08 | Topical metronidazole maintains remissions of rosacea. ( Aly, R; Baker, MO; Bayles, C; Coleman, E; Czernielewski, JM; Dahl, MV; Herndon, JH; Katz, HI; Krueger, GG; Millikan, LE; Odom, RB; Parker, F; Patrignelli, R; Reusser, B; Tuley, MR; Weidner, M; Wolf, JE, 1998) |
| "Seventy-four patients with three endoscopically verified duodenal ulcers during the past 2 years received triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days." | 5.07 | Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. ( Berstad, A; Wilhelmsen, I, 1994) |
| "The goals of this study were to assess the effectiveness of a new triple therapy consisting of amoxicillin and metronidazole with plaunotol in the eradication of Helicobacter pylori infection in humans, and to determine whether this treatment regimen reduces the rate of recurrence of gastric ulcer in patients infected with H." | 5.07 | Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate. ( Karita, M; Morshed, MG; Okita, K; Ouchi, K, 1994) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 5.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| " Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy." | 5.07 | Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. ( Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA, 1993) |
| "88 Patients who had previously been in a prospective random control trial of two regimens of antibiotic treatment (ampicillin and metronidazole for one compared with four days) before incision, curettage, and primary closure of perianal abscess or pilonidal sinus." | 5.07 | Outcome at three to five years of primary closure of perianal and pilonidal abscess. A randomised, double-blind clinical trial with a complete three-year followup of one compared with four days' treatment with ampicillin and metronidazole. ( Gottrup, F; Lundhus, E, 1993) |
| " pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77)." | 5.07 | One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "In this study, 26 patients with duodenal ulcers refractory to treatment with H2-receptor antagonists for 8-12 weeks were randomly assigned to eight weeks of treatment with colloidal bismuth subcitrate (120 mg four times a day) alone (N = 12) or in combination with tetracycline hydrochloride (500 mg four times a day, days 0-14) and metronidazole (500 mg three times a day, days 15-28)." | 5.07 | Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates. ( Hatzis, A; Mantzaris, GJ; Petraki, K; Spiliades, C; Tamvakologos, G; Triadaphyllou, G, 1993) |
| "Duodenal ulcer relapse rates after therapy with sucralfate or bismuth are lower than those after H2-receptor antagonist therapy." | 5.07 | Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. ( Jaskiewicz, K; Lastovica, A; Le Roux, E; Louw, JA; Lucke, W; Marks, IN; Winter, T; Zak, J, 1992) |
| " pylori-positive patients with (n = 42) or without (n = 42) duodenal ulcer were randomized to receive ranitidine, bismuth, or bismuth plus antibiotics." | 5.07 | Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication. ( Corbishley, CM; Goggin, PM; Jackson, PA; Marrero, JM; Northfield, TC; Spychal, RT, 1992) |
| "110 patients suffering from laparoscopical verified salpingitis and desire for a baby, were treated with tetracycline (oxytetracycline or doxycycline; TC)/metronidazole (n = 67), augmentan (n = 22) or cipropfloxacin/metronidazole (n = 21)." | 5.07 | [Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study]. ( Barten, G; Gerber, B; Splitt, G; Wilken, H; Zacharias, K, 1992) |
| "The efficacy of metronidazole and doxycycline in preventing recurrent periodontitis was studied in 23 patients." | 5.07 | Serial doxycycline and metronidazole in prevention of recurrent periodontitis in high-risk patients. ( Aitken, S; Birek, P; Kulkarni, GV; Lee, WL; McCulloch, CA, 1992) |
| "The probability of recurrence for patients who received triple therapy plus ranitidine was significantly lower than that for patients who received ranitidine alone: for patients with duodenal ulcer, 12% (95% CI, 1% to 24%) compared with 95% (CI, 84% to 100%); for patients with gastric ulcer, 13% (CI, 4% to 31%) compared with 74% (44% to 100%)." | 5.07 | Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. ( Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA, 1992) |
| "50 patients with intractable duodenal ulcer were randomly assigned to 4 weeks of treatment with colloidal bismuth subcitrate (CBS) alone (26 patients) or with amoxicillin and metronidazole (24 patients)." | 5.06 | Cure of duodenal ulcer associated with eradication of Helicobacter pylori. ( Rauws, EA; Tytgat, GN, 1990) |
| "In a double-blind placebo-controlled trial using triple tetracycline (Deteclo, Lederle) 300 mg twice daily for two weeks in conjunction with metronidazole (Flagyl, May & Baker) 400 mg or matching placebo twice daily for seven days, it was shown that the addition of anti-anaerobic therapy did not significantly affect the number of cases of persistent urethritis or the relapse of patients with non-gonococcal urethritis (NGU)." | 5.06 | Efficacy of combined metronidazole and triple tetracycline therapy in the treatment of non-gonococcal urethritis. ( Duerden, BI; Kinghorn, GR; Talbot, MD; Woolley, PD, 1990) |
| "Vaginitis associated with the presence of Gardnerella vaginalis (confirmed by culture) was treated either with metronidazole or with one of the two nitroimidazole derivatives; nimorazole or tinidazole, as a single oral 2 g dose." | 5.06 | Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis. ( Deighton, R; Mohanty, KC, 1987) |
| "In a clinical trial of metronidazole for dracunculiasis (75 cases), the drug was effective in giving symptomatic relief but had no preventive or vermicidal action." | 5.04 | Efficacy of metronidazole in dracunculiasis. A clinical trial. ( Rathore, HS; Sharma, MM; Sharma, VP, 1979) |
| "Sixty patients with parasitologically confirmed giardiasis were treated with metronidazole using four different regimens administered to four groups of 15 patients each." | 5.04 | Comparison of four dosage schedules in the treatment of giardiasis with metronidazole. ( Jokipii, AM; Jokipii, L, 1978) |
| "At present, vancomycin (VCM) and metronidazole (MNZ) are used for the first-line standard treatment of Clostridioides difficile infection (CDI)." | 4.98 | Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. ( Enoki, Y; Igarashi, Y; Kunishima, H; Matsumoto, K; Mikamo, H; Mori, N; Morinaga, Y; Nakamura, A; Ohge, H; Suzuki, H; Taguchi, K; Tashiro, S; Yamagishi, Y; Yanagihara, K; Yoshizawa, S, 2018) |
| "Pancreatitis is a very rare adverse effect of metronidazole with only six cases of metronidazole-induced pancreatitis reported in the English literature so far." | 4.82 | Metronidazole-induced pancreatitis. A case report and review of literature. ( Casey, KJ; Nigwekar, SU, 2004) |
| " Since the aetiology of antibiotic-associated colitis was discovered 14 years ago, two antibiotics in particular, metronidazole and vancomycin, have been used to treat C." | 4.78 | Clostridium difficile infection: responses, relapses and re-infections. ( Spencer, RC; Wilcox, MH, 1992) |
| "We sought to assess the effectiveness of oral vancomycin compared to metronidazole on recurrence and mortality among hospitalized patients with non-severe Clostridioides difficile infection (CDI)." | 4.12 | Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study. ( Bazazhina, A; Najjar-Debbiny, R; Saliba, W; Schwartz, N; Shaked, P; Weber, G, 2022) |
| "The shift away from metronidazole as a preferred option in initial non-severe Clostridioides difficile infection did not improve the composite of treatment failure or recurrence." | 4.02 | Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study. ( Campbell, DL; Gentry, CA; Williams, RJ, 2021) |
| " difficile-associated diarrhea treated with metronidazole, oral vancomycin, combination (metronidazole and oral vancomycin), or switch therapy (metronidazole to oral vancomycin)." | 3.91 | Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy. ( Kupiec, KE; Liu, C; Miller, JL; Schmidt, SA; Skrepnek, GH; Smith, WJ; Tieu, JD, 2019) |
| "Current guidelines recommend oral vancomycin or fidaxomicin for the treatment of mild-to-moderate Clostridium difficile associated diarrhea (CDAD), while metronidazole is recommended as an alternative when oral vancomycin and fidaxomicin are unavailable." | 3.88 | Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study. ( Anders, S; Garcia-Diaz, J; Hand, J; Li, J; Nguyen, CT; Staffeld-Coit, C, 2018) |
| "A pooled analysis was performed on 1366 rosacea subjects from four randomized controlled trials with IGA before and after treatment (ivermectin, metronidazole or vehicle)." | 3.85 | Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis. ( Jackson, JM; Kerrouche, N; Schäfer, G; Schaller, M; Tan, J; Webster, G, 2017) |
| " difficile may contributed to the recurrent CDB episodes and liver abscess formation in necrotic liver tissue following TACE, and long-term metronidazole therapy was considered to be effective to C." | 3.85 | Recurrent bacteremia and liver abscess caused by Clostridium difficile: A case report. ( Iguchi, M; Kuzuya, T; Mikamo, H; Morioka, H; Yagi, T, 2017) |
| "The concept that the gut microbiota plays a major role in the development of pouchitis in ulcerative colitis patients after restorative proctocolectomy with ileal pouch-anal anastomosis, is widely accepted and supported by a widespread use of some antibiotics (metronidazole and/or ciprofloxacin, rifaximin) to treat this condition." | 3.80 | Role of probiotics in the management of pouchitis. ( Guslandi, M, 2014) |
| "We present the first case of metronidazole-related acute pancreatitis during a relapse of ulcerative colitis." | 3.74 | Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. ( Ekonomou, IA; Giannoulis, EK; Giannoulis, KE; Savopoulos, CG; Tsesmeli, NE; Vretou, EE, 2007) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 3.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| "The peripheral distribution of spiramycin and metronidazole, which are combined in the proprietary drug "Rodogyl", has been studied in gingival fluid, saliva and blood after a single administration to 12 healthy volunteers and after repeated administration to 4 patients with recurring severe periodontitis." | 3.69 | Kinetics of spiramycin/metronidazole (Rodogyl) in human gingival crevicular fluid, saliva and blood. ( Cimasoni, G; Le Liboux, A; Pichard, E; Rotzetter, PA, 1994) |
| " pylori-positive patients with recurrent peptic ulcer diseases, 29 of whom were given triple therapy (amoxycillin and metronidazole for 1 week and plaunotol for 4 weeks)." | 3.69 | Evaluation of a new bismuth-free triple therapy in nude mice and humans. ( Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M, 1995) |
| "We report on the microbiological and clinical effects of mechanical debridement in combination with metronidazole plus amoxicillin therapy in 118 patients with Actinobacillus actinomycetemcomitans-associated periodontitis." | 3.68 | Microbiological and clinical results of metronidazole plus amoxicillin therapy in Actinobacillus actinomycetemcomitans-associated periodontitis. ( de Graaff, J; Tijhof, CJ; van Winkelhoff, AJ, 1992) |
| "60 patients with recurrent duodenal ulcers were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 3.68 | [Treatment of stomach ulcer with bismuth subnitrate, oxytetracycline and metronidazole]. ( Berstad, A; Berstad, K; Hundal, O; Wilhelmsen, I, 1992) |
| "Forty-eight patients with endoscopically proven duodenal ulcer (DU) and Helicobacter pylori infection detected by 14C-urea breath test (BT) were assigned to 5 days of treatment with furazolidone, metronidazole, and amoxicillin in addition to eventual classical anti-ulcer agents if necessary." | 3.68 | Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. ( Brandao, MJ; Castro, LP; Chausson, Y; Coelho, LG; Costa, EL; Maia, AF; Passos, MC; Rodrigues, DC, 1992) |
| "Twenty-two patients suffering from rosacea papulosa or rosacea papulo-pustulosa were treated with Metronidazole at a low dosage (125 or 250 mg/d) for 2 to 6 months." | 3.67 | [Treatment of rosacea with metronidazole internally and externally]. ( Prinz, L, 1984) |
| "Six men with nongonococcal urethritis (NGU) who remained symptomatic after specific therapy with different antibiotic regimens were empirically treated with either of two regimens of oral metronidazole: 500 mg." | 3.66 | Use of oral metronidazole HCl (Flagyl) for posturethritis syndrome. ( Toth, A, 1982) |
| "Early relapse in Crohn's disease (CD) is associated with a more severe disease course." | 3.30 | Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of ( Benninga, MA; Comeau, A; de Jonge, WJ; de Meij, T; Dunn, KA; Heyman, MB; Langille, M; Otley, A; Sunseri, W; Sylvester, F; Van Limbergen, JE; Verburgt, CM; Verstraete, S, 2023) |
| "The primary outcome is BV recurrence defined as ≥3 Amsel criteria and NS = 4-10 within 12 weeks of enrolment." | 2.94 | Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence. ( Bateson, D; Bradshaw, CS; Chow, EPF; Donovan, B; Doyle, M; Fairley, CK; Hocking, JS; Law, MG; McGuiness, C; Petoumenos, K; Plummer, EL; Vodstrcil, LA, 2020) |
| "'Metronidazole Versus lactic acId for Treating bacterial vAginosis' (VITA) is a UK-based randomised controlled trial assessing clinical and cost-effectiveness of topical lactic acid gel compared to oral metronidazole antibiotic for treating second and subsequent BV episodes." | 2.90 | Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial. ( Anstey Watkins, J; Brittain, C; Griffiths, F; Kai, J; Ross, JDC; Thandi, S, 2019) |
| "12." | 2.90 | One-day versus four-day antibiotic treatment for acute right colonic uncomplicated diverticulitis: A randomized clinical trial. ( Lee, BH; Park, HC; Park, JH, 2019) |
| "Recurrent Clostridium difficile infection is considered as a significant health care burden." | 2.87 | The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients. ( Aoyama, N; Dorr, MB; Fujimoto, G; Mikamo, H; Sawata, M; Yoshinari, T, 2018) |
| "difficile infection (CDI) recurrence (rCDI) in adults at high risk for rCDI." | 2.87 | Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. ( Dorr, MB; Dubberke, ER; Ellison, MC; Eves, K; Gerding, DN; Guris, D; Hanson, ME; Kao, D; Kelly, CP; Kumar, PN; Lee, C; Rahav, G; Yacyshyn, B, 2018) |
| "To determine the late recurrence rate of appendicitis after antibiotic therapy for the treatment of uncomplicated acute appendicitis." | 2.87 | Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial. ( Aarnio, M; Grönroos, JM; Hurme, S; Jartti, A; Mecklin, JP; Nordström, P; Paajanen, H; Rantanen, T; Rautio, T; Salminen, P; Sand, J; Tuominen, R; Virtanen, J, 2018) |
| "Of these 22, only 1 patient (5%) had recurrence of acute appendicitis during follow-up." | 2.80 | Nonoperative treatment with antibiotics versus surgery for acute nonperforated appendicitis in children: a pilot randomized controlled trial. ( Almström, M; Eaton, S; Hall, NJ; Naji, H; Patkova, B; Pierro, A; Svensson, JF; Wester, T, 2015) |
| "Most patients with Crohn's disease need an intestinal resection, but a majority will subsequently experience disease recurrence and require further surgery." | 2.80 | Crohn's disease management after intestinal resection: a randomised trial. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Sparrow, M; Woods, R, 2015) |
| "Endoscopic recurrence (Rutgeerts score i2-i4) occurred in 33 of 73 (45%) thiopurine vs." | 2.80 | Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis. ( Andrews, JM; Bampton, PA; Bell, SJ; Brown, SJ; Connell, WR; De Cruz, P; Debinski, H; Desmond, PV; Elliott, PR; Florin, TH; Gearry, RB; Gibson, PR; Gorelik, A; Hamilton, AL; Jakobovits, S; Johnston, MJ; Kamm, MA; Krejany, EO; Kronborg, I; Lawrance, IC; Leong, RW; Liew, D; Macrae, FA; Prideaux, L; Radford-Smith, G; Ritchie, KJ; Selby, W; Woods, R, 2015) |
| "BV recurrence was not reduced by vitamin D supplementation (intention-to-treat hazard ratio, 1." | 2.79 | A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis. ( Anderson, J; Carr Reese, P; Davis, JA; Ervin, M; Fichorova, RN; Fields, KS; Jackson, RD; Klebanoff, MA; Roberts, MW; Turner, AN, 2014) |
| "To estimate risk of H." | 2.78 | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. ( Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M, 2013) |
| "Bacterial vaginosis (BV) recurrence posttreatment is common." | 2.78 | Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use. ( Bradshaw, CS; De Guingand, D; Fairley, CK; Garland, SM; Hocking, JS; Law, M; Morton, AN; Pirotta, M; Vodstrcil, LA, 2013) |
| "Rosacea is a chronic skin disease of unknown etiology, affecting the central areas of the face skin (cheeks, chin, nose, forehead) and is characterized by periods of remission and exacerbation." | 2.78 | [New possibilities in the treatment of early stages of rosacea]. ( Katsitadze, A; Tsiskarishvili, NV; Tsiskarishvili, Ts, 2013) |
| "Metronidazole treatment led to a further PI decline from 3." | 2.77 | No advantage for antibiotic treatment over placebo in Blastocystis hominis-positive children with recurrent abdominal pain. ( Braegger, CP; Buehr, P; Friedt, M; Heyland, K, 2012) |
| "Primary outcome was BV recurrence (NS of 7-10) on self-collected vaginal-swabs over 6-months." | 2.77 | Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial. ( Bradshaw, CS; De Guingand, D; Fairley, CK; Fehler, G; Garland, SM; Hocking, JS; Morrow, A; Morton, AN; Pirotta, M; Vodstrcil, LA; Walker, S, 2012) |
| "The 11 recurrences were classified as 3 probable reinfections (27%), 2 probable infections from a new sexual partner (18%), and 6 probable treatment failures (55%); 2 of the 6 patients who experienced probable treatment failure had isolates with mild resistance to metronidazole." | 2.73 | Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. ( Clark, RA; Curtin, E; Kissinger, P; Leichliter, JS; Martin, DH; Schmidt, N; Secor, WE, 2008) |
| "Eleven patients with moderate to active Crohn's disease were enrolled in this trial to receive either L." | 2.71 | Lactobacillus GG in inducing and maintaining remission of Crohn's disease. ( Herfarth, HH; Rath, HC; Sartor, RB; Schultz, M; Timmer, A; Vanderhoof, JA, 2004) |
| "Clinical recurrence and reappearance of C." | 2.71 | A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. ( Odenholt, I; Wullt, M, 2004) |
| "The best surgical technique for treating pilonidal sinus disease is controversial." | 2.71 | Modified lay-open (incision, curettage, partial lateral wall excision and marsupialization) versus total excision with primary closure in the treatment of chronic sacrococcygeal pilonidal sinus: a prospective, randomized clinical trial with a complete two ( Gencosmanoglu, R; Inceoglu, R, 2005) |
| "Vancomycin was significantly more effective in clearing C." | 2.70 | Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. ( Elmer, GW; McFarland, LV; Surawicz, CM, 2002) |
| "In this study, periodontal disease progression was successfully arrested in 95% of the initially compromised lesions, while 2% to 5% experienced discrete or recurrent episodes of loss of periodontal support." | 2.70 | Aggressive periodontitis: 5-year follow-up of treatment. ( Buchmann, R; Lange, DE; Nunn, ME; Van Dyke, TE, 2002) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| "pylori eradication rate and ulcer recurrence rate were compared." | 2.69 | Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study. ( Chen, J; Chen, SY; Wang, JY; Zhang, SS; Zhang, XD, 1999) |
| "The ulcer recurrences appeared in patients with H." | 2.69 | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. ( Mach, T; Zahradnik-Bilska, J, 1999) |
| "With regard to ulcer recurrence, 3 independent predictors were identified: failed H." | 2.69 | Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial. ( Barkun, AN; Barkun, J; Fallone, CA; Joseph, L; Kostyk, R; Loo, V, 1999) |
| "After chronic dosing of S." | 2.69 | Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients. ( Danko, L; Elmer, GW; Greenberg, RN; McFarland, LV; Surawicz, CM, 1999) |
| "There was no recurrence of the volvulus at 1 to 6 years follow up but 8 patients (9." | 2.68 | Extraperitonealization for sigmoid volvulus: a reappraisal. ( Khanna, AK; Kumar, K; Misra, MK, 1995) |
| "Healing of gastric ulcer is rapid and recurrence is infrequent after successful H pylori eradication." | 2.68 | Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group. ( Gormsen, MH; Kivilaakso, E; Pikkarainen, P; Seppälä, K; Sipponen, P, 1995) |
| "To determine the 12-month posttherapy recurrence (recrudescence) of Helicobacter pylori in patients with healed duodenal ulcer after apparent eradication of the organism with anti-H." | 2.68 | Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. ( Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX, 1995) |
| "The incidence of severe endoscopic recurrence was significantly reduced by metronidazole (3 of 23; 13%) as compared with placebo (12 of 28; 43%; P = 0." | 2.68 | Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. ( Aerts, R; Geboes, K; Hiele, M; Kerremans, R; Peeters, M; Penninckx, F; Rutgeerts, P, 1995) |
| "91%)." | 2.68 | Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. ( Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | 2.68 | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H." | 2.68 | Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. ( Goh, KL; Navaratnam, P; Peh, SC, 1996) |
| "Rapid recurrence of H." | 2.68 | Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. ( Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J, 1997) |
| " pylori than ranitidine when given with amoxicillin plus metronidazole for the treatment of duodenal ulcer, as both early reinfection and ulcer recurrence are diminished." | 2.68 | Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer. ( Blanco, M; Carpintero, P; Pajares, JM, 1997) |
| "To detect DU recurrence, the gastroscopy was performed at 6, 12, 18, and 24 months after therapy." | 2.67 | The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study. ( Choi, JH; Jung, MH; Kim, NY; Lee, KH; Oh, HS; Wee, SH, 1994) |
| "pylori) eradication and duodenal ulcer recurrence." | 2.67 | Eradication of Helicobacter pylori infection and the recurrence of duodenal ulcers. ( Chen, CY; Chen, LT; Jan, CM; Lin, SR; Liu, CS; Perng, DS; Wang, WM, 1993) |
| "Duration of subjective symptoms, recurrence of symptoms, clinically diagnosed cure, adverse events." | 2.67 | Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial. ( Bezemer, PD; Boeke, AJ; Dekker, JH; Kostense, PJ; van Eijk, JT, 1993) |
| "Treatment with metronidazole was successful (< or = two clinical signs of bacterial vaginosis) in eight of 10 cases of erythromycin treatment failure." | 2.67 | Erythromycin versus metronidazole in the treatment of bacterial vaginosis. ( Holst, E; Hovelius, B; Mårdh, PA; Wathne, B, 1993) |
| "pylori on the recurrence of duodenal ulcer, we treated 104 patients with H." | 2.67 | Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Nemec, H; Schütze, K; Taufer, M; Wurzer, H, 1993) |
| "Duodenal ulcer recurrence and gastritis are reduced with successful Helicobacter pylori treatment." | 2.67 | Patient factors affecting Helicobacter pylori eradication with triple therapy. ( Cutler, AF; Schubert, TT, 1993) |
| "Fifty-three women with bacterial vaginosis (clue cells of at least 20% plus vaginal pH of at least 4." | 2.67 | Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis. ( Briselden, AM; Eschenbach, DA; Hillier, SL; Lipinski, C, 1993) |
| "About half of patients with Crohn's disease (CD) require surgery within 10 years of diagnosis." | 2.66 | Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease. ( Bravo-Soto, GA; Candia, R; Hernandez, C; Monrroy, H; Nguyen, GC, 2020) |
| "Some workers have suggested that the recurrence of symptoms may in fact be reinfection by male consorts, but no controlled studies have been undertaken to confirm this." | 2.66 | Should male consorts of women with bacterial vaginosis be treated? ( Alaksen, K; Bymose, B; Erkkola, R; Jerve, F; Moi, H; Nelleman, G; Tornqvist, E, 1989) |
| "Many patients with Crohn's disease present with the complications of infection." | 2.65 | Infection and the use of antibiotics in Crohn's disease. ( Keighley, MR, 1984) |
| " A dosage of 15-25 mg/kg a day for 5 days is recommended." | 2.65 | Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine) and metronidazole (Flagyl). ( Kavousi, S, 1979) |
| "Guinea worm disease is endemic in West Africa." | 2.64 | Failure of thiabendazole and metronidazole in the treatment and suppression of guinea worm disease. ( Belcher, DW; Ward, WB; Wunapa, FK, 1975) |
| "Some reasons for recurrence include the persistence of residual infection, resistance, and possibly reinfection from either male or female partners." | 2.61 | Characterization and Treatment of Recurrent Bacterial Vaginosis. ( Faught, BM; Reyes, S, 2019) |
| "Secnidazole 2 g was not different from metronidazole (500 mg bid for 5 days), or from secnidazole plus vaginal metronidazole, or 2 g single dose of oral metronidazole or from 2 g secnidazole plus vaginal ornidazole." | 2.61 | Secnidazole for treatment of bacterial vaginosis: a systematic review. ( Abd El Aziz, MA; Abedi, P; Jahanfar, S; Judge, HM; Sharifipour, F, 2019) |
| "Multiple recurrences should be treated with vancomycin or fidaxomicin; if necessary, a vancomycin taper regimen may also be used." | 2.55 | [Individualized treatment strategies for Clostridium difficile infections]. ( Bachmann, O; Dersch, P; Solbach, P, 2017) |
| "Fidaxomicin treatment results in lower recurrence rates than vancomycin and metronidazole, but has higher acquisition costs in Europe and the USA." | 2.55 | A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection. ( Burton, HE; Mitchell, SA; Watt, M, 2017) |
| "More failures and recurrence with metronidazole have led to treatment algorithms suggesting its use for mild infections and switching to vancomycin if there is no clinical improvement." | 2.52 | Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection. ( Marra, F; Ng, K, 2015) |
| "The first recurrence can be treated with the same therapeutic agent and, for subsequent recurrences, vancomycin in a tapered and/or pulsed regimen is recommended." | 2.52 | Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options. ( Doron, S; Gorbach, S; Mizusawa, M, 2015) |
| "Metronidazole (MTZ) has been the treatment of choice for women for decades, and single dose has been considered the first line of therapy." | 2.52 | Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. ( Kissinger, P, 2015) |
| "20 percent of the patients have recurrence after metronidazole or vancomycin treatment, and each recurrence increases the chance of a further one." | 2.49 | [Clostridium difficile infection: epidemiology, disease burden and therapy]. ( Baji, P; Banai, J; Brodszky, V; Gulácsi, L; Kertész, A; Kopcsóné Németh, I; Ludwig, E; Péntek, M; Prinz, G; Reményi, P; Strbák, B; Zsoldiné Urbán, E, 2013) |
| "difficile colitis has become more challenging with the increasing failure of therapeutic response to metronidazole and oral vancomycin." | 2.48 | Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature. ( Baban, TA; El-Herte, RI; Kanj, SS, 2012) |
| "Data regarding treatment failure and recurrence following metronidazole and vancomycin treatment were extracted and analysed." | 2.48 | Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. ( Falagas, ME; Patouni, K; Polyzos, KA; Rafailidis, PI; Samonis, G; Vardakas, KZ, 2012) |
| "Clostridium difficile infection is increasing in incidence and severity." | 2.47 | Comparative effectiveness of Clostridium difficile treatments: a systematic review. ( Bliss, D; Butler, M; Drekonja, DM; Filice, GA; MacDonald, R; Rector, TS; Wilt, TJ, 2011) |
| "Crohn's disease is a chronic, progressive disabling condition ultimately leading to stricturing and/or penetrating complications." | 2.46 | [Postoperative recurrence of Crohn's disease, and its prevention]. ( Lakatos, L; Lakatos, PL, 2010) |
| "Relapse is frequent and must be distinguished from reinfection." | 2.45 | [Clostridium-difficile-associated diarrhea]. ( Bujanda, L; Cosme, A, 2009) |
| "However, if the first recurrence is characterized as severe, vancomycin should be used." | 2.45 | Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. ( Johnson, S, 2009) |
| "Hepatic encephalopathy is characterized by neuropsychiatric abnormalities in patients with liver failure." | 2.45 | Hepatic encephalopathy: pathophysiology and emerging therapies. ( Shaikh, OS; Sundaram, V, 2009) |
| "Metronidazole has been recommended as initial therapy since the late 1990s and continues to be the first choice for all but seriously ill patients and those with complicated or fulminant infections or multiple recurrences of CDI, for whom vancomycin is recommended." | 2.44 | Treatment of Clostridium difficile infection. ( Gerding, DN; Muto, CA; Owens, RC, 2008) |
| "This article reviews the possible treatments for pouchitis, focusing especially on treatment with probiotics, which seem to be a new and promising alternative to antibiotics." | 2.43 | [Probiotics--should we change the treatment strategy for pouchitis?]. ( Kjeldsen, J; Klinge, LG, 2006) |
| "Oral vancomycin is an option for patients who cannot take or fail treatment with oral metronidazole." | 2.43 | Past, present, and future therapies for Clostridium difficile-associated disease. ( Cicogna, CE; Kuyumjian, AG; Surowiec, D; Wynd, MA, 2006) |
| " Metronidazole and 6-mercaptopurine or azathioprine also seem to be of benefit in postoperative prophylaxis of disease recurrence, but additional controlled studies are required to define better the efficacy and dose-response of these agents." | 2.41 | Medical therapy to reduce postoperative Crohn's disease recurrence. ( Achkar, JP; Hanauer, SB, 2000) |
| "The lowest costs and recurrence rates were achieved by 3 regimens: standard triple therapy (a combination of bismuth subsalicylate, metronidazole, and tetracycline hydrochloride) for 14 days ($223, with 18% recurrence); a combination of clarithromycin, metronidazole, and a proton pump inhibitor for 7 days ($235, with 15% recurrence); and standard triple therapy with a proton pump inhibitor for 7 days ($236, with 14% recurrence)." | 2.40 | Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. ( Freston, JW; Murphy, K; Taylor, JL; Zagari, M, 1997) |
| "Crohn's recurrence is the appearance of objective signs defined radiologically, endoscopically or pathologically of Crohn's disease in the bowel of a patient who has previously had a resection of all macroscopically diseased tissue." | 2.40 | [Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection]. ( Rutgeerts, P; Vermeire, S, 1998) |
| "pylori infection decreases recurrence rates and facilitates healing, antibiotic therapy is indicated for all H." | 2.39 | Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. ( Soll, AH, 1996) |
| " Bacterial vaginosis responds readily to treatment with metronidazole at a dosage of 400 mg twice daily for seven days, although a proportion of patients suffer a recurrence of symptoms." | 2.38 | Bacterial vaginosis. ( Levett, PN, 1989) |
| "Pseudomembranous colitis is caused by release of toxins from Clostridium difficile when it colonizes the large intestine." | 2.37 | Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea. ( Burdon, DW, 1984) |
| "Early and late recurrences occurred in 36." | 1.91 | Risk factors for Recurrent Clostridioides Difficile Infection in Children. ( Cacace, J; Goldman, DL; Lee, P; Nemati, K; Silver, EJ, 2023) |
| "Of the 28 women, 25% failed to clear bacterial vaginosis; 35." | 1.72 | Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis. ( Alcaide, M; Chandra, N; Doncel, GF; Fichorova, R; Gale, M; Gustin, AT; Klatt, NR; Schifanella, L; Thurman, AR, 2022) |
| "Epidemiology of Clostridioides difficile infection (CDI) in paediatric cancer patients is uncertain." | 1.72 | Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. ( Aftandilian, CC; Agyeman, PKA; Castagnola, E; Chirra, KM; Dupuis, LL; Groll, AH; Haeusler, GM; Lehrnbecher, T; Loves, R; Phillips, B; Schneider, C; Sung, L; van de Wetering, M, 2022) |
| "The efficacy of antibiotic treatment of pouchitis might be attributed to the establishment of an antibiotic-resistant microbiome with low inflammatory potential." | 1.56 | Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy. ( Bar, N; Dotan, I; Dubinsky, V; Godny, L; Golan, N; Gophna, U; Keizer, D; Rabinowitz, K; Reshef, L; Tulchinsky, H; Yadgar, K; Zonensain, K, 2020) |
| "Metronidazole was used in 94% of the first episodes and in 73% and 50% of the first and second recurrences, respectively." | 1.56 | Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study. ( Bartlomé, N; Bucheli Laffer, E; Fankhauser, H; Fux, CA; Haubitz, S; Spelters, C, 2020) |
| "The cost of treating Clostridioides difficile infection (CDI), particularly recurrent disease, is high." | 1.56 | Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan. ( English, M; Okumura, H; Shoji, S; Ueyama, M, 2020) |
| "40% P<0." | 1.56 | Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial. ( Ardolino, LI; Barattini, DF; Biriș, M; Casolati, E; Crișan, C; Murina, F; Sîrbu, D, 2020) |
| "Severe Clostridioides difficile infection (CDI) is associated with poorer outcomes." | 1.51 | Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore. ( Chow, A; Lye, DC; Ng, TM; Tay, HL, 2019) |
| "Forty-five (11%) experienced a recurrence." | 1.51 | Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children. ( Alabaster, A; Dang, R; Greenhow, TL; Miranda-Katz, M; Parmar, D, 2019) |
| "To identify factors associated with recurrence in 027+ and 027- CDI, a multivariate analysis was performed in each patient group." | 1.51 | Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes. ( Aceti, A; Andreoni, M; Antonelli, G; Carfagna, P; Cauda, R; Delle Rose, D; Falcone, M; Fantoni, M; Farcomeni, A; Fontana, C; Goldoni, P; Iraci, F; Mastroianni, C; Murri, R; Petrosillo, N; Raponi, G; Sanguinetti, M; Santino, I; Tiseo, G; Venditti, M, 2019) |
| "Recurrence of Crohn's disease after surgical resection and primary anastomosis is an important clinical challenge." | 1.51 | Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. ( Cohen, RD; Glick, LR; Hurst, RD; Hyman, NH; Ollech, JE; Rubin, DT; Sossenheimer, PH, 2019) |
| "Following all forms of therapy for bacterial vaginosis (BV), recurrence rates are extremely high." | 1.51 | Prognostic Indicators of Recurrence of Bacterial Vaginosis. ( Aguin, T; Akins, RA; Boikov, D; Gill, G; Kaur, N; Sobel, JD; Woznicki, NA, 2019) |
| "Oral treatment with metronidazole or vancomycin is recommended, but there is a major problem with symptomatic recurrence after treatment." | 1.48 | The 'ins and outs' of faecal microbiota transplant for recurrent Clostridium difficile diarrhoea at Wits Donald Gordon Medical Centre, Johannesburg, South Africa. ( Drennan, K; Fabian, J; Gaylard, PC; Hepple, A; Karlsson, K; Lee, S; Lowman, W; McNamara, L; Simons, G, 2018) |
| "An outbreak of Clostridium difficile infection (CDI) caused by ribotype 027 (B1/NAP1) began in our hospital in November 2014, and produced 141 episodes in the following months." | 1.46 | An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. ( Alcalá, L; Bouza, E; de Egea, V; González-Del Vecchio, M; Marín, M; Muñoz, P; Reigadas, E; Valerio, M, 2017) |
| "Adults with hematological malignancies are at high-risk of Clostridium difficile infection (CDI), but no guidelines for CDI treatment are available in this population." | 1.46 | Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable? ( Boyle, E; Galperine, T; Guery, B; Héquette-Ruz, R; Herbaux, C; Robin, C, 2017) |
| "Metronidazole was used in 70." | 1.46 | Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country. ( Boccuzzi, E; Borali, E; Castellazzi, L; Cursi, L; De Giacomo, C; De Vita, MV; Esposito, S; Garazzino, S; Guarino, A; Lancella, L; Lo Vecchio, A; Mainetti, M; Tagliabue, C, 2017) |
| "Few studies have focused on multiple recurrences." | 1.43 | Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection. ( Abou Chakra, CN; Marcil-Héguy, A; Nault, V; Pépin, J; Sheitoyan-Pesant, C; Valiquette, L, 2016) |
| "Amebic liver abscess is a rare disease in high-income countries." | 1.43 | Recurrent amebic liver abscesses over a 16-year period: a case report. ( Creemers-Schild, D; van Genderen, PJ; van Hellemond, JJ; Visser, LG; Wismans, PJ, 2016) |
| "Biodiversity was lower in Crohn's disease patients at the time of surgery, increased after surgery, but still differed from healthy subjects." | 1.42 | Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study. ( Buckley, M; De Cruz, P; Kamm, MA; Kang, S; Kirkwood, CD; Lockett, T; McSweeney, C; Morrison, M; Prideaux, L; Sim, WH; Wagner, J, 2015) |
| "Recurrence of the symptoms and recurrence of the D." | 1.42 | [Dientamoeba fragilis infection as cause of severe abdominal discomfort and flatulence]. ( Halkjær, S; Petersen, AM; Stensvold, CR, 2015) |
| "Vulvovaginal candidiasis affects 75% of women at least once." | 1.42 | Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis. ( van Schalkwyk, J; Yudin, MH, 2015) |
| "Metronidazole was initiated in 97% of patients, with 32% switching to oral vancomycin." | 1.42 | Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections. ( Jacobson, SM; Slain, D, 2015) |
| "Clostridium difficile infection is considered a major cause of nosocomial diarrhoea in developed countries and is increasingly becoming more important as an etiologic agent of community diarrhoea, also in patients without risk factors." | 1.40 | [Epidemiology of Clostridium difficile-associated disease (CDAD) in Salamanca]. ( Calvo-García, N; de Frutos-Serna, M; García-Sánchez, JE; Hernández-Egido, S; María-Blázquez, A; Siller-Ruiz, M, 2014) |
| "Metronidazole was the primary treatment for 91 of 94 patients, 7 of 8 cases refractory to metronidazole had no response to vancomycin, and none was due to NAP1/027." | 1.40 | Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027. ( Chung, D; Huang, YT; Jakubowski, AA; Kaltsas, A; Kamboj, M; Papanicolaou, G; Sepkowitz, K; Sheahan, A; Sun, J; Wu, S; Xiao, K, 2014) |
| "Patients with one or more recurrence were included in this study." | 1.40 | Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas. ( Aitken, SL; DuPont, HL; Garey, KW; Joseph, TB; Lasco, TM; Palmer, HR; Shah, DN; Xie, Y, 2014) |
| "Recurrence is rare and it can be addressed efficiently with the administration of a second course of antibiotics." | 1.40 | Long-term results of nonoperative treatment for uncomplicated acute appendicitis. ( Aygen, E; Kırkıl, C; Yiğit, MV, 2014) |
| "Hence the diagnosis of pseudomembranous colitis became apparent." | 1.40 | Emphysematous cystitis due to recurrent Clostridium difficile infection. ( Dees, A; Jonkman, JG; van Genderen, ME; van Rijn, M, 2014) |
| "Treatment with metronidazole, vancomycin or both for 10 or more days did not prevent recurrences." | 1.39 | Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center. ( Cioara, A; Filipescu, I; Flonta, M; Lupse, M; Todor, N, 2013) |
| "The incidence and severity of Clostridium difficile infections (CDI) have increased in Western countries." | 1.39 | Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. ( Cheon, JH; Choi, CH; Eun, CS; Han, DS; Huh, KC; Jang, BI; Jung, SA; Kim, HS; Kim, JS; Kim, WH; Kim, YH; Kim, YS; Lee, KM; Lee, SH; Park, YS; Shin, SJ; Song, HJ; Yang, SK; Ye, BD, 2013) |
| "Vancomycin treatment of infected mice was associated with improved clinical, diarrhea, and histopathology scores and survival during treatment." | 1.39 | Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. ( Guerrant, RL; Hoffman, PS; Kolling, GL; Li, Y; Moore, JH; Riggins, MS; van Opstal, EJ; Warren, CA, 2013) |
| "Day-case rate, postoperative pain (measured by a visual analogic scale, 1-10), admissions, re-admissions, early postoperative situation and recurrence were evaluated in the study." | 1.38 | Day case stapled anopexy for the treatment of haemorrhoids and rectal mucosal prolapse. ( Carbonell Roure, J; Estrada Ferrer, O; García Torralbo, E; Heredia Budó, A; Hidalgo Grau, LA; Llorca Cardeñosa, S; Suñol Sala, X, 2012) |
| "Pouchitis is the most common long-term complication after restorative total proctocolectomy and IPAA for ulcerative colitis." | 1.38 | The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis. ( Funayama, Y; Haneda, S; Ogawa, H; Sasaki, I; Shibata, C; Suzuki, H; Takahashi, K; Watanabe, K, 2012) |
| "Recurrence of amebic liver abscess is uncommon." | 1.38 | Recurrent amebic liver abscess. ( Mittal, A; Prakash, A; Singal, DK, 2012) |
| "The patient was diagnosed as severe Clostridium difficile infection based on clinical presentation, labs and imaging studies." | 1.37 | Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection. ( Cheema, FH; Kanwal, S; Korsten, MA; Luthra, M; Majeed, UM; Rafiullah, F; Sohail, MR, 2011) |
| "The prevalence of Clostridium difficile infection (CDI) in pediatric patients with inflammatory bowel disease (IBD) is still not sufficiently recognized." | 1.36 | Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. ( Banaszkiewicz, A; Brazier, JS; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; van Belkum, A; Wultańska, D, 2010) |
| "Persistent bacterial vaginosis is associated with several bacteria in the Clostridiales order, Megasphaera phylotype 2, and P." | 1.35 | Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women. ( Fiedler, TL; Fredricks, DN; Marrazzo, JM; Ringwood, K; Thomas, KK, 2008) |
| " Treatment with penicillin G was very effective in the acute stage, and chronic administration of metronidazole prevented relapse of the disease." | 1.35 | An unusual case of chronic relapsing tetanus associated with mandibular osteomyelitis. ( Fujimuro, M; Jackson, M; Kawarabayashi, T; Kimura, T; Matsubara, E; Nakahata, N; Seino, Y; Shirahama, I; Shoji, M; Suzuki, C; Takamura, A; Tomiyama, M; Wakasaya, Y; Watanabe, M; Yamamoto-Watanabe, Y, 2009) |
| "We present a case of recurrent bacterial vaginosis (BV) of neovagina in a transsexual patient successfully managed by using metronidazole gel and occasional douching." | 1.34 | A case of successful management of recurrent bacterial vaginosis of neovagina after male to female gender reassignment surgery. ( Bradbeer, C; Jain, A, 2007) |
| "Metronidazole as adjuvant treatment does not appear to protect against early symptomatic recurrence." | 1.34 | Early symptomatic recurrence after intestinal resection in Crohn's disease is unpredictable. ( Bradford, IM; Kurer, MA; Leveson, SH; Stamou, KM; Wilson, TR, 2007) |
| "Secondary outcome was recurrence within 60 days." | 1.34 | Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. ( Brazeau, I; Gagnon, S; Pépin, J; Routhier, S; Valiquette, L, 2007) |
| "Bacterial vaginosis is the most prevalent disease of the female genital tract." | 1.33 | Gram stain as a relapse predictor of bacterial vaginosis after metronidazole treatment. ( Huang, M; Wang, JH, 2005) |
| "The frequency of recurrences within 60 days after the initial diagnosis was measured using Kaplan-Meier analysis, and Cox regression was used for multivariate analysis." | 1.33 | Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. ( Alary, ME; Bourassa, C; Fulop, K; Godin, D; Pepin, J; Raiche, E; Ruel, J; Valiquette, L, 2005) |
| "Outcome data such as recurrence and intractability, and clinical features were retrospectively analysed." | 1.33 | Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease. ( Chang, DK; Kim, JH; Kim, JJ; Kim, YH; Lee, H; Paik, SW; Rhee, JC; Rhee, PL; Son, HJ, 2006) |
| "Seventy-one H." | 1.33 | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. ( Castro-Fernández, M; Cosme, A; Gisbert, JP; Gómez, B; Herrerías, JM; Luna, M; Monés, J; Olivares, D; Pajares, JM; Sánchez-Pobre, P, 2006) |
| "We wished to determine recurrences of bacterial vaginosis (BV) after treatment over the course of 12 months and to establish factors associated with recurrence." | 1.33 | High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. ( Bradshaw, CS; Fairley, CK; Garland, SM; Hocking, J; Horvath, LB; Kuzevska, I; Morris, MB; Morton, AN; Moss, LM, 2006) |
| "loss of attachment." | 1.33 | Studies on periodontitis and analyses of individuals at risk for periodontal diseases. ( Jansson, H, 2006) |
| "vaginalis." | 1.33 | The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy. ( Bradshaw, CS; Fairley, CK; Garland, SM; Morton, AN; Rudland, E; Tabrizi, SN, 2006) |
| "The morphological substrate of Crohn's disease in the Hydro-MRI images is reliably detected." | 1.32 | [Follow up of Crohn's disease under therapy with hydro-MRI]. ( Encke, J; Erb, G; Flosdorff, P; Ganten, M; Grüber-Hoffmann, B; Hansmann, J, 2003) |
| "The medical treatment of acute pouchitis was usually oral metronidazole (250 mg twice daily) for 2 weeks or oral ciprofloxacin (200 mg thrice daily) in patients who could not tolerate metronidazole." | 1.32 | Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients. ( Ikeuchi, H; Nakamura, M; Nakano, H; Noda, M; Uchino, M; Yamamura, T; Yanagi, H, 2004) |
| "Diarrhea is common in oncology patients; if it becomes chronic and relapsing, it can be debilitating, hinder planned management, and be difficult to treat." | 1.32 | Probiotics in relapsing and chronic diarrhea. ( Benchimol, EI; Mack, DR, 2004) |
| "Granulomatous cheilitis is a difficult disease to treat because of recurrences." | 1.32 | Treatment and follow-up of persistent granulomatous cheilitis with intralesional steroid and metronidazole. ( Akpolat, N; Cicek, D; Coskun, B; Saral, Y, 2004) |
| "Recurrent bacterial vaginosis is a difficult clinical condition." | 1.32 | Treatment of recurrent bacterial vaginosis with tinidazole. ( Baylson, FA; Nyirjesy, P; Weitz, MV, 2004) |
| "Despite the high initial success rates, recurrence of CDAD remains a significant problem in 20% to 30% of cases, with increased cost and substantial morbidity." | 1.32 | Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment. ( Oldfield, EC, 2004) |
| "The post-treatment recurrence rate of H." | 1.32 | Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia. ( Maaroos, HI; Oona, M; Rägo, T, 2004) |
| "Factors associated with recurrences include endogenous reinfection by spore formation, selective IgG1 or IgA deficiency or infection with mutated strains of Clostridium difficile." | 1.31 | [Recurrent Clostridium difficile enterocolitis]. ( Ballmer, PE; Bergamin, B; Hess, T; Imoberdorf, R; Jost, R, 2000) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "We determined late recrudescence rates, true reinfection, and ulcer recurrence." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "Therefore, the recurrence rate of H." | 1.31 | Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease. ( Kleibeuker, JH; Thijs, JC; van der Wouden, EJ; van Zwet, AA, 2001) |
| "The conservative treatment of ano-rectal fistulae in Crohn's disease is selected according to the clinical activity and chronicity of the underlying disease." | 1.30 | [Conservative therapy of fistulas of the anorectal area in Crohn disease]. ( Brucks, U; Malfertheiner, P; Peitz, U, 1999) |
| "After 1 year, no patient had H." | 1.30 | Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study. ( Annibale, B; D'Ambra, G; Delle Fave, G; Marcheggiano, A; Martino, G; Paoletti, M, 1999) |
| "Non puerperal mastitis is an inflammatory disease that resembles carcinoma, the course is insidious and frequently this entity is misdiagnosed." | 1.29 | [Non-puerperal mastitis. Clinical study of 30 patients]. ( Moreno, G; Paredes López, A, 1995) |
| "This shows that recurrence of H pylori infection is probably caused by recrudescence and that the discriminatory power of randomly amplified polymorphic DNA fingerprinting is a practicable and discriminatory typing scheme for H pylori." | 1.29 | Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting. ( Keane, CT; Marshall, DG; O'Morain, CA; Smyth, CJ; Windle, HJ; Xia, HX, 1995) |
| "There was no recurrence of ulcer in 17 H." | 1.29 | Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. ( Chen, CY; Chen, LT; Jan, CM; Lin, SR; Liu, CS; Perng, DS; Wang, WM, 1994) |
| "Midline nasal dermoid cysts are congenital lesions resulting from aberrant embryological development." | 1.29 | Nasal dermoid sinus cysts: an unusual presentation, computed tomographic scan findings, and surgical results. ( Armstrong, DC; Bortoluzzi, P; Posnick, JC, 1994) |
| " The patient's vaginitis was treated with gentian violet and she was discharged on a tapering dosage of prednisone." | 1.29 | Metronidazole hypersensitivity. ( Choudhury, T; Knowles, S; Shear, NH, 1994) |
| "pylori recurrence." | 1.29 | Long-term Helicobacter pylori recurrence after successful eradication with triple therapy. ( Cutler, AF; Schubert, TT, 1993) |
| "Four cases of perianal group A streptococcal infection presented with typical features of this condition; but because of lack of recognition appropriate therapy was delayed." | 1.29 | Perianal group A streptococcal infection. ( Guppy, DH, 1993) |
| "Oral vancomycin was given alone in 41 (36%) patients, metronidazole was used in 36 (32%) patients, and a combination was given in 15 (13%) patients." | 1.29 | The clinical spectrum of Clostridium difficile colitis in immunocompromised patients. ( Schweitzer, MA; Silver, DL; Stellato, TA; Sweiss, I, 1996) |
| "The ferrets were monitored for recrudescence by repeated cultures of endoscopic gastric mucosal biopsies." | 1.29 | Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets. ( Batchelder, M; Fox, JG; Hayward, A; Murphy, JC; Palley, L; Shames, B; Yan, L, 1996) |
| "pylori and cured DU, there has been no recurrence of ulcer, regardless of smoking status." | 1.28 | Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. ( Andrews, P; Borody, TJ; Brandl, S; George, LL; Jankiewicz, E; Ostapowicz, N, 1992) |
| "The giardiasis was eventually controlled by initial metronidazole and subsequent mepacrine therapy, but side effects necessitated the withdrawal of both of these drugs." | 1.28 | Common variable hypogammaglobulinemia. A case report. ( Girdwood, AH; Marks, IN; Price, SK; Ress, SR; Ruttenberg, D, 1990) |
| "Recurrent perineal Crohn's disease can be an extremely debilitating complication that may be difficult to treat." | 1.28 | Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen. ( Brady, CE; Cooley, BJ; Davis, JC, 1989) |
| "Both patients with ulcerative colitis had a clinical remission." | 1.28 | Cyclosporin A treatment in inflammatory bowel disease. ( Ditschuneit, H; Fleig, WE; Rehklau, E; Stange, EF, 1989) |
| "All patients had ileocolitis or pancolitis." | 1.27 | Metronidazole therapy for Crohn's disease and associated fistulae. ( Jakobovits, J; Schuster, MM, 1984) |
| "The recurrence was the result of reinfection of the liver by persistent organisms in the bowel, emphasizing the importance of giving a lumicide in the initial treatment of this lesion." | 1.27 | Recurrence of hepatic amebiasis after successful treatment with metronidazole. ( Dooley, CP; O'Morain, CA, 1988) |
| "Oral metronidazole is an effective, cheap, alternative to vancomycin therapy." | 1.27 | Changing epidemiology, diagnosis, and treatment of Clostridium difficile toxin-associated colitis. ( Beart, RW; Talbot, RW; Walker, RC, 1986) |
| "Vaginitis is one of the most common complaints of women in the United States today." | 1.27 | Vaginitis. ( Friedrich, EG, 1985) |
| " Dosage reduction was associated with exacerbation of disease activity in all patients, but in all, the perineal manifestations of disease healed promptly when the full dosage of metronidazole was reinstituted." | 1.26 | Metronidazole therapy for perineal Crohn's disease: a follow-up study. ( Bernstein, LH; Boley, SJ; Brandt, LJ; Frank, MS, 1982) |
| "Metronidazole was given in various dosage regimens to 97 patients having microscopically diagnosed trichomoniasis." | 1.24 | Trichomoniasis. Clinical trial of metronidazole (Flagyl). ( MONROE, SE, 1963) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 76 (14.93) | 18.7374 |
| 1990's | 143 (28.09) | 18.2507 |
| 2000's | 125 (24.56) | 29.6817 |
| 2010's | 139 (27.31) | 24.3611 |
| 2020's | 26 (5.11) | 2.80 |
| Authors | Studies |
|---|---|
| Gustin, AT | 1 |
| Thurman, AR | 1 |
| Chandra, N | 1 |
| Schifanella, L | 1 |
| Alcaide, M | 1 |
| Fichorova, R | 1 |
| Doncel, GF | 1 |
| Gale, M | 1 |
| Klatt, NR | 1 |
| Najjar-Debbiny, R | 1 |
| Bazazhina, A | 1 |
| Schwartz, N | 1 |
| Shaked, P | 1 |
| Saliba, W | 1 |
| Weber, G | 1 |
| Haeusler, GM | 1 |
| Lehrnbecher, T | 1 |
| Agyeman, PKA | 1 |
| Loves, R | 1 |
| Castagnola, E | 1 |
| Groll, AH | 1 |
| van de Wetering, M | 1 |
| Aftandilian, CC | 1 |
| Phillips, B | 1 |
| Chirra, KM | 1 |
| Schneider, C | 1 |
| Dupuis, LL | 1 |
| Sung, L | 1 |
| Verburgt, CM | 1 |
| Dunn, KA | 1 |
| Otley, A | 1 |
| Heyman, MB | 1 |
| Verstraete, S | 1 |
| Sunseri, W | 1 |
| Sylvester, F | 1 |
| de Meij, T | 1 |
| Comeau, A | 1 |
| Langille, M | 1 |
| de Jonge, WJ | 1 |
| Benninga, MA | 1 |
| Van Limbergen, JE | 1 |
| Lee, P | 1 |
| Nemati, K | 1 |
| Silver, EJ | 1 |
| Cacace, J | 1 |
| Goldman, DL | 1 |
| Faught, BM | 1 |
| Reyes, S | 1 |
| Tay, HL | 1 |
| Chow, A | 1 |
| Ng, TM | 1 |
| Lye, DC | 1 |
| Dubinsky, V | 1 |
| Reshef, L | 1 |
| Bar, N | 1 |
| Keizer, D | 1 |
| Golan, N | 1 |
| Rabinowitz, K | 1 |
| Godny, L | 1 |
| Yadgar, K | 1 |
| Zonensain, K | 1 |
| Tulchinsky, H | 1 |
| Gophna, U | 1 |
| Dotan, I | 1 |
| Okumura, H | 2 |
| Fukushima, A | 1 |
| Taieb, V | 1 |
| Shoji, S | 2 |
| English, M | 2 |
| Parmar, D | 1 |
| Dang, R | 1 |
| Miranda-Katz, M | 1 |
| Alabaster, A | 1 |
| Greenhow, TL | 1 |
| Abd El Aziz, MA | 1 |
| Sharifipour, F | 1 |
| Abedi, P | 1 |
| Jahanfar, S | 1 |
| Judge, HM | 1 |
| Anstey Watkins, J | 1 |
| Ross, JDC | 2 |
| Thandi, S | 2 |
| Brittain, C | 2 |
| Kai, J | 2 |
| Griffiths, F | 2 |
| Armstrong-Buisseret, L | 1 |
| David, M | 1 |
| Dean, G | 1 |
| Hepburn, T | 1 |
| Jackson, L | 1 |
| Montgomery, A | 1 |
| Roberts, T | 1 |
| Muzny, CA | 1 |
| Van Gerwen, OT | 1 |
| Kissinger, P | 4 |
| Haubitz, S | 1 |
| Bartlomé, N | 1 |
| Bucheli Laffer, E | 1 |
| Spelters, C | 1 |
| Fankhauser, H | 1 |
| Fux, CA | 1 |
| Kimura, T | 5 |
| Stanhope, S | 1 |
| Sugitani, T | 2 |
| Ueyama, M | 1 |
| Happel, AU | 1 |
| Singh, R | 1 |
| Mitchev, N | 1 |
| Mlisana, K | 1 |
| Jaspan, HB | 1 |
| Barnabas, SL | 1 |
| Passmore, JS | 1 |
| Phatharacharukul, P | 1 |
| Purpura, RD | 1 |
| Gandhi, D | 1 |
| Xu, H | 1 |
| Bickett-Burkhart, K | 1 |
| Chalasani, N | 1 |
| Fischer, M | 1 |
| Orman, ES | 1 |
| Coudray, MS | 1 |
| Sheehan, DM | 1 |
| Li, T | 1 |
| Cook, RL | 2 |
| Schwebke, J | 1 |
| Madhivanan, P | 1 |
| Candia, R | 1 |
| Bravo-Soto, GA | 1 |
| Monrroy, H | 1 |
| Hernandez, C | 1 |
| Nguyen, GC | 1 |
| van de Wijgert, JHHM | 1 |
| Verwijs, MC | 1 |
| Cohen, CR | 1 |
| Parks, T | 1 |
| Hemmerling, A | 1 |
| Finucane, TE | 1 |
| Vodstrcil, LA | 3 |
| Plummer, EL | 1 |
| Doyle, M | 1 |
| Fairley, CK | 5 |
| McGuiness, C | 1 |
| Bateson, D | 1 |
| Hocking, JS | 3 |
| Law, MG | 1 |
| Petoumenos, K | 1 |
| Donovan, B | 1 |
| Chow, EPF | 1 |
| Bradshaw, CS | 5 |
| Ramirez, J | 1 |
| Polivkova, S | 2 |
| Krutova, M | 1 |
| Capek, V | 1 |
| Sykorova, B | 1 |
| Benes, J | 2 |
| Qian, C | 1 |
| Abourizk, N | 1 |
| Rizk, MA | 1 |
| Kim, J | 2 |
| Smith, DL | 1 |
| Westra, KC | 1 |
| McLaughlin, JP | 1 |
| Murina, F | 1 |
| Crișan, C | 1 |
| Biriș, M | 1 |
| Sîrbu, D | 1 |
| Barattini, DF | 1 |
| Ardolino, LI | 1 |
| Casolati, E | 1 |
| Gentry, CA | 1 |
| Campbell, DL | 1 |
| Williams, RJ | 1 |
| Badawi, NM | 1 |
| Elkafrawy, MA | 1 |
| Yehia, RM | 1 |
| Attia, DA | 1 |
| Bouza, E | 1 |
| Alcalá, L | 1 |
| Marín, M | 1 |
| Valerio, M | 1 |
| Reigadas, E | 1 |
| Muñoz, P | 1 |
| González-Del Vecchio, M | 1 |
| de Egea, V | 1 |
| Beetz, O | 1 |
| Kleine, M | 1 |
| Vondran, FWR | 1 |
| Cammann, S | 1 |
| Klempnauer, J | 1 |
| Kettler, B | 1 |
| Solbach, P | 1 |
| Dersch, P | 1 |
| Bachmann, O | 1 |
| Webster, G | 1 |
| Schaller, M | 1 |
| Tan, J | 1 |
| Jackson, JM | 1 |
| Kerrouche, N | 1 |
| Schäfer, G | 1 |
| Sippola, S | 1 |
| Grönroos, J | 1 |
| Tuominen, R | 2 |
| Paajanen, H | 2 |
| Rautio, T | 2 |
| Nordström, P | 2 |
| Aarnio, M | 2 |
| Rantanen, T | 2 |
| Hurme, S | 2 |
| Salminen, P | 2 |
| Wu, MA | 1 |
| Leidi, F | 1 |
| Psoinos, CM | 1 |
| Collins, CE | 1 |
| Ayturk, MD | 1 |
| Anderson, FA | 1 |
| Santry, HP | 1 |
| Manthey, CF | 1 |
| Eckmann, L | 1 |
| Fuhrmann, V | 1 |
| Robin, C | 1 |
| Héquette-Ruz, R | 1 |
| Guery, B | 1 |
| Boyle, E | 1 |
| Herbaux, C | 1 |
| Galperine, T | 1 |
| Morioka, H | 1 |
| Iguchi, M | 1 |
| Kuzuya, T | 1 |
| Mikamo, H | 3 |
| Yagi, T | 1 |
| Burton, HE | 1 |
| Mitchell, SA | 1 |
| Watt, M | 1 |
| Aoyama, N | 1 |
| Sawata, M | 1 |
| Fujimoto, G | 1 |
| Dorr, MB | 2 |
| Yoshinari, T | 1 |
| Tieu, JD | 1 |
| Schmidt, SA | 1 |
| Miller, JL | 1 |
| Kupiec, KE | 1 |
| Skrepnek, GH | 1 |
| Liu, C | 2 |
| Smith, WJ | 1 |
| Nguyen, CT | 1 |
| Li, J | 1 |
| Anders, S | 1 |
| Garcia-Diaz, J | 1 |
| Staffeld-Coit, C | 1 |
| Hand, J | 1 |
| Goyal, H | 1 |
| Perisetti, A | 1 |
| Rehman, MR | 1 |
| Singla, U | 1 |
| Gerding, DN | 4 |
| Kelly, CP | 5 |
| Rahav, G | 1 |
| Lee, C | 1 |
| Dubberke, ER | 1 |
| Kumar, PN | 1 |
| Yacyshyn, B | 1 |
| Kao, D | 1 |
| Eves, K | 1 |
| Ellison, MC | 1 |
| Hanson, ME | 1 |
| Guris, D | 1 |
| Lee, S | 1 |
| Drennan, K | 1 |
| Simons, G | 1 |
| Hepple, A | 1 |
| Karlsson, K | 1 |
| Lowman, W | 1 |
| Gaylard, PC | 1 |
| McNamara, L | 1 |
| Fabian, J | 1 |
| Juul, FE | 1 |
| Garborg, K | 1 |
| Bretthauer, M | 1 |
| Skudal, H | 1 |
| Øines, MN | 1 |
| Wiig, H | 1 |
| Rose, Ø | 1 |
| Seip, B | 1 |
| Lamont, JT | 3 |
| Midtvedt, T | 1 |
| Valeur, J | 1 |
| Kalager, M | 1 |
| Holme, Ø | 1 |
| Helsingen, L | 1 |
| Løberg, M | 1 |
| Adami, HO | 1 |
| Falcone, M | 1 |
| Tiseo, G | 1 |
| Iraci, F | 1 |
| Raponi, G | 1 |
| Goldoni, P | 1 |
| Delle Rose, D | 1 |
| Santino, I | 1 |
| Carfagna, P | 1 |
| Murri, R | 1 |
| Fantoni, M | 1 |
| Fontana, C | 1 |
| Sanguinetti, M | 1 |
| Farcomeni, A | 1 |
| Antonelli, G | 1 |
| Aceti, A | 1 |
| Mastroianni, C | 1 |
| Andreoni, M | 1 |
| Cauda, R | 1 |
| Petrosillo, N | 1 |
| Venditti, M | 1 |
| Agudo-Fernández, S | 1 |
| González Blanco, A | 1 |
| Igarashi, Y | 1 |
| Tashiro, S | 1 |
| Enoki, Y | 1 |
| Taguchi, K | 1 |
| Matsumoto, K | 1 |
| Ohge, H | 1 |
| Suzuki, H | 2 |
| Nakamura, A | 1 |
| Mori, N | 1 |
| Morinaga, Y | 1 |
| Yamagishi, Y | 1 |
| Yoshizawa, S | 1 |
| Yanagihara, K | 1 |
| Kunishima, H | 1 |
| Sobrino-García, M | 1 |
| Gómez-Cardeñosa, A | 1 |
| Moreno-Rodilla, E | 1 |
| Muñoz-Bellido, FJ | 1 |
| Lázaro-Sastre, M | 1 |
| Dávila, I | 1 |
| Mecklin, JP | 1 |
| Sand, J | 1 |
| Virtanen, J | 1 |
| Jartti, A | 1 |
| Grönroos, JM | 1 |
| Russo, R | 1 |
| Karadja, E | 1 |
| De Seta, F | 1 |
| Rhyne, RR | 1 |
| Hale, AL | 1 |
| Watson, DS | 1 |
| Smith, DE | 1 |
| Glick, LR | 1 |
| Sossenheimer, PH | 1 |
| Ollech, JE | 1 |
| Cohen, RD | 1 |
| Hyman, NH | 1 |
| Hurst, RD | 1 |
| Rubin, DT | 1 |
| Sobel, JD | 4 |
| Kaur, N | 1 |
| Woznicki, NA | 1 |
| Boikov, D | 1 |
| Aguin, T | 1 |
| Gill, G | 1 |
| Akins, RA | 2 |
| Snijder, R | 1 |
| Genovese, C | 1 |
| Cianci, A | 1 |
| Corsello, S | 1 |
| Ettore, G | 1 |
| Mattana, P | 1 |
| Tempera, G | 1 |
| Duclaux-Loras, R | 1 |
| Berthiller, J | 1 |
| Ferroni, A | 1 |
| Chardot, C | 1 |
| Goulet, O | 1 |
| Lacaille, F | 1 |
| Norsa, L | 1 |
| Xiao, B | 1 |
| Wu, C | 1 |
| Song, W | 1 |
| Niu, X | 1 |
| Qin, N | 1 |
| Liu, Z | 1 |
| Xu, Q | 1 |
| Park, JH | 1 |
| Park, HC | 3 |
| Lee, BH | 3 |
| Morgan, DR | 1 |
| Torres, J | 1 |
| Sexton, R | 1 |
| Herrero, R | 1 |
| Salazar-Martínez, E | 1 |
| Greenberg, ER | 1 |
| Bravo, LE | 1 |
| Dominguez, RL | 1 |
| Ferreccio, C | 1 |
| Lazcano-Ponce, EC | 1 |
| Meza-Montenegro, MM | 1 |
| Peña, EM | 1 |
| Peña, R | 1 |
| Correa, P | 1 |
| Martínez, ME | 1 |
| Chey, WD | 1 |
| Valdivieso, M | 1 |
| Anderson, GL | 1 |
| Goodman, GE | 1 |
| Crowley, JJ | 1 |
| Baker, LH | 1 |
| Benajah, DA | 1 |
| Lahbabi, M | 1 |
| Alaoui, S | 1 |
| El Rhazi, K | 1 |
| El Abkari, M | 1 |
| Nejjari, C | 1 |
| Amarti, A | 1 |
| Bennani, B | 1 |
| Mahmoud, M | 1 |
| Ibrahimi, SA | 1 |
| Kjær, S | 1 |
| Rud, B | 1 |
| Bay-Nielsen, M | 1 |
| Woods, JL | 1 |
| Scurlock, AM | 1 |
| Hensel, DJ | 1 |
| Vanderpas, J | 1 |
| Bontems, P | 1 |
| Miendje Deyi, VY | 1 |
| Cadranel, S | 1 |
| Gulácsi, L | 1 |
| Kertész, A | 1 |
| Kopcsóné Németh, I | 1 |
| Banai, J | 1 |
| Ludwig, E | 1 |
| Prinz, G | 2 |
| Reményi, P | 1 |
| Strbák, B | 1 |
| Zsoldiné Urbán, E | 1 |
| Baji, P | 1 |
| Péntek, M | 1 |
| Brodszky, V | 1 |
| Motzkus-Feagans, C | 1 |
| Pakyz, AL | 1 |
| Ratliff, SM | 1 |
| Bajaj, JS | 1 |
| Lapane, KL | 1 |
| Aguin, TJ | 1 |
| Dev, YP | 1 |
| Goyal, OP | 1 |
| Kim, MS | 1 |
| Kim, N | 2 |
| Kim, SE | 1 |
| Jo, HJ | 1 |
| Shin, CM | 1 |
| Park, YS | 2 |
| Lee, DH | 2 |
| Ebigbo, A | 1 |
| Messmann, H | 1 |
| Weis, S | 1 |
| John, E | 1 |
| Lippmann, N | 1 |
| Mössner, J | 1 |
| Lübbert, C | 1 |
| Guslandi, M | 1 |
| Lupse, M | 1 |
| Flonta, M | 1 |
| Cioara, A | 1 |
| Filipescu, I | 1 |
| Todor, N | 1 |
| Leise, MD | 1 |
| Poterucha, JJ | 1 |
| Kamath, PS | 1 |
| Kim, WR | 1 |
| Kim, MJ | 2 |
| Seña, AC | 1 |
| Bachmann, LH | 1 |
| Hobbs, MM | 1 |
| Johnson, S | 3 |
| Louie, TJ | 1 |
| Cornely, OA | 1 |
| Chasan-Taber, S | 1 |
| Fitts, D | 1 |
| Gelone, SP | 1 |
| Broom, C | 1 |
| Davidson, DM | 1 |
| Siller-Ruiz, M | 1 |
| Calvo-García, N | 1 |
| Hernández-Egido, S | 1 |
| María-Blázquez, A | 1 |
| de Frutos-Serna, M | 1 |
| García-Sánchez, JE | 1 |
| Turner, AN | 1 |
| Carr Reese, P | 1 |
| Fields, KS | 1 |
| Anderson, J | 1 |
| Ervin, M | 1 |
| Davis, JA | 1 |
| Fichorova, RN | 1 |
| Roberts, MW | 1 |
| Klebanoff, MA | 1 |
| Jackson, RD | 1 |
| Kamboj, M | 1 |
| Xiao, K | 1 |
| Kaltsas, A | 1 |
| Huang, YT | 1 |
| Sun, J | 1 |
| Chung, D | 1 |
| Wu, S | 1 |
| Sheahan, A | 1 |
| Sepkowitz, K | 1 |
| Jakubowski, AA | 1 |
| Papanicolaou, G | 1 |
| Aitken, SL | 1 |
| Joseph, TB | 1 |
| Shah, DN | 1 |
| Lasco, TM | 1 |
| Palmer, HR | 1 |
| DuPont, HL | 1 |
| Xie, Y | 1 |
| Garey, KW | 1 |
| Svensson, JF | 1 |
| Patkova, B | 1 |
| Almström, M | 1 |
| Naji, H | 1 |
| Hall, NJ | 1 |
| Eaton, S | 1 |
| Pierro, A | 1 |
| Wester, T | 1 |
| De Cruz, P | 3 |
| Kang, S | 1 |
| Wagner, J | 1 |
| Buckley, M | 2 |
| Sim, WH | 1 |
| Prideaux, L | 3 |
| Lockett, T | 1 |
| McSweeney, C | 1 |
| Morrison, M | 1 |
| Kirkwood, CD | 1 |
| Kamm, MA | 4 |
| Kırkıl, C | 1 |
| Yiğit, MV | 1 |
| Aygen, E | 1 |
| van Genderen, ME | 1 |
| Jonkman, JG | 1 |
| van Rijn, M | 1 |
| Dees, A | 1 |
| Mukku, KK | 1 |
| Raju, S | 1 |
| Yelanati, R | 1 |
| Hamilton, AL | 2 |
| Ritchie, KJ | 2 |
| Krejany, EO | 2 |
| Gorelik, A | 2 |
| Liew, D | 2 |
| Lawrance, IC | 2 |
| Andrews, JM | 2 |
| Bampton, PA | 2 |
| Gibson, PR | 2 |
| Sparrow, M | 1 |
| Leong, RW | 2 |
| Florin, TH | 2 |
| Gearry, RB | 2 |
| Radford-Smith, G | 2 |
| Macrae, FA | 2 |
| Debinski, H | 2 |
| Selby, W | 2 |
| Kronborg, I | 2 |
| Johnston, MJ | 2 |
| Woods, R | 2 |
| Elliott, PR | 2 |
| Bell, SJ | 2 |
| Brown, SJ | 2 |
| Connell, WR | 2 |
| Desmond, PV | 2 |
| Soriano, MM | 1 |
| Keller, JJ | 1 |
| Kuijper, EJ | 1 |
| Halkjær, S | 1 |
| Stensvold, CR | 2 |
| Petersen, AM | 1 |
| Stollman, N | 1 |
| Smith, M | 1 |
| Giovanelli, A | 1 |
| Mendolia, G | 1 |
| Burns, L | 1 |
| Didyk, E | 1 |
| Burgess, J | 1 |
| Noh, A | 1 |
| Edelstein, C | 1 |
| Alm, E | 1 |
| Kassam, Z | 1 |
| van Schalkwyk, J | 1 |
| Yudin, MH | 1 |
| Carreiro, FT | 1 |
| Coelho, SC | 1 |
| Horta, AB | 1 |
| Sá, J | 1 |
| Marra, F | 1 |
| Ng, K | 1 |
| Recine, N | 1 |
| Palma, E | 1 |
| Domenici, L | 1 |
| Giorgini, M | 1 |
| Imperiale, L | 1 |
| Sassu, C | 1 |
| Musella, A | 1 |
| Marchetti, C | 1 |
| Muzii, L | 1 |
| Benedetti Panici, P | 1 |
| Mizusawa, M | 1 |
| Doron, S | 1 |
| Gorbach, S | 1 |
| Jakobovits, S | 1 |
| Matta, SK | 1 |
| Greenberg, A | 1 |
| Singh, A | 1 |
| Reibetanz, J | 1 |
| Germer, CT | 1 |
| Babics, A | 1 |
| Roussellier, P | 1 |
| Jacobson, SM | 1 |
| Slain, D | 1 |
| Sheitoyan-Pesant, C | 1 |
| Abou Chakra, CN | 1 |
| Pépin, J | 3 |
| Marcil-Héguy, A | 1 |
| Nault, V | 1 |
| Valiquette, L | 3 |
| Popa, D | 1 |
| Laszlo, M | 1 |
| Ciobanu, L | 1 |
| Ucenic, E | 1 |
| Mihalache, M | 1 |
| Pascu, O | 1 |
| Wikstén, JE | 1 |
| Pitkäranta, A | 1 |
| Blomgren, K | 1 |
| Wiedel, N | 1 |
| Gilbert, J | 1 |
| Baloun, B | 1 |
| Nelson, C | 1 |
| García-Lozano, T | 1 |
| Aznar-Oroval, E | 1 |
| Martín-Utrilla, S | 1 |
| Peretz, A | 1 |
| Tkhawkho, L | 1 |
| Pastukh, N | 1 |
| Brodsky, D | 1 |
| Halevi, CN | 1 |
| Nitzan, O | 1 |
| Gergely Szabo, B | 1 |
| Kadar, B | 1 |
| Szidonia Lenart, K | 1 |
| Dezsenyi, B | 1 |
| Kunovszki, P | 1 |
| Fried, K | 1 |
| Kamotsay, K | 1 |
| Nikolova, R | 1 |
| Lo Vecchio, A | 1 |
| Lancella, L | 1 |
| Tagliabue, C | 1 |
| De Giacomo, C | 1 |
| Garazzino, S | 1 |
| Mainetti, M | 1 |
| Cursi, L | 1 |
| Borali, E | 1 |
| De Vita, MV | 1 |
| Boccuzzi, E | 1 |
| Castellazzi, L | 1 |
| Esposito, S | 1 |
| Guarino, A | 1 |
| Amaya-Guio, J | 1 |
| Viveros-Carreño, DA | 1 |
| Sierra-Barrios, EM | 1 |
| Martinez-Velasquez, MY | 1 |
| Grillo-Ardila, CF | 1 |
| Creemers-Schild, D | 1 |
| van Genderen, PJ | 1 |
| Visser, LG | 1 |
| van Hellemond, JJ | 1 |
| Wismans, PJ | 1 |
| Fashandi, AZ | 1 |
| Martin, AN | 1 |
| Wang, PT | 1 |
| Hedrick, TL | 1 |
| Friel, CM | 1 |
| Smith, PW | 1 |
| Hays, RA | 1 |
| Hallowell, PT | 1 |
| O'Brien, G | 1 |
| Méneret, A | 1 |
| Tassart, M | 1 |
| Khalil, A | 1 |
| Roques, S | 1 |
| Barbut, F | 1 |
| Bachmeyer, C | 1 |
| Marrazzo, JM | 2 |
| Thomas, KK | 2 |
| Fiedler, TL | 2 |
| Ringwood, K | 1 |
| Fredricks, DN | 3 |
| Younas, M | 1 |
| Shah, S | 1 |
| Talaat, A | 1 |
| Wensaas, KA | 1 |
| Langeland, N | 1 |
| Rortveit, G | 1 |
| Amar, S | 1 |
| Wu, SC | 1 |
| Madan, M | 1 |
| Bujanda, L | 1 |
| Cosme, A | 2 |
| Kurtzman, J | 1 |
| Chandiramani, M | 1 |
| Briley, A | 1 |
| Poston, L | 1 |
| Das, A | 1 |
| Shennan, A | 1 |
| Bago, J | 1 |
| Pevec, B | 1 |
| Tomić, M | 1 |
| Marusić, M | 1 |
| Bakula, V | 1 |
| Bago, P | 1 |
| Paz, Z | 1 |
| Altman, A | 1 |
| Sundaram, V | 1 |
| Shaikh, OS | 1 |
| Wakasaya, Y | 1 |
| Watanabe, M | 1 |
| Tomiyama, M | 1 |
| Suzuki, C | 1 |
| Jackson, M | 1 |
| Fujimuro, M | 1 |
| Seino, Y | 1 |
| Kawarabayashi, T | 1 |
| Yamamoto-Watanabe, Y | 1 |
| Matsubara, E | 1 |
| Shirahama, I | 1 |
| Takamura, A | 1 |
| Nakahata, N | 1 |
| Shoji, M | 1 |
| Bunge, KE | 1 |
| Beigi, RH | 1 |
| Meyn, LA | 1 |
| Hillier, SL | 2 |
| He, X | 1 |
| Bennett, AE | 2 |
| Lian, L | 1 |
| Shen, B | 2 |
| Scheppach, W | 1 |
| Thulkar, J | 1 |
| Kriplani, A | 1 |
| Agarwal, N | 1 |
| Stanley, JD | 1 |
| Burns, RP | 1 |
| Vogelberg, C | 1 |
| Monecke, S | 1 |
| Ditzen, A | 1 |
| Stopsack, K | 1 |
| Heinrich-Gräfe, U | 1 |
| Pöhlmann, C | 1 |
| Srinivasan, S | 1 |
| Mitchell, CM | 1 |
| Agnew, KJ | 1 |
| Lakatos, L | 1 |
| Lakatos, PL | 1 |
| Wultańska, D | 1 |
| Banaszkiewicz, A | 1 |
| Radzikowski, A | 1 |
| Obuch-Woszczatyński, P | 1 |
| Młynarczyk, G | 1 |
| Brazier, JS | 1 |
| Pituch, H | 1 |
| van Belkum, A | 1 |
| Uehara, T | 1 |
| Kato, K | 2 |
| Ohkusa, T | 1 |
| Sugitani, M | 1 |
| Ishii, Y | 1 |
| Nemoto, N | 1 |
| Moriyama, M | 1 |
| Kim, JW | 1 |
| Lee, KL | 1 |
| Jeong, JB | 1 |
| Kim, BG | 1 |
| Shin, S | 1 |
| Kim, JS | 3 |
| Jung, HC | 2 |
| Song, IS | 2 |
| Grewal, NS | 1 |
| Salim, A | 1 |
| Salkind, AR | 1 |
| Join-Lambert, O | 1 |
| Coignard, H | 1 |
| Jais, JP | 1 |
| Guet-Revillet, H | 1 |
| Poirée, S | 1 |
| Fraitag, S | 1 |
| Jullien, V | 1 |
| Ribadeau-Dumas, F | 1 |
| Thèze, J | 1 |
| Le Guern, AS | 1 |
| Behillil, S | 1 |
| Leflèche, A | 1 |
| Berche, P | 1 |
| Consigny, PH | 1 |
| Lortholary, O | 1 |
| Nassif, X | 1 |
| Nassif, A | 1 |
| Phiri, R | 1 |
| Feller, L | 1 |
| Blignaut, E | 1 |
| Zafiropoulos, GG | 1 |
| di Prisco, MO | 1 |
| Deli, G | 1 |
| Hoffmann, O | 1 |
| Kasaj, A | 1 |
| Hwang, EW | 1 |
| Cheung, L | 1 |
| Mojtahed, A | 1 |
| Cartwright, CA | 1 |
| Gatski, M | 1 |
| Martin, DH | 2 |
| Levison, J | 1 |
| Mena, L | 1 |
| Clark, RA | 2 |
| Murphy, M | 1 |
| Henderson, H | 1 |
| Schmidt, N | 2 |
| Anacleto, TP | 1 |
| Lopes, LR | 1 |
| Andreollo, NA | 1 |
| Bernis Filho, WO | 1 |
| Resck, MC | 1 |
| Macedo, A | 1 |
| Surawicz, CM | 6 |
| Alexander, J | 1 |
| Mischnik, A | 1 |
| Zimmermann, S | 1 |
| Bekeredjian-Ding, I | 1 |
| Egermann, M | 1 |
| Romero-Pizarro, Y | 1 |
| Muñoz-Algarra, M | 1 |
| Fernández-Mateos, C | 1 |
| Sánchez-Romero, I | 1 |
| Hidalgo Grau, LA | 1 |
| Heredia Budó, A | 1 |
| Llorca Cardeñosa, S | 1 |
| Carbonell Roure, J | 1 |
| Estrada Ferrer, O | 1 |
| García Torralbo, E | 1 |
| Suñol Sala, X | 1 |
| Pomazkin, VI | 1 |
| Drekonja, DM | 2 |
| Amundson, WH | 1 |
| Decarolis, DD | 1 |
| Kuskowski, MA | 1 |
| Lederle, FA | 1 |
| Johnson, JR | 1 |
| Wang'ondu, RW | 1 |
| Murray, TS | 1 |
| Heyland, K | 1 |
| Friedt, M | 1 |
| Buehr, P | 1 |
| Braegger, CP | 1 |
| Gardner, E | 1 |
| Meghani, N | 1 |
| Mancuso, P | 1 |
| Thomson, A | 1 |
| Pai, H | 1 |
| Seo, MR | 1 |
| Kang, JO | 1 |
| El-Herte, RI | 1 |
| Baban, TA | 1 |
| Kanj, SS | 1 |
| Venugopal, AA | 1 |
| Riederer, K | 1 |
| Patel, SM | 1 |
| Szpunar, S | 1 |
| Jahamy, H | 1 |
| Valenti, S | 1 |
| Shemes, SP | 1 |
| Khatib, R | 1 |
| Johnson, LB | 1 |
| Butler, M | 1 |
| MacDonald, R | 1 |
| Bliss, D | 1 |
| Filice, GA | 1 |
| Rector, TS | 1 |
| Wilt, TJ | 1 |
| Vardakas, KZ | 1 |
| Polyzos, KA | 1 |
| Patouni, K | 1 |
| Rafailidis, PI | 1 |
| Samonis, G | 1 |
| Falagas, ME | 1 |
| Ogawa, H | 1 |
| Shibata, C | 1 |
| Haneda, S | 1 |
| Watanabe, K | 1 |
| Takahashi, K | 1 |
| Funayama, Y | 1 |
| Sasaki, I | 1 |
| Pirotta, M | 2 |
| De Guingand, D | 2 |
| Morton, AN | 4 |
| Garland, SM | 4 |
| Fehler, G | 1 |
| Morrow, A | 1 |
| Walker, S | 1 |
| Armbruster, S | 1 |
| Goldkind, L | 1 |
| Rafiullah, F | 1 |
| Kanwal, S | 1 |
| Majeed, UM | 1 |
| Korsten, MA | 1 |
| Cheema, FH | 1 |
| Luthra, M | 1 |
| Sohail, MR | 1 |
| Mitchell, C | 1 |
| Manhart, LE | 1 |
| Thomas, K | 1 |
| Fiedler, T | 1 |
| Marrazzo, J | 1 |
| Kim, YS | 1 |
| Han, DS | 1 |
| Kim, YH | 2 |
| Kim, WH | 1 |
| Kim, HS | 2 |
| Song, HJ | 1 |
| Shin, SJ | 1 |
| Yang, SK | 1 |
| Ye, BD | 1 |
| Eun, CS | 1 |
| Lee, KM | 1 |
| Lee, SH | 1 |
| Jang, BI | 1 |
| Jung, SA | 1 |
| Cheon, JH | 2 |
| Choi, CH | 1 |
| Huh, KC | 1 |
| Kandel, C | 1 |
| Moayedi, Y | 1 |
| Bunce, PE | 1 |
| Singal, DK | 1 |
| Mittal, A | 1 |
| Prakash, A | 1 |
| Nassour, I | 1 |
| Carchman, EH | 1 |
| Simmons, RL | 1 |
| Zuckerbraun, BS | 1 |
| Kareem, T | 1 |
| Mattila, E | 1 |
| Arkkila, P | 1 |
| Mattila, PS | 1 |
| Tarkka, E | 1 |
| Tissari, P | 1 |
| Anttila, VJ | 1 |
| Warren, CA | 1 |
| van Opstal, EJ | 1 |
| Riggins, MS | 1 |
| Li, Y | 1 |
| Moore, JH | 1 |
| Kolling, GL | 1 |
| Guerrant, RL | 2 |
| Hoffman, PS | 1 |
| Law, M | 1 |
| Tsiskarishvili, NV | 1 |
| Katsitadze, A | 1 |
| Tsiskarishvili, Ts | 1 |
| Jussila, A | 1 |
| Färkkilä, M | 1 |
| Järvinen, HJ | 1 |
| McFarland, LV | 4 |
| Elmer, GW | 4 |
| McNamara, D | 1 |
| Gilvarry, J | 2 |
| O'Morain, C | 1 |
| Chaudhuri, A | 1 |
| Bekdash, BA | 1 |
| Papanikolaou, EG | 1 |
| Tsanadis, G | 1 |
| Dalkalitsis, N | 1 |
| Lolis, D | 1 |
| Schuster, MJ | 1 |
| Ganten, M | 1 |
| Encke, J | 1 |
| Flosdorff, P | 1 |
| Grüber-Hoffmann, B | 1 |
| Erb, G | 1 |
| Hansmann, J | 1 |
| Lenzen-Grossimlinghaus, R | 1 |
| Strohmeyer, G | 1 |
| Dupas, JL | 1 |
| Bruley des Varannes, S | 1 |
| Jansson, H | 3 |
| Bratthall, G | 2 |
| Söderholm, G | 2 |
| Kanno, M | 1 |
| Wullt, M | 3 |
| Hagslätt, ML | 1 |
| Odenholt, I | 3 |
| MONROE, SE | 1 |
| Heinonen, PK | 1 |
| Leinonen, M | 1 |
| Szczesny, A | 1 |
| Martirosian, G | 1 |
| Dejaco, C | 1 |
| Harrer, M | 1 |
| Waldhoer, T | 1 |
| Miehsler, W | 1 |
| Vogelsang, H | 1 |
| Reinisch, W | 1 |
| Mimura, T | 1 |
| Rizzello, F | 1 |
| Helwig, U | 1 |
| Poggioli, G | 1 |
| Schreiber, S | 1 |
| Talbot, IC | 1 |
| Nicholls, RJ | 1 |
| Gionchetti, P | 1 |
| Campieri, M | 1 |
| Schultz, M | 1 |
| Timmer, A | 1 |
| Herfarth, HH | 1 |
| Sartor, RB | 1 |
| Vanderhoof, JA | 1 |
| Rath, HC | 1 |
| Lane, E | 1 |
| Lobetti, R | 1 |
| Burroughs, R | 1 |
| Ikeuchi, H | 1 |
| Nakano, H | 1 |
| Uchino, M | 1 |
| Nakamura, M | 1 |
| Yanagi, H | 1 |
| Noda, M | 1 |
| Yamamura, T | 1 |
| Poutanen, SM | 1 |
| Simor, AE | 1 |
| Chen, XX | 1 |
| Ou, BY | 1 |
| Wu, XY | 1 |
| Zhou, XL | 1 |
| Tang, HF | 1 |
| Qü, YP | 1 |
| Shang, SQ | 1 |
| Farrell, S | 1 |
| Milliken, I | 1 |
| Doherty, GM | 1 |
| Murphy, JL | 1 |
| Wootton, SA | 1 |
| McCallion, WA | 1 |
| Hamberg, K | 1 |
| Benchimol, EI | 1 |
| Mack, DR | 1 |
| Alfonsi, GA | 1 |
| Shlay, JC | 1 |
| Parker, S | 1 |
| Neher, JO | 1 |
| Coskun, B | 1 |
| Saral, Y | 1 |
| Cicek, D | 1 |
| Akpolat, N | 1 |
| Sherman, PM | 1 |
| Baylson, FA | 1 |
| Nyirjesy, P | 1 |
| Weitz, MV | 1 |
| French, L | 1 |
| Horton, J | 1 |
| Matousek, M | 1 |
| Nigwekar, SU | 1 |
| Casey, KJ | 1 |
| Oldfield, EC | 2 |
| Elizalde, JI | 1 |
| Pérez-Pujol, S | 1 |
| Heras, M | 1 |
| Sionis, A | 1 |
| Casanovas, N | 1 |
| Martorell, T | 1 |
| Lozano, M | 1 |
| González, J | 1 |
| Escolar, G | 1 |
| Sanz, G | 1 |
| Piqué, JM | 1 |
| Gunaid, AA | 1 |
| Hassan, NA | 1 |
| Murray-Lyon, IM | 1 |
| Gencosmanoglu, R | 1 |
| Inceoglu, R | 1 |
| Oona, M | 1 |
| Rägo, T | 1 |
| Maaroos, HI | 1 |
| Huang, M | 1 |
| Wang, JH | 1 |
| Alary, ME | 1 |
| Raiche, E | 1 |
| Ruel, J | 1 |
| Fulop, K | 1 |
| Godin, D | 1 |
| Bourassa, C | 1 |
| Horvat, D | 1 |
| Vcev, A | 1 |
| Soldo, I | 1 |
| Timarac, J | 1 |
| Dmitrović, B | 1 |
| Misević, T | 1 |
| Ivezić, Z | 1 |
| Kraljik, N | 1 |
| Lee, JH | 1 |
| Park, MJ | 1 |
| Kim, JM | 1 |
| Prieto, A | 1 |
| De Barrio, M | 1 |
| Infante, S | 1 |
| Torres, A | 1 |
| Rubio, M | 1 |
| Olalde, S | 1 |
| Cassano, N | 1 |
| Scoppio, BM | 1 |
| Loviglio, MC | 1 |
| Vena, GA | 1 |
| Brzezinski, A | 1 |
| Fazio, VW | 1 |
| Remzi, FH | 1 |
| Achkar, JP | 2 |
| Sherman, K | 1 |
| Lashner, BA | 1 |
| Lee, H | 1 |
| Kim, JH | 1 |
| Chang, DK | 1 |
| Son, HJ | 1 |
| Rhee, PL | 1 |
| Kim, JJ | 1 |
| Paik, SW | 1 |
| Rhee, JC | 1 |
| Simoes, JA | 1 |
| Bahamondes, LG | 1 |
| Camargo, RP | 1 |
| Alves, VM | 1 |
| Zaneveld, LJ | 1 |
| Waller, DP | 1 |
| Schwartz, J | 1 |
| Callahan, MM | 1 |
| Mauck, CK | 1 |
| Andrews, WW | 1 |
| Goldenberg, RL | 1 |
| Hauth, JC | 1 |
| Cliver, SP | 1 |
| Copper, R | 1 |
| Conner, M | 1 |
| Gisbert, JP | 3 |
| Luna, M | 1 |
| Gómez, B | 1 |
| Herrerías, JM | 1 |
| Monés, J | 1 |
| Castro-Fernández, M | 1 |
| Sánchez-Pobre, P | 1 |
| Olivares, D | 1 |
| Pajares, JM | 4 |
| Decena, DC | 1 |
| Co, JT | 1 |
| Manalastas, RM | 1 |
| Palaypayon, EP | 1 |
| Padolina, CS | 1 |
| Sison, JM | 1 |
| Dancel, LA | 1 |
| Lelis, MA | 1 |
| Hocking, J | 1 |
| Morris, MB | 1 |
| Moss, LM | 1 |
| Horvath, LB | 1 |
| Kuzevska, I | 1 |
| Tran, TT | 1 |
| Quandalle, P | 1 |
| Tabrizi, SN | 1 |
| Rudland, E | 1 |
| Modi, BP | 1 |
| Langer, M | 1 |
| Duggan, C | 1 |
| Kim, HB | 1 |
| Jaksic, T | 1 |
| Klinge, LG | 1 |
| Kjeldsen, J | 1 |
| Myer, L | 1 |
| Kuhn, L | 1 |
| Denny, L | 1 |
| Wright, TC | 1 |
| Surowiec, D | 1 |
| Kuyumjian, AG | 1 |
| Wynd, MA | 1 |
| Cicogna, CE | 1 |
| Eschenbach, DA | 3 |
| Heins, JR | 1 |
| Jain, A | 1 |
| Bradbeer, C | 1 |
| Musher, DM | 1 |
| Logan, N | 1 |
| Mehendiratta, V | 1 |
| Melgarejo, NA | 1 |
| Garud, S | 1 |
| Hamill, RJ | 1 |
| Khan, S | 1 |
| Sharrack, B | 1 |
| Sewell, WA | 1 |
| Pareja Sierra, T | 1 |
| Hornillos Calvo, M | 1 |
| Johansson Hagslätt, ML | 1 |
| Berggren, A | 1 |
| Kurer, MA | 1 |
| Stamou, KM | 1 |
| Wilson, TR | 1 |
| Bradford, IM | 1 |
| Leveson, SH | 1 |
| Pakyz, A | 1 |
| Leiknes, T | 1 |
| Leknes, KN | 1 |
| Böe, OE | 1 |
| Skavland, RJ | 1 |
| Lie, T | 1 |
| Tsesmeli, NE | 1 |
| Giannoulis, KE | 1 |
| Savopoulos, CG | 1 |
| Vretou, EE | 1 |
| Ekonomou, IA | 1 |
| Giannoulis, EK | 1 |
| Gagnon, S | 1 |
| Routhier, S | 1 |
| Brazeau, I | 1 |
| Shen, EP | 1 |
| Kibadi, K | 1 |
| Muto, CA | 1 |
| Owens, RC | 1 |
| Secor, WE | 1 |
| Leichliter, JS | 1 |
| Curtin, E | 1 |
| Raina, A | 1 |
| Kiss, L | 1 |
| Yadav, D | 2 |
| Singleton, JW | 1 |
| Ewe, K | 1 |
| Karbach, U | 1 |
| Nielsen, PG | 1 |
| Prinz, L | 1 |
| Critchlow, CW | 1 |
| Watkins, H | 1 |
| Smith, K | 1 |
| Spiegel, CA | 1 |
| Chen, KC | 1 |
| Holmes, KK | 1 |
| Keighley, MR | 2 |
| Bartlett, JG | 1 |
| Burdon, DW | 2 |
| Lundström, A | 1 |
| Johansson, LA | 1 |
| Hamp, SE | 1 |
| Mitchell, SR | 1 |
| Gaver, WR | 1 |
| Jakobovits, J | 1 |
| Schuster, MM | 1 |
| Balsdon, MJ | 1 |
| Rüttgers, H | 1 |
| Lorenz, U | 1 |
| Stone, HH | 1 |
| Schubert, S | 1 |
| Granz, W | 1 |
| Schenker, U | 1 |
| Schulz, HG | 1 |
| Toth, A | 1 |
| Brandt, LJ | 2 |
| Bernstein, LH | 1 |
| Boley, SJ | 1 |
| Frank, MS | 1 |
| Thiel, H | 1 |
| Ecker, KW | 1 |
| Gouet, D | 1 |
| Rouffineau, J | 1 |
| Chauvin, C | 1 |
| Abadie, JC | 1 |
| Ribet, M | 1 |
| Becq Giradon, B | 1 |
| Fleury, FJ | 1 |
| Meuwissen, SG | 1 |
| Rietra, PJ | 1 |
| Mulder, CJ | 1 |
| Reiss, M | 1 |
| Visser, J | 1 |
| Van Leeuwen, AM | 1 |
| Bauer, AG | 1 |
| Schalm, SW | 1 |
| Stuiver, PC | 1 |
| Nisselle, P | 1 |
| Portnoy, D | 1 |
| Soneji, A | 1 |
| Murray, D | 1 |
| Richards, GK | 1 |
| Reilly, S | 1 |
| Timmis, P | 1 |
| Beeden, AG | 1 |
| Willis, AT | 1 |
| Molinié, C | 1 |
| Daly, JP | 1 |
| Essioux, H | 1 |
| Burlaton, JP | 1 |
| Bernard, J | 1 |
| Lesbordes, J | 1 |
| Laverdant, C | 1 |
| Labenz, J | 4 |
| Stolte, M | 1 |
| Peitz, U | 2 |
| Tillenburg, B | 1 |
| Köhl, H | 1 |
| Becker, T | 1 |
| Börsch, G | 4 |
| Wilson, WH | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Khanna, AK | 1 |
| Misra, MK | 1 |
| Kumar, K | 1 |
| Seppälä, K | 1 |
| Pikkarainen, P | 1 |
| Sipponen, P | 1 |
| Kivilaakso, E | 1 |
| Gormsen, MH | 1 |
| Chong, SK | 1 |
| Lou, Q | 1 |
| Asnicar, MA | 1 |
| Zimmerman, SE | 1 |
| Croffie, JM | 1 |
| Lee, CH | 1 |
| Fitzgerald, JF | 1 |
| Bell, GD | 3 |
| Powell, KU | 2 |
| Fennerty, MB | 2 |
| Xia, HX | 2 |
| Beattie, S | 1 |
| Hamilton, H | 1 |
| Keane, CT | 2 |
| Sweeney, EC | 1 |
| O'Morain, CA | 3 |
| Paredes López, A | 1 |
| Moreno, G | 1 |
| Saberi-Firoozi, M | 1 |
| Massarrat, S | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Dehbashi, N | 1 |
| Windle, HJ | 1 |
| Marshall, DG | 1 |
| Smyth, CJ | 1 |
| de Miguel, I | 1 |
| Muñoz, JL | 1 |
| Ramos, A | 1 |
| García-Rodríguez, JA | 1 |
| Lazzaroni, M | 2 |
| Maconi, G | 2 |
| Bargiggia, S | 2 |
| Minguzzi, M | 1 |
| Bianchi Porro, G | 2 |
| Wewer, V | 2 |
| Christiansen, KM | 1 |
| Andersen, LP | 2 |
| Henriksen, FW | 1 |
| Hansen, JP | 2 |
| Tvede, M | 2 |
| Krasilnikoff, PA | 2 |
| Boixeda, D | 2 |
| de Rafael, L | 1 |
| Martín de Argila, C | 1 |
| Bermejo, F | 1 |
| García Plaza, A | 1 |
| Bunke, HJ | 1 |
| Schultheis, A | 1 |
| Meyer, G | 1 |
| Düsel, W | 1 |
| Orth, T | 1 |
| Protzer, U | 1 |
| Mayet, WJ | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Rutgeerts, P | 2 |
| Hiele, M | 1 |
| Geboes, K | 1 |
| Peeters, M | 1 |
| Penninckx, F | 1 |
| Aerts, R | 1 |
| Kerremans, R | 1 |
| Sung, JJ | 3 |
| Chung, SC | 3 |
| Ling, TK | 3 |
| Yung, MY | 2 |
| Leung, VK | 2 |
| Ng, EK | 2 |
| Li, MK | 1 |
| Cheng, AF | 3 |
| Li, AK | 2 |
| Rotzetter, PA | 1 |
| Le Liboux, A | 1 |
| Pichard, E | 1 |
| Cimasoni, G | 1 |
| Wilhelmsen, I | 3 |
| Berstad, A | 3 |
| Kim, NY | 1 |
| Oh, HS | 1 |
| Jung, MH | 1 |
| Wee, SH | 1 |
| Choi, JH | 1 |
| Lee, KH | 1 |
| Bano, P | 1 |
| Shahab, SM | 1 |
| Rau, BK | 1 |
| Harikrishnan, KM | 1 |
| Krishna, S | 1 |
| Guerra, A | 1 |
| Bogen, M | 1 |
| Müller, W | 1 |
| Pedrinis, E | 1 |
| Archimandritis, A | 1 |
| Balatsos, V | 1 |
| Delis, V | 1 |
| Mentis, A | 1 |
| Kastanas, K | 1 |
| Scandalis, N | 1 |
| Laguna del Estal, P | 1 |
| Moya, MS | 1 |
| Martín, T | 1 |
| Lucero, MJ | 1 |
| Salgado, R | 1 |
| Wang, WM | 2 |
| Chen, CY | 2 |
| Jan, CM | 2 |
| Chen, LT | 2 |
| Perng, DS | 2 |
| Lin, SR | 2 |
| Liu, CS | 2 |
| Cartmill, TD | 1 |
| Panigrahi, H | 1 |
| Worsley, MA | 1 |
| McCann, DC | 1 |
| Nice, CN | 1 |
| Keith, E | 1 |
| Rühl, GH | 1 |
| Bertrams, J | 1 |
| Lin, JT | 1 |
| Wang, JT | 1 |
| Wu, MS | 1 |
| Lee, WY | 1 |
| Yang, JC | 1 |
| Wang, TH | 1 |
| Asaka, M | 2 |
| Ohtaki, T | 1 |
| Kato, M | 2 |
| Kudo, M | 2 |
| Meguro, T | 2 |
| Horita, S | 1 |
| Inoue, K | 2 |
| Neeman, A | 1 |
| Kadish, U | 1 |
| Reinke, CM | 1 |
| Messick, CR | 1 |
| Stölzle, L | 1 |
| Holtmann, G | 1 |
| Layer, P | 1 |
| Karita, M | 2 |
| Morshed, MG | 1 |
| Ouchi, K | 1 |
| Okita, K | 2 |
| Martínez, MJ | 1 |
| Posnick, JC | 1 |
| Bortoluzzi, P | 1 |
| Armstrong, DC | 1 |
| Baron, JR | 1 |
| Kelly, RB | 1 |
| Weberg, R | 1 |
| Berstad, K | 2 |
| Hausken, T | 1 |
| Hundal, O | 2 |
| Knowles, S | 1 |
| Choudhury, T | 1 |
| Shear, NH | 1 |
| Reinhardt, V | 1 |
| Boeke, AJ | 1 |
| Dekker, JH | 1 |
| van Eijk, JT | 1 |
| Kostense, PJ | 1 |
| Bezemer, PD | 1 |
| Kihira, K | 1 |
| Sato, K | 2 |
| Yoshida, Y | 1 |
| Takimoto, T | 1 |
| Taniguchi, Y | 1 |
| Kimura, K | 1 |
| Graham, DY | 3 |
| Hepps, KS | 1 |
| Ramirez, FC | 1 |
| Lew, GM | 2 |
| Saeed, ZA | 2 |
| Lundhus, E | 1 |
| Gottrup, F | 1 |
| Hosking, SW | 1 |
| Laine, L | 2 |
| Vigneri, S | 1 |
| Savarino, V | 1 |
| Termini, R | 1 |
| Mela, GS | 1 |
| Miyazaki, T | 1 |
| Cutler, AF | 2 |
| Schubert, TT | 2 |
| Wathne, B | 1 |
| Holst, E | 1 |
| Hovelius, B | 1 |
| Mårdh, PA | 1 |
| Voolmann, T | 1 |
| Boreham, P | 1 |
| Hentschel, E | 2 |
| Brandstätter, G | 2 |
| Dragosics, B | 2 |
| Hirschl, AM | 2 |
| Nemec, H | 2 |
| Schütze, K | 2 |
| Taufer, M | 2 |
| Wurzer, H | 1 |
| Andersen, T | 1 |
| Andersen, JR | 1 |
| Franzmann, MB | 1 |
| Guppy, DH | 1 |
| Lipinski, C | 1 |
| Briselden, AM | 1 |
| Mantzaris, GJ | 1 |
| Hatzis, A | 1 |
| Tamvakologos, G | 1 |
| Petraki, K | 1 |
| Spiliades, C | 1 |
| Triadaphyllou, G | 1 |
| Miralles, J | 1 |
| Barnadas, MA | 1 |
| de Moragas, JM | 1 |
| Oyarzún, E | 1 |
| Gómez, R | 1 |
| Montiel, F | 1 |
| Tsuda, M | 1 |
| Sugiyama, T | 1 |
| Nakazawa, T | 1 |
| Soll, AH | 1 |
| Arranz-Caso, JA | 1 |
| Albarrán-Hernández, F | 1 |
| Cuadrado-Gómez, LM | 1 |
| Gonzalez-Palacios, R | 1 |
| Vakil, N | 1 |
| Schweitzer, MA | 1 |
| Sweiss, I | 1 |
| Silver, DL | 1 |
| Stellato, TA | 1 |
| Ferrari, A | 1 |
| Rebecchi, AM | 1 |
| Manenti, F | 1 |
| D'Alimonte, P | 1 |
| Trespi, E | 1 |
| Perego, M | 1 |
| Alvisi, C | 1 |
| Villani, L | 1 |
| Luinetti, O | 1 |
| Fiocca, R | 1 |
| Franceschi, M | 1 |
| Cesana, B | 1 |
| Solcia, E | 1 |
| Figueroa, G | 1 |
| Acuña, R | 1 |
| Troncoso, M | 1 |
| Portell, DP | 1 |
| Toledo, MS | 1 |
| Albornoz, V | 1 |
| Vigneaux, J | 1 |
| Shirotani, T | 1 |
| Okada, M | 1 |
| Murayama, H | 1 |
| Maeda, K | 1 |
| Seo, M | 1 |
| Okabe, N | 1 |
| Nakahara, T | 1 |
| Oh, K | 1 |
| Nakayama, Y | 1 |
| Hoshiko, K | 1 |
| Oda, K | 1 |
| Okumura, M | 1 |
| Wenisch, C | 1 |
| Parschalk, B | 1 |
| Hasenhündl, M | 1 |
| Graninger, W | 1 |
| Santander, C | 1 |
| Grávalos, RG | 1 |
| Gómez-Cedenilla, A | 1 |
| Cantero, J | 1 |
| Tsimmerman, IaS | 1 |
| Kiseleva, RP | 1 |
| Freĭnd, GG | 1 |
| Avsar, E | 1 |
| Kalayci, C | 1 |
| Tözün, N | 1 |
| Lawrence, R | 1 |
| Kiziltas, S | 1 |
| Gültekin, O | 1 |
| Ulusoy, NB | 1 |
| Bate, CM | 1 |
| Axon, AT | 1 |
| Tildesley, G | 1 |
| Martin, JL | 1 |
| Taylor, MD | 1 |
| Richardson, PD | 1 |
| Lai, JY | 1 |
| De Boer, WA | 1 |
| Driessen, WM | 1 |
| Geuskens, LM | 1 |
| Winceslaus, SJ | 1 |
| Calver, G | 1 |
| Goh, KL | 1 |
| Navaratnam, P | 1 |
| Peh, SC | 1 |
| Taylor, JL | 1 |
| Zagari, M | 1 |
| Murphy, K | 1 |
| Freston, JW | 1 |
| Fekety, R | 2 |
| Greenberg, RN | 3 |
| Mulligan, ME | 1 |
| Dayal, VM | 1 |
| Kumar, P | 1 |
| Kamal, J | 1 |
| Shahi, SK | 1 |
| Agrawal, BK | 1 |
| Lerang, F | 1 |
| Moum, B | 1 |
| Ragnhildstveit, E | 1 |
| Haug, JB | 1 |
| Hauge, T | 1 |
| Tolås, P | 1 |
| Aubert, E | 1 |
| Henriksen, M | 1 |
| Efskind, PS | 1 |
| Nicolaysen, K | 1 |
| Søberg, T | 1 |
| Odegaard, A | 1 |
| Berge, T | 1 |
| Harris, A | 1 |
| Malshe, PC | 1 |
| Suriani, R | 1 |
| Ravizza, M | 1 |
| Pallante, C | 1 |
| Mazzucco, D | 1 |
| Cardesi, E | 1 |
| Colozza, M | 1 |
| Malandrino, M | 1 |
| Oneglio, R | 1 |
| Orso Giacone, G | 1 |
| Dusio, P | 1 |
| Vajo, M | 1 |
| Batchelder, M | 1 |
| Fox, JG | 1 |
| Hayward, A | 1 |
| Yan, L | 1 |
| Shames, B | 1 |
| Murphy, JC | 1 |
| Palley, L | 1 |
| Ramirez-Ramos, A | 1 |
| Gilman, RH | 1 |
| Leon-Barua, R | 1 |
| Recavarren-Arce, S | 1 |
| Watanabe, J | 1 |
| Salazar, G | 1 |
| Checkley, W | 1 |
| McDonald, J | 1 |
| Valdez, Y | 1 |
| Cordero, L | 1 |
| Carrazco, J | 1 |
| Carpintero, P | 1 |
| Blanco, M | 1 |
| Leung, WK | 1 |
| Suen, R | 1 |
| Chan, FK | 1 |
| Lau, JY | 1 |
| Lee, YT | 1 |
| Carnicer, J | 1 |
| Vermeire, S | 1 |
| Dahl, MV | 1 |
| Katz, HI | 1 |
| Krueger, GG | 1 |
| Millikan, LE | 1 |
| Odom, RB | 1 |
| Parker, F | 1 |
| Wolf, JE | 1 |
| Aly, R | 1 |
| Bayles, C | 1 |
| Reusser, B | 1 |
| Weidner, M | 1 |
| Coleman, E | 1 |
| Patrignelli, R | 1 |
| Tuley, MR | 1 |
| Baker, MO | 1 |
| Herndon, JH | 1 |
| Czernielewski, JM | 1 |
| Saraçoğlu, F | 1 |
| Göl, K | 1 |
| Sahin, I | 1 |
| Türkkani, B | 1 |
| Atalay, C | 1 |
| Oztopçu, C | 1 |
| Nair, S | 1 |
| Corpuz, M | 1 |
| Pitchumoni, CS | 1 |
| Calvet, X | 1 |
| Campo, R | 1 |
| Brullet, E | 1 |
| Rué, M | 1 |
| Rubin, M | 1 |
| Sekine, H | 1 |
| Ohara, S | 1 |
| Iijima, K | 1 |
| Pattman, RS | 1 |
| Chen, SY | 1 |
| Wang, JY | 1 |
| Chen, J | 1 |
| Zhang, XD | 1 |
| Zhang, SS | 1 |
| Brucks, U | 1 |
| Malfertheiner, P | 2 |
| Kosche, KA | 1 |
| Greenwald, DA | 1 |
| Berkman, D | 1 |
| Mach, T | 1 |
| Zahradnik-Bilska, J | 1 |
| Fallone, CA | 1 |
| Loo, V | 1 |
| Joseph, L | 1 |
| Barkun, J | 1 |
| Kostyk, R | 1 |
| Barkun, AN | 1 |
| Riep, B | 1 |
| Purucker, P | 1 |
| Bernimoulin, JP | 1 |
| Danko, L | 1 |
| Martino, G | 1 |
| Paoletti, M | 1 |
| Marcheggiano, A | 1 |
| D'Ambra, G | 1 |
| Delle Fave, G | 1 |
| Annibale, B | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Shamaly, H | 1 |
| Berkowitz, D | 1 |
| Rosenthal, E | 1 |
| Naveh, Y | 1 |
| Vermeulen, C | 1 |
| Lemaire, V | 1 |
| Lioté, F | 1 |
| Buchmann, R | 2 |
| Müller, RF | 1 |
| Heinecke, A | 1 |
| Lange, DE | 2 |
| Hanauer, SB | 1 |
| Alcantara, CS | 1 |
| Bergamin, B | 1 |
| Hess, T | 1 |
| Jost, R | 1 |
| Ballmer, PE | 1 |
| Imoberdorf, R | 1 |
| Houry, S | 1 |
| Adamsson, I | 1 |
| Edlund, C | 1 |
| Seensalu, R | 1 |
| Engstrand, L | 1 |
| Sakurai, T | 1 |
| Hajiro, K | 1 |
| Takakuwa, H | 1 |
| Nishi, A | 1 |
| Aihara, M | 1 |
| Chiba, T | 1 |
| Maheshwar, AA | 1 |
| Jones, MB | 1 |
| Evans, RA | 1 |
| Shiotani, A | 1 |
| Okada, K | 1 |
| Yanaoka, K | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Sakurane, M | 1 |
| Matsunaka, M | 1 |
| Serino, G | 1 |
| Rosling, B | 1 |
| Ramberg, P | 1 |
| Hellström, MK | 1 |
| Socransky, SS | 1 |
| Lindhe, J | 1 |
| Hanna, L | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 1 |
| Kyne, L | 1 |
| Nagahara, A | 2 |
| Miwa, H | 2 |
| Ohkura, R | 1 |
| Yamada, T | 1 |
| Hojo, M | 2 |
| Sato, N | 2 |
| Kate, V | 1 |
| Ananthakrishnan, N | 1 |
| Badrinath, S | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Ahmad, MM | 1 |
| Glatz-Krieger, K | 1 |
| Terracciano, L | 1 |
| Bauerfeind, P | 1 |
| Beglinger, C | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Paerregaard, A | 1 |
| Gernow, A | 1 |
| Matzen, P | 1 |
| van der Wouden, EJ | 1 |
| Thijs, JC | 1 |
| van Zwet, AA | 1 |
| Kleibeuker, JH | 1 |
| Sharma, VK | 1 |
| Sahai, AV | 1 |
| Corder, FA | 1 |
| Howden, CW | 1 |
| Kamagate, A | 1 |
| Kone, D | 1 |
| Coulibaly, NT | 1 |
| Brou, E | 1 |
| Sixou, M | 1 |
| Schmitt-Grohé, S | 1 |
| Wiggert, E | 1 |
| Steffan, J | 1 |
| Handke, R | 1 |
| Zielen, S | 1 |
| Nguyen, HN | 1 |
| Loesche, WJ | 1 |
| Giordano, JR | 1 |
| Soehren, S | 1 |
| Kaciroti, N | 1 |
| Knippig, C | 1 |
| Arand, F | 1 |
| Leodolter, A | 1 |
| Nilius, M | 1 |
| Bayerdörffer, E | 1 |
| Klein, U | 1 |
| Nunn, ME | 1 |
| Van Dyke, TE | 1 |
| Matuchansky, C | 1 |
| Leach, RD | 1 |
| Eykyn, SJ | 1 |
| Phillips, I | 1 |
| Corrin, B | 1 |
| Belcher, DW | 1 |
| Wunapa, FK | 1 |
| Ward, WB | 1 |
| Sharma, VP | 1 |
| Rathore, HS | 1 |
| Sharma, MM | 1 |
| Chapman, JD | 1 |
| Kawamura, N | 1 |
| Skornetskiĭ, BD | 1 |
| Gavrilenko, IaV | 1 |
| Kavousi, S | 1 |
| Miller, LH | 1 |
| Neva, FA | 1 |
| Gill, F | 1 |
| Shevliakov, LV | 1 |
| Jokipii, L | 1 |
| Jokipii, AM | 1 |
| Hayward, MJ | 1 |
| Roy, RB | 1 |
| Kean, BH | 1 |
| Dykers, JR | 1 |
| van Winkelhoff, AJ | 1 |
| Tijhof, CJ | 1 |
| de Graaff, J | 1 |
| Takács, G | 1 |
| Wilcox, MH | 1 |
| Spencer, RC | 1 |
| Louw, JA | 1 |
| Zak, J | 1 |
| Lucke, W | 1 |
| Le Roux, E | 1 |
| Jaskiewicz, K | 1 |
| Winter, T | 1 |
| Lastovica, A | 1 |
| Marks, IN | 2 |
| Borody, TJ | 3 |
| George, LL | 3 |
| Brandl, S | 3 |
| Andrews, P | 2 |
| Jankiewicz, E | 1 |
| Ostapowicz, N | 1 |
| Goggin, PM | 1 |
| Marrero, JM | 1 |
| Spychal, RT | 1 |
| Jackson, PA | 1 |
| Corbishley, CM | 1 |
| Northfield, TC | 1 |
| Coelho, LG | 2 |
| Passos, MC | 2 |
| Chausson, Y | 2 |
| Costa, EL | 1 |
| Maia, AF | 1 |
| Brandao, MJ | 1 |
| Rodrigues, DC | 1 |
| Castro, LP | 1 |
| Gerber, B | 1 |
| Wilken, H | 1 |
| Zacharias, K | 1 |
| Barten, G | 1 |
| Splitt, G | 1 |
| Aitken, S | 1 |
| Birek, P | 1 |
| Kulkarni, GV | 1 |
| Lee, WL | 1 |
| McCulloch, CA | 1 |
| Klein, PD | 1 |
| Evans, DG | 1 |
| Evans, DJ | 1 |
| Malaty, HM | 1 |
| Redondo-Lopez, V | 1 |
| Schmitt, C | 1 |
| Meriwether, C | 1 |
| Hirschl, A | 1 |
| Dru, M | 1 |
| Castro, Lde P | 1 |
| Telalbasic, S | 1 |
| Pikula, ZP | 1 |
| Kapidzic, M | 1 |
| Lind, CD | 1 |
| Blaser, MJ | 1 |
| Hjortrup, A | 1 |
| Moesgaard, F | 1 |
| Kjaergård, J | 1 |
| Rauws, EA | 1 |
| Tytgat, GN | 1 |
| Devine, M | 1 |
| Moore-Jones, D | 1 |
| Walton, M | 1 |
| Elta, GH | 1 |
| Woolley, PD | 1 |
| Kinghorn, GR | 1 |
| Talbot, MD | 1 |
| Duerden, BI | 1 |
| Tronstad, L | 1 |
| Kreshtool, D | 1 |
| Barnett, F | 1 |
| Vasil'ev, MM | 1 |
| Tulainova, IK | 1 |
| Narzykulov, RM | 1 |
| Pritchard, TJ | 1 |
| Schoetz, DJ | 1 |
| Roberts, PL | 1 |
| Murray, JJ | 1 |
| Coller, JA | 1 |
| Veidenheimer, MC | 1 |
| Ruttenberg, D | 1 |
| Ress, SR | 1 |
| Price, SK | 1 |
| Girdwood, AH | 1 |
| Plotnick, BH | 1 |
| Cohen, I | 1 |
| Tsang, T | 1 |
| Cullinane, T | 1 |
| Yusuf, H | 1 |
| Cobley, TD | 1 |
| Martens, F | 1 |
| Van Velthofen, V | 1 |
| Calliauw, L | 1 |
| Mengel, MB | 1 |
| Berg, AO | 1 |
| Weaver, CH | 1 |
| Herman, DJ | 1 |
| Herman, SJ | 1 |
| Hughes, VL | 1 |
| Koepsell, TD | 1 |
| Moi, H | 1 |
| Erkkola, R | 1 |
| Jerve, F | 1 |
| Nelleman, G | 1 |
| Bymose, B | 1 |
| Alaksen, K | 1 |
| Tornqvist, E | 1 |
| Cole, P | 1 |
| Noonan, S | 1 |
| Morgan, A | 1 |
| Lenne, J | 1 |
| Hyland, L | 1 |
| Borody, EG | 1 |
| Levett, PN | 1 |
| Brady, CE | 1 |
| Cooley, BJ | 1 |
| Davis, JC | 1 |
| Stange, EF | 1 |
| Fleig, WE | 1 |
| Rehklau, E | 1 |
| Ditschuneit, H | 1 |
| Dooley, CP | 1 |
| Gusberti, FA | 1 |
| Syed, SA | 1 |
| Lang, NP | 1 |
| Sanford, KA | 1 |
| Mayle, JE | 1 |
| Dean, HA | 1 |
| Greenbaum, DS | 1 |
| Krajden, S | 1 |
| Lossick, JG | 1 |
| Wilk, E | 1 |
| Yang, J | 1 |
| Keystone, JS | 1 |
| Elliott, K | 1 |
| Mohanty, KC | 1 |
| Deighton, R | 1 |
| Seal, D | 1 |
| Borriello, SP | 1 |
| Barclay, F | 1 |
| Welch, A | 1 |
| Piper, M | 1 |
| Bonnycastle, M | 1 |
| Talbot, RW | 1 |
| Walker, RC | 1 |
| Beart, RW | 1 |
| Shepherd, HA | 1 |
| Barr, GD | 1 |
| Jewell, DP | 1 |
| Drutz, HP | 1 |
| Sousan, L | 1 |
| Friedrich, EG | 1 |
| Ambrose, NS | 1 |
| Allan, RN | 1 |
| Youngs, D | 1 |
| Barnes, P | 1 |
| Lennard-Jones, JE | 1 |
| Young, G | 1 |
| McDonald, M | 1 |
| Vannatta, JB | 1 |
| Adamson, D | 1 |
| Mullican, K | 1 |
| Pothoulakis, H | 1 |
| Triadafilopoulos, G | 1 |
| Gitlin, N | 1 |
| Kale, OO | 1 |
| Everett, ED | 1 |
| Stiles, MA | 1 |
| Kretchman, LA | 1 |
| Morton, RS | 1 |
| Woodcock, KR | 1 |
| Dennerstein, GJ | 1 |
| Bhandari, B | 1 |
| Upadhyay, R | 1 |
| Powell, SJ | 1 |
| Rubidge, CJ | 1 |
| Elsdondew, R | 1 |
| Csonka, GW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Evaluation of the Impact of Bacterial Vaginosis and Its Treatment on Mucosal Susceptibility to HIV-1 Infection and Endpoints of Cervico-Vaginal Safety[NCT01347632] | 35 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)[NCT04070352] | 50 participants (Anticipated) | Observational | 2019-08-01 | Enrolling by invitation | |||
| Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile[NCT05192148] | 840 participants (Anticipated) | Interventional | 2021-11-30 | Recruiting | |||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium Difficile Toxin A), MK-6072 (Human Monoclonal Antibody to [NCT01241552] | Phase 3 | 1,452 participants (Actual) | Interventional | 2011-10-10 | Completed | ||
| A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to Clostridium Difficile Toxin B), and MK-3415A (Human Monoclonal Antibodies to Clostridium[NCT01513239] | Phase 3 | 1,203 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study[NCT04300426] | Phase 2 | 75 participants (Actual) | Interventional | 2020-09-24 | Completed | ||
| COmparative Effectiveness of intestinaL microbiOta Versus vaNcomycin for Primary c. Difficile Infection - randomiZEd Trials[NCT03796650] | Phase 3 | 188 participants (Anticipated) | Interventional | 2019-07-17 | Recruiting | ||
| Lyophilized Fecal Microbiome Transfer for Primary Clostridioides Difficile Infection (DONATE Study): a Multicenter Randomized Controlled Trial[NCT05709184] | 196 participants (Anticipated) | Interventional | 2023-03-31 | Not yet recruiting | |||
| PROSPECTIVE STUDY OF PREDISPOSING FACTORS OF REFRACTARY Clostridium Difficile INFECTION. INFLUENCE OF THE GUT MICROBIOMA[NCT04259931] | 50 participants (Anticipated) | Observational | 2020-03-01 | Not yet recruiting | |||
| Study of Surgical Treatment (Open Appendicectomy) Versus Antibiotic Treatment (Ertapenem) in the Treatment of Acute Uncomplicated Appendicitis[NCT01022567] | 530 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | |||
| Are the Changes in Immature Granulocyte Count and Percentage Significant in the Decision to Continue Medical Treatment of Uncomplicated Acute Appendicitis Cases[NCT04462588] | 64 participants (Actual) | Observational [Patient Registry] | 2019-06-01 | Completed | |||
| The Use of Low Dose Metronidazole to Decrease Postoperative Pain After Endometriosis Surgery: A Prospective, Randomized, Placebo-Controlled Trial[NCT04554693] | Phase 4 | 90 participants (Anticipated) | Interventional | 2020-10-19 | Recruiting | ||
| A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori[NCT01061437] | Phase 3 | 1,859 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study[NCT02674802] | 3,500 participants (Anticipated) | Observational | 2015-12-31 | Recruiting | |||
| Study Protocol for A Randomized Controlled Trial of Incision and Drainage Versus Ultrasound-Guided Needle Aspiration for Uncomplicated Skin Abscesses[NCT04127071] | 40 participants (Anticipated) | Interventional | 2020-06-01 | Not yet recruiting | |||
| Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis[NCT02185456] | Early Phase 1 | 200 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| [NCT01792700] | Phase 4 | 648 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole, in Patients With C.Difficile - Associated Diarrhea[NCT00106509] | Phase 3 | 520 participants | Interventional | 2005-03-31 | Completed | ||
| A Randomized, Double-Blind Study of GT267-004 Versus Vancomycin, and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea[NCT00196794] | Phase 3 | 520 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Phase III,Randomized,Double-blinded Clinical Trial to Evaluate the Effectiveness and Safety of Oral Vancomycin Vs Placebo in the Prevention of Recurrence of C.Difficile Infection in Patients Under Treatment With Systemic Antibiotic Therapy[NCT05320068] | Phase 3 | 108 participants (Anticipated) | Interventional | 2022-08-02 | Recruiting | ||
| Vitamin D and Sexual Health (the DASH Study)[NCT01450462] | 118 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| Conservative Treatment of Acute Appendicitis in Children Pilot Trial[NCT01572558] | 51 participants (Actual) | Interventional | 2012-02-29 | Completed | |||
| Preoperative Immature Granulocyte Count and Percentage for Complicated and Uncomplicated Appendisitis[NCT04440150] | 70 participants (Actual) | Interventional | 2018-06-01 | Completed | |||
| "Post-Operative Crohn's Disease Endoscopic Recurrence POCER Study: Endoscopic Guided Therapeutic Intervention & Determination of Cause"[NCT00989560] | Phase 3 | 175 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics[NCT02951702] | Phase 4 | 51 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Lactobacilli Implementation to Restore a Balanced Vaginal Ecosystem: a Promising Solution Against Vaginosis, Vaginitis and HPV Infection[NCT03372395] | Phase 2 | 117 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Probiotics Role in HPV Clearance When Coexisting Vaginal Infections[NCT05109533] | 483 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Trichomonas Vaginalis Repeat Infections Among HIV Negative Women[NCT01832480] | Phase 3 | 623 participants (Actual) | Interventional | 2014-10-06 | Completed | ||
| Post-Operative Crohn's Disease Outcome in Children (The POPCORN Trial): a Prospective Comparative Non-interventional Open Study[NCT03681652] | 100 participants (Anticipated) | Observational | 2019-02-11 | Recruiting | |||
| Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection[NCT04138706] | Phase 3 | 552 participants (Anticipated) | Interventional | 2020-11-19 | Recruiting | ||
| Penicillin and Metronidazole in Treatment of Peritonsillar Abscess - Prospective, Double-blind, Randomized, Placebo-controlled Study[NCT01255670] | 200 participants (Actual) | Interventional | 2010-02-28 | Completed | |||
| Fecal Calprotectin Level in Differentiating Between Inflammatory and Non-inflammatory Diarrhea in Patients With Nosocomial Diarrhea[NCT04491799] | 135 participants (Actual) | Observational | 2019-02-01 | Completed | |||
| Prospective Multicenter Cross Sectional Study of the American International Biotechnology (AIBiotech) Gynecologene Test for the Evaluation of Bacterial Vaginosis/Vaginitis in Symptomatic Women[NCT02558179] | 300 participants (Anticipated) | Observational [Patient Registry] | 2015-09-30 | Enrolling by invitation | |||
| Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity[NCT02445989] | Phase 4 | 120 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women[NCT03062020] | 258 participants (Anticipated) | Interventional | 2016-11-16 | Recruiting | |||
| Baseline Study of Vaginal Microbiota in Healthy Chinses Female Population[NCT04887636] | 10,000 participants (Anticipated) | Observational [Patient Registry] | 2021-05-21 | Recruiting | |||
| A Multicentric Randomized Double-Blind Phase 3 Trial Evaluating the Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Active Hidradenitis Suppurativa Patients Versus Tetracycline Derivative[NCT05821478] | Phase 3 | 92 participants (Anticipated) | Interventional | 2023-11-15 | Not yet recruiting | ||
| The Comparison of the Adjuvant Effect of Probiotics Between Delivery Via Colonoscopic Spray and Oral Administration in Patients With Clostridioides Difficile Colitis Receiving Vancomycin Treatment[NCT05770726] | 60 participants (Anticipated) | Interventional | 2023-04-21 | Not yet recruiting | |||
| Phase 2 Placebo-controlled Randomized Trial of LACTIN-V (Lactobacillus Crispatus CTV-05) Among Women at High Risk of HIV Acquisition in Durban, South Africa[NCT05022212] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-10 | Recruiting | ||
| Comparative Effectiveness Clinical Early of Transvaginal and Laparoscopic Approaches for Drainage of Tubo -Ovarian Abscess. Randomized Noninferiority[NCT03166982] | 80 participants (Anticipated) | Interventional | 2016-10-26 | Recruiting | |||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| Comparative Study of 2 Weeks Versus 4 Weeks Treatment With Vancomycin for Clostridium Difficile Colitis[NCT00861887] | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to Difficult enrollment) | |||
| Exploring the Mechanism of a Probiotic Combination VSL#3 in Irritable Bowel Syndrome: a Randomized Double Blind Placebo Controlled Study[NCT00786123] | 40 participants (Anticipated) | Interventional | 2006-05-31 | Completed | |||
| Effects of Flourish HEC Vaginal Care System on Vaginal Microbiome in Women With Recurrent Bacterial Vaginosis[NCT05701722] | 400 participants (Anticipated) | Interventional | 2023-03-29 | Recruiting | |||
| A Phase IIa Study of the Colonization Efficiency, Safety and Acceptability of LACTIN-V Administered Vaginally to Women With Bacterial Vaginosis[NCT00635622] | Phase 2 | 40 participants (Anticipated) | Interventional | 2008-04-30 | Completed | ||
| Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda[NCT02905890] | Phase 4 | 250 participants (Actual) | Interventional | 2017-10-02 | Completed | ||
| A Phase I Study of the Safety of LACTIN-V Administered Vaginally to Healthy Women[NCT00537576] | Phase 1 | 12 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Effects of Flourish HEC Vaginal Care System on Reduction of Pain in Women With Localized Provoked Vulvodynia[NCT05478746] | 40 participants (Anticipated) | Interventional | 2022-09-26 | Enrolling by invitation | |||
| A Multicenter, Open Label, Non-comparative, 3 Months Study to Assess the Performance and Safety of the New Medical Device Polybactum® in Reducing the Frequency of Recurrent Bacterial Vaginosis[NCT02863536] | 56 participants (Actual) | Interventional | 2016-09-08 | Completed | |||
| Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir[NCT02707198] | Phase 2 | 2 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Study was not feasible to complete at study site) | ||
| e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls[NCT01579617] | 637 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV)[NCT02042287] | Phase 4 | 32 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Clostridioides Difficile Infection: Prospective Cohort Analyzing CLInic Evolution and Bacterial Clearance[NCT06030245] | 100 participants (Anticipated) | Observational | 2023-09-18 | Recruiting | |||
| Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD)[NCT00182429] | Phase 3 | 100 participants | Interventional | 2004-02-29 | Completed | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 26.2 |
| MK-6072 + SOC | 15.1 |
| MK-3415A + SOC | 17.0 |
| Placebo + SOC | 33.2 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol-specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT01241552)
Timeframe: Up to 28 days
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 0.4 |
| MK-6072 + SOC | 0.3 |
| MK-3415A + SOC | 0.0 |
| Placebo + SOC | 0.0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 33.3 |
| MK-6072 + SOC | 26.2 |
| MK-3415A + SOC | 25.0 |
| Placebo + SOC | 39.4 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 24.6 |
| MK-6072 + SOC | 23.1 |
| MK-3415A + SOC | 19.8 |
| Placebo + SOC | 35.8 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. A drug-related AE was an AE determined by the investigator to be related to the drug. (NCT01241552)
Timeframe: Up to 28 days
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 7.2 |
| MK-6072 + SOC | 8.2 |
| MK-3415A + SOC | 6.2 |
| Placebo + SOC | 5.0 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. (NCT01241552)
Timeframe: Up to 28 days
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 27.7 |
| MK-6072 + SOC | 21.5 |
| MK-3415A + SOC | 14.7 |
| Placebo + SOC | 20.0 |
A SAE is any AE occurring at any dose or during any use of Sponsor's product that: results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or is a cancer, or is associated with an overdose (whether accidental or intentional); or is other important medical events. A serious drug-related AE was a SAE determined by the investigator to be related to the drug. (NCT01241552)
Timeframe: Up to 28 days
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 1.3 |
| MK-6072 + SOC | 1.0 |
| MK-3415A + SOC | 0.5 |
| Placebo + SOC | 0.3 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the baseline CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 35.5 |
| MK-6072 + SOC | 22.4 |
| MK-3415A + SOC | 21.3 |
| Placebo + SOC | 33.3 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Clinically severe CDI is defined as a Zar Score ≥ 2 based on the presence of 1 or more of the following: 1) age >60 years old (1 point); 2)body temperature >38.3°C (>100°F) (1 point); 3) albumin level ˂2.5 mg/dL (1 point); 4) peripheral white blood cell count >15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points). (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 25.8 |
| MK-6072 + SOC | 10.4 |
| MK-3415A + SOC | 12.9 |
| Placebo + SOC | 25.0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic Clostridium (C.) difficile following clinical cure of the initial CDI episode (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 25.9 |
| MK-6072 + SOC | 17.4 |
| MK-3415A + SOC | 15.9 |
| Placebo + SOC | 27.6 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. Compromised immunity is defined as follows: an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 18.2 |
| MK-6072 + SOC | 17.2 |
| MK-3415A + SOC | 11.5 |
| Placebo + SOC | 28.3 |
Global Cure is defined as the clinical cure of the initial CDI episode and no CDI recurrence through Week 12. Clinical cure is defined as participants who received ≤ 14 day regimen of SOC therapy and have no diarrhea (≤2 loose stools per 24 hours) for two consecutive days following completion of SOC therapy for the initial CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 47.0 |
| MK-6072 + SOC | 60.1 |
| MK-3415A + SOC | 58.7 |
| Placebo + SOC | 55.2 |
Infusion-specific AEs included local infusion site AEs; and systemic AEs which include nausea, vomiting, chills, fatigue, feeling hot, infusion site conditions (bruising, coldness, erythema, extravasation, pain, phlebitis, pruritus), pyrexia, arthralgia, musculoskeletal pain, myalgia, dizziness, headache, dysphonia, nasal congestion, pruritus, rash, pruritic rash, urticaria, flushing, hot flush, hypertension, and hypotension. (NCT01241552)
Timeframe: Up to 24 hours
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 11.1 |
| MK-6072 + SOC | 11.8 |
| MK-3415A + SOC | 8.8 |
| Placebo + SOC | 7.5 |
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended signs (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol-specific procedure, whether or not considered related to the medicinal product or protocol specific procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. (NCT01241552)
Timeframe: Up to 28 days
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 67.2 |
| MK-6072 + SOC | 65.4 |
| MK-3415A + SOC | 59.7 |
| Placebo + SOC | 62.0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool test for toxigenic C. difficile following clinical cure of the initial CDI episode. (NCT01241552)
Timeframe: Up to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415 + SOC | 33.3 |
| MK-6072 + SOC | 26.1 |
| MK-3415A + SOC | 10.8 |
| Placebo + SOC | 36.1 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. (NCT01513239)
Timeframe: Up to 4 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 0 |
| MK-6072 + SOC | 0 |
| Placebo + SOC | 0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile after clinical cure of the initial CDI episode. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 14.9 |
| MK-6072 + SOC | 15.7 |
| Placebo + SOC | 25.7 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 17.4 |
| MK-6072 + SOC | 15.6 |
| Placebo + SOC | 29.6 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 20.2 |
| MK-6072 + SOC | 23.9 |
| Placebo + SOC | 42.7 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. An epidemic strain includes ribotypes 027, 014, 002, 001, 106 or 020. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 14.7 |
| MK-6072 + SOC | 18.6 |
| Placebo + SOC | 29.1 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 20.6 |
| MK-6072 + SOC | 19.0 |
| Placebo + SOC | 33.0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. Participants with clinically severe CDI have a Zar Score greater than or equal to 2 points based on the presence of 1 or more of the following: 1) age >60 years old (1 point); 2) body temperature >38.3°C (>100°F) (1 point); 3) albumin level ˂2.5 mg/dl (1 point); 4) peripheral white blood cell count >15,000 cells/mm^3 within 48 hours (1 point); 5) endoscopic evidence of pseudomembranous colitis (2 points); and 6) treatment in Intensive Care Unit (2 points). (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 11.3 |
| MK-6072 + SOC | 10.9 |
| Placebo + SOC | 20.0 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. Compromised immunity is an active hematological malignancy (including leukemia, lymphoma, multiple myeloma), an active malignancy requiring recent cytotoxic chemotherapy, receipt of a prior hematopoietic stem cell transplant, receipt of a prior solid organ transplant, asplenia, or neutropenia/pancytopenia due to other conditions. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 16.5 |
| MK-6072 + SOC | 12.1 |
| Placebo + SOC | 26.2 |
CDI recurrence is defined as the development of a new episode of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive lab stool test (local or central) for toxigenic C. difficile. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. The 027 ribotype is a more virulent, epidemic strain responsible for several outbreaks of disease associated with an increased risk of severity and mortality. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 12.8 |
| MK-6072 + SOC | 20.9 |
| Placebo + SOC | 32.8 |
Global cure is defined as the clinical cure of the initial CDI episode with no CDI recurrence through Week 12. Clinical cure is defined as no diarrhea [2 or fewer loose stools per 24 hours] for 2 consecutive days following completion of SOC therapy for the initial CDI episode in participants who received =< 14 day regimen. (NCT01513239)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 57.4 |
| MK-6072 + SOC | 66.8 |
| Placebo + SOC | 52.1 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. (NCT01513239)
Timeframe: Up to 4 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 57.4 |
| MK-6072 + SOC | 58.1 |
| Placebo + SOC | 60.4 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. A drug-related adverse event is determined by the investigator to be related to the drug. (NCT01513239)
Timeframe: Up to 4 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 6.7 |
| MK-6072 + SOC | 6.8 |
| Placebo + SOC | 6.8 |
An adverse event (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the medicinal product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the medicinal product, is also an adverse event. (NCT01513239)
Timeframe: Up to 24 hours
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 7.2 |
| MK-6072 + SOC | 8.8 |
| Placebo + SOC | 7.6 |
A serious adverse event (SAE) is any AE occurring at any dose or during any use of the medicinal product that results in death; or is life threatening; or results in a persistent or significant disability/incapacity; or results in or prolongs an existing inpatient hospitalization; or is a congenital anomaly/birth defect; or other important medical events. A serious drug-related adverse event is determined by the investigator to be related to the drug. (NCT01513239)
Timeframe: Up to 4 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| MK-3415A + SOC | 0.8 |
| MK-6072 + SOC | 0.0 |
| Placebo + SOC | 0.3 |
A successful treatment is determined by resolution of the appendicitis by means of the assigned treatment. (NCT01022567)
Timeframe: Up to 10 years
| Intervention | percentage of successful treatment (Number) |
|---|---|
| Appendectomy | 99.6 |
| Antibiotic Therapy | 72.7 |
The incidence of clostridium difficile infection as detected for GDH/toxin positive or PCR if the GDH/toxin is equivocal. (NCT02951702)
Timeframe: Within 4 weeks from the completion of antibiotic treatment
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 2 |
| Vancomycin | 0 |
This is the time from the start of antibiotics to the diagnosis of clostridium difficile. (NCT02951702)
Timeframe: Within 4 weeks from completion of antibiotic treatment
| Intervention | days (Mean) |
|---|---|
| Control | 2 |
| Vancomycin | 0 |
Severity as defined by the IDSA/SHEA guidelines (mild to moderate, defined as white-cell count less than 15,000 cells/µL or increase in serum creatinine (SCr) by <1.5 times the baseline; severe, defined as white-cell count greater than 15,000 cells/µL or increase in SCr by >1.5 times the baseline; and fulminant, defined as the criteria above for severe with shock, hypotension, ileus, or megacolon) (NCT02951702)
Timeframe: Within 4 weeks from completion of antibiotic treatment
| Intervention | participants (Number) | |
|---|---|---|
| Mild-Mod | Severe | |
| Control | 1 | 1 |
| Vancomycin | 0 | 0 |
Presence of TV is assessed by nucleic acid amplification test (NAAT) of vaginal swab collected 4 weeks post treatment completion. (NCT01832480)
Timeframe: 4 weeks post treatment completion
| Intervention | Participants (Count of Participants) |
|---|---|
| Trichomonas (TV) Positive After 2 g Dose | 58 |
| Trichomonas (TV) Positive After Metronidazole (MTZ) Multi Dose | 34 |
Number of participants recovering from peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo. (NCT01255670)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Penicillin and Metronidazole | 74 |
| Penicillin and Placebo | 80 |
Number of participants with recurrence of peritonsillar abscess having metronidazole in addition to penicillin or penicillin and placebo. (NCT01255670)
Timeframe: 56 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Penicillin and Metronidazole | 10 |
| Penicillin and Placebo | 10 |
"Acceptability and overall satisfaction with the study product was measured using the response to the following question: I would use the product again with the following response options (strongly agree, agree, neutral, disagree, strongly disagree)~Acceptability is reported as the number of women in each group who strongly agreed or agreed with the statement that they would use the product again." (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 3 |
| Medium Dose Applicator | 3 |
| High Dose Applicator | 2 |
| Placebo Control Substance Low Dose | 1 |
| Placebo Control Substance Medium Dose | 0 |
| Placebo Control Substance High Dose | 1 |
Safety was measured by comparing the number of women experiencing adverse events of grade 3 or higher during the study. (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 0 |
| Medium Dose Applicator | 0 |
| High Dose Applicator | 0 |
| Placebo Control Substance Low Dose | 0 |
| Placebo Control Substance Medium Dose | 0 |
| Placebo Control Substance High Dose | 0 |
Tolerability was measured as proportion of women remaining in the study, and NOT prematurely exiting the trial due to an adverse event. (NCT00537576)
Timeframe: 35 days
| Intervention | participants (Number) |
|---|---|
| Low Dose Applicator | 3 |
| Medium Dose Applicator | 3 |
| High Dose Applicator | 3 |
| Placebo Control Substance Low Dose | 1 |
| Placebo Control Substance Medium Dose | 1 |
| Placebo Control Substance High Dose | 1 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
75 reviews available for metronidazole and Recrudescence
| Article | Year |
|---|---|
Characterization and Treatment of Recurrent Bacterial Vaginosis.
Topics: Anti-Bacterial Agents; Antiprotozoal Agents; Clindamycin; Female; Humans; Metronidazole; Recurrence; | 2019 |
Fidaxomicin compared with vancomycin and metronidazole for the treatment of Clostridioides (Clostridium) difficile infection: A network meta-analysis.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fidaxomicin; Humans; Metron | 2020 |
Secnidazole for treatment of bacterial vaginosis: a systematic review.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Anti-Bacterial Agents; Drug Therapy, Comb | 2019 |
Updates in trichomonas treatment including persistent infection and 5-nitroimidazole hypersensitivity.
Topics: Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Hypersensitivity; Female; Humans; Male; | 2020 |
Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Dise | 2020 |
[Individualized treatment strategies for Clostridium difficile infections].
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fecal Micr | 2017 |
Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?
Topics: Animals; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Design; Human | 2017 |
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridium Infections; Cost-Benefit Analysis; Drug Costs; F | 2017 |
New and emerging therapies in treatment of Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infection; Fecal Micr | 2018 |
Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Human | 2018 |
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrim | 2019 |
[Clostridium difficile infection: epidemiology, disease burden and therapy].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Cost | 2013 |
Management of hepatic encephalopathy in the hospital.
Topics: Disease Management; Drug Therapy, Combination; Gastrointestinal Agents; Hepatic Encephalopathy; Huma | 2014 |
Persistent and recurrent Trichomonas vaginalis infections: epidemiology, treatment and management considerations.
Topics: Antitrichomonal Agents; Drug Resistance; Female; Humans; Male; Metronidazole; Recurrence; Sexually T | 2014 |
Treatment of Clostridium difficile infections.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Admin | 2015 |
Treatment of recurrent and severe Clostridium difficile infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; F | 2015 |
Controversies Around Epidemiology, Diagnosis and Treatment of Clostridium difficile Infection.
Topics: Aminoglycosides; Anti-Bacterial Agents; Enterocolitis, Pseudomembranous; Fecal Microbiota Transplant | 2015 |
Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
Topics: Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diar | 2015 |
Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues.
Topics: Drug Resistance; Female; Herpes Genitalis; HIV Infections; Humans; Metronidazole; Recurrence; Treatm | 2015 |
Antibiotic treatment for the sexual partners of women with bacterial vaginosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Clindamycin; Female; Humans; Indazoles; Lincosamides; Male | 2016 |
[Clostridium-difficile-associated diarrhea].
Topics: Aged; Anti-Bacterial Agents; Bacterial Toxins; Biological Therapy; Clostridioides difficile; Colecto | 2009 |
A 76-year-old man with recurrent Clostridium difficile-associated diarrhea: review of C. difficile infection.
Topics: Aged; Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Diarrhea; Enterocolitis, Ps | 2009 |
Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Cross Infection; Diarrhea; Entero | 2009 |
Hepatic encephalopathy: pathophysiology and emerging therapies.
Topics: Ammonia; Anti-Infective Agents; Drug Therapy, Combination; Dyskinesias; Gastrointestinal Agents; Hep | 2009 |
[Infections with Clostridium difficile following antibiotic therapy].
Topics: Administration, Oral; Algorithms; Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides diffi | 2009 |
Clostridium difficile and the surgeon.
Topics: Anti-Infective Agents; Clostridioides difficile; Colectomy; Enterocolitis, Pseudomembranous; Feces; | 2010 |
[Postoperative recurrence of Crohn's disease, and its prevention].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colonoscopy; Crohn Dis | 2010 |
Clostridium difficile: an update for the primary care clinician.
Topics: Anti-Infective Agents; Clostridioides difficile; Cross Infection; Diarrhea; Enterocolitis, Pseudomem | 2010 |
Treatment of refractory and recurrent Clostridium difficile infection.
Topics: Clostridioides difficile; Colectomy; Enterocolitis, Pseudomembranous; Humans; Metronidazole; Recurre | 2011 |
[Postoperative recurrence of subdural empyema].
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Combined Modality Therap | 2011 |
Recurrent refractory Clostridium difficile colitis treated successfully with rifaximin and tigecycline: a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Colitis; Drug Therapy | 2012 |
Comparative effectiveness of Clostridium difficile treatments: a systematic review.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Comparativ | 2011 |
Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence.
Topics: Anti-Bacterial Agents; Asia; Clostridioides difficile; Clostridium Infections; Europe; Humans; Metro | 2012 |
Current strategies for management of initial Clostridium difficile infection.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Cross Infection; Diarrhea; Enter | 2012 |
Novel management strategies in the treatment of severe Clostridium difficile infection.
Topics: Algorithms; Anti-Infective Agents; Colectomy; Enterocolitis, Pseudomembranous; Humans; Ileostomy; Im | 2012 |
[Can the postoperative relapse of Crohn disease be influenced?].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Clinical Trials as Top | 2001 |
[Helicobacter pylori. Update 2002].
Topics: Adenocarcinoma; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2002 |
[First line therapy for Helicobacter pylori eradication in France].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance; D | 2003 |
[How to treat after Helicobacter pylori eradication failure?].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2003 |
[Treatment of infections associated with Clostridium difficile].
Topics: Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Drug Resistance; Enterocolitis, Pseudomem | 2003 |
Clostridium difficile-associated diarrhea in adults.
Topics: Anti-Infective Agents; Bacterial Typing Techniques; Canada; Carrier State; Clostridioides difficile; | 2004 |
Antibiotics ineffective for prevention of recurrent MI.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydophila pneumoniae; Humans; Metronidazole; Myocardial Inf | 2004 |
Clinical inquiries. What is the best approach for managing recurrent bacterial vaginosis?
Topics: Anti-Infective Agents; Evidence-Based Medicine; Female; Humans; Metronidazole; Recurrence; Risk Fact | 2004 |
Appropriate strategies for testing and treating Helicobacter pylori in children: when and how?
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Breath Tests; Carrier State; Child; Ch | 2004 |
Abnormal vaginal discharge: what does and does not work in treating underlying causes.
Topics: Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Clindamycin; Female; Humans; Me | 2004 |
Metronidazole-induced pancreatitis. A case report and review of literature.
Topics: Diagnostic Errors; Female; Humans; Metronidazole; Middle Aged; Pancreatitis; Pancreatitis, Alcoholic | 2004 |
Clostridium difficile-associated diarrhea: resurgence with a vengeance.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Disease Outbreaks | 2006 |
[Probiotics--should we change the treatment strategy for pouchitis?].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Evidence-Based Medicine; Humans; Metron | 2006 |
Past, present, and future therapies for Clostridium difficile-associated disease.
Topics: Clostridioides difficile; Enterocolitis, Pseudomembranous; Forecasting; Humans; Metronidazole; Probi | 2006 |
Clostridium difficile-associated disease.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Enzyme Inhibitors; | 2006 |
Treatment of Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Disease Management; Enterocolitis, Pseudomembranous | 2008 |
Antibiotic-associated colitis.
Topics: Ampicillin; Animals; Anti-Bacterial Agents; Cholestyramine Resin; Clindamycin; Clostridium; Clostrid | 1984 |
Treatment of pseudomembranous colitis and antibiotic-associated diarrhoea.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacitracin; Diarrhea; Enterocolitis, Pseudomembranous; Female; H | 1984 |
Gardnerella vaginalis and its clinical syndrome.
Topics: Amoxicillin; Ampicillin; Culture Media; Female; Gardnerella vaginalis; Gentian Violet; Haemophilus; | 1982 |
Update on Clostridium difficile-induced colitis, Part 2.
Topics: Administration, Oral; Anti-Bacterial Agents; Capsules; Clostridioides difficile; Drug Costs; Enteroc | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gas | 1994 |
[Treatment of Helicobacter pylori infection in children].
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Helicobacter I | 1994 |
Selections from current literature: issues in the management of vaginitis.
Topics: Candidiasis, Vulvovaginal; Chronic Disease; Clotrimazole; Female; Humans; Male; Metronidazole; Recur | 1993 |
[Bacterial vaginosis II. Related pathology and therapy].
Topics: Anti-Bacterial Agents; Chorioamnionitis; Clindamycin; Endometritis; Female; Humans; Metronidazole; O | 1995 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; | 1996 |
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Dru | 1997 |
Clostridium difficile infection.
Topics: Administration, Oral; Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Colon; Diar | 1998 |
[Drug prevention of Crohn disease recurrence in the neo-terminal ileum after ileocolic resection].
Topics: Anti-Inflammatory Agents; Budesonide; Colon; Crohn Disease; Follow-Up Studies; Humans; Ileum; Mesala | 1998 |
Medical therapy to reduce postoperative Crohn's disease recurrence.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Glucocorticoids; Huma | 2000 |
Update on Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Community-Acquired Infections; Disease Outbreaks; Ente | 2000 |
Recurrent Clostridium difficile diarrhoea.
Topics: Anion Exchange Resins; Anti-Bacterial Agents; Anti-Infective Agents; Enterocolitis, Pseudomembranous | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2001 |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, | 2002 |
Hypoxic sensitizers--implications for radiation therapy.
Topics: Animals; Female; Glioblastoma; Humans; Metronidazole; Misonidazole; Neoplasms; Oxygen Consumption; R | 1979 |
Clostridium difficile infection: responses, relapses and re-infections.
Topics: Clinical Trials as Topic; Cross Infection; Disease Outbreaks; Enterocolitis, Pseudomembranous; Human | 1992 |
[Current status of Clostridium difficile: recent advances in diagnostic materials and treatment of colitis and diarrheas associated with antibiotic therapy].
Topics: Causality; Clinical Protocols; Colectomy; Enterocolitis, Pseudomembranous; Female; Humans; Male; Met | 1991 |
Helicobacter pylori and duodenal ulceration.
Topics: Cimetidine; Duodenal Ulcer; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Human | 1991 |
Bacterial vaginosis.
Topics: Bacterial Infections; Diagnosis, Differential; Female; Humans; Metronidazole; Recurrence; Vaginal Di | 1989 |
Vaginitis: diagnosis and treatment.
Topics: Adult; Candidiasis; Clinical Laboratory Techniques; Diagnosis, Differential; Female; Haemophilus Inf | 1972 |
149 trials available for metronidazole and Recrudescence
| Article | Year |
|---|---|
Personalised azithromycin+metronidazole (PAZAZ), in combination with standard induction therapy, to achieve a faecal microbiome community structure and metagenome changes associated with sustained remission in paediatric Crohn's disease (CD): protocol of
Topics: Anti-Bacterial Agents; Azithromycin; Bayes Theorem; Child; Crohn Disease; Humans; Induction Chemothe | 2023 |
Acceptability of and treatment preferences for recurrent bacterial vaginosis-Topical lactic acid gel or oral metronidazole antibiotic: Qualitative findings from the VITA trial.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Bacterial Agents; Female; Gels; Humans; L | 2019 |
Metronidazole versus lactic acid for treating bacterial vaginosis (VITA): protocol for a randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosi
Topics: Administration, Intravaginal; Anti-Bacterial Agents; Comparative Effectiveness Research; Cost-Benefi | 2019 |
Testing the regulatory framework in South Africa - a single-blind randomized pilot trial of commercial probiotic supplementation to standard therapy in women with bacterial vaginosis.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Dietary Supplements; Drug Approval; Fema | 2020 |
Treating male partners of women with bacterial vaginosis (StepUp): a protocol for a randomised controlled trial to assess the clinical effectiveness of male partner treatment for reducing the risk of BV recurrence.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Australia; Clindamycin; F | 2020 |
Clinical comparative study of optimized metronidazole loaded lipid nanocarrier vaginal emulgel for management of bacterial vaginosis and its recurrence.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Bacterial Agents; Chemistry, Pharmaceutical; D | 2021 |
Economic evaluation of antibiotic therapy versus appendicectomy for the treatment of uncomplicated acute appendicitis from the APPAC randomized clinical trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactams; C | 2017 |
The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Neutralizing | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibodies, Monoclon | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Fecal Microbiota Transplantation for Primary Clostridium difficile Infection.
Topics: Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Fecal Microbiota Transplant | 2018 |
Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactams; D | 2018 |
Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactams; D | 2018 |
Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactams; D | 2018 |
Five-Year Follow-up of Antibiotic Therapy for Uncomplicated Acute Appendicitis in the APPAC Randomized Clinical Trial.
Topics: Acute Disease; Adolescent; Adult; Anti-Bacterial Agents; Appendectomy; Appendicitis; beta-Lactams; D | 2018 |
Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial.
Topics: Adolescent; Adult; Combined Modality Therapy; Double-Blind Method; Female; Humans; Lactobacillus; La | 2019 |
One-day versus four-day antibiotic treatment for acute right colonic uncomplicated diverticulitis: A randomized clinical trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Cefmetazole; Diverticulitis, Colonic; | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath | 2013 |
Ultrasound-guided drainage of subcutaneous abscesses on the trunk is feasible.
Topics: Abscess; Adolescent; Adult; Anti-Bacterial Agents; Dicloxacillin; Drainage; Drug Therapy, Combinatio | 2013 |
High-dose vaginal metronidazole for recurrent bacterial vaginosis--a pilot study.
Topics: Adult; Anti-Infective Agents; Female; Humans; Metronidazole; Miconazole; Pilot Projects; Recurrence; | 2014 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Fr | 2013 |
[Challenges of Clostridium difficile infection].
Topics: Aminoglycosides; Biodiversity; Cause of Death; Colonoscopy; Cross Infection; Disinfection; Enterocol | 2013 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infecti | 2014 |
A blinded, randomized controlled trial of high-dose vitamin D supplementation to reduce recurrence of bacterial vaginosis.
Topics: Adult; Anti-Infective Agents; Cholecalciferol; Dietary Supplements; Double-Blind Method; Female; Hum | 2014 |
The outcome of antibiotic therapy for uncomplicated appendicitis with diameters ≤ 10 mm.
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cephalosp | 2014 |
Nonoperative treatment with antibiotics versus surgery for acute nonperforated appendicitis in children: a pilot randomized controlled trial.
Topics: Abdominal Pain; Acute Disease; Adolescent; Anti-Bacterial Agents; Appendectomy; Appendicitis; Child; | 2015 |
Crohn's disease management after intestinal resection: a randomised trial.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Azathioprine; Colonoscopy; Crohn Disease; Fema | 2015 |
Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients - a POCER study analysis.
Topics: Adalimumab; Adult; Aged; Azathioprine; Colonoscopy; Crohn Disease; Drug Therapy, Combination; Female | 2015 |
[Optimal management of Crohn's disease after intestinal resection].
Topics: Adalimumab; Colonoscopy; Combined Modality Therapy; Crohn Disease; Humans; Metronidazole; Postoperat | 2015 |
Metronidazole in conjunction with penicillin neither prevents recurrence nor enhances recovery from peritonsillar abscess when compared with penicillin alone: a prospective, double-blind, randomized, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Double-Blind Method; Drainage; Dr | 2016 |
[Recurrences in Clostridium difficile infections in cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides difficile; Clostridium Infecti | 2016 |
Quantitative fetal fibronectin screening in asymptomatic high-risk patients and the spectrum of risk for recurrent preterm delivery.
Topics: Adult; Anti-Infective Agents; Female; Fetal Blood; Fibronectins; Gestational Age; Humans; Kaplan-Mei | 2009 |
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Sc | 2009 |
Probiotic and metronidazole treatment for recurrent bacterial vaginosis.
Topics: Administration, Intravaginal; Anti-Infective Agents; Female; Gels; Humans; Metronidazole; Pilot Proj | 2010 |
Efficacy of antibiotic combination therapy in patients with active ulcerative colitis, including refractory or steroid-dependent cases.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biomarkers; Colitis, Ulcerative; Colon; Colonoscopy; Drug | 2010 |
The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Dose-Response Relationship, Dru | 2011 |
No advantage for antibiotic treatment over placebo in Blastocystis hominis-positive children with recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Anti-Bacterial Agents; Blastocystis hominis; Blastocystis Infections; Ch | 2012 |
Efficacy of oral metronidazole with vaginal clindamycin or vaginal probiotic for bacterial vaginosis: randomised placebo-controlled double-blind trial.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Clinda | 2012 |
Recurrence of bacterial vaginosis is significantly associated with posttreatment sexual activities and hormonal contraceptive use.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Austra | 2013 |
[New possibilities in the treatment of early stages of rosacea].
Topics: Administration, Topical; Adrenergic beta-Antagonists; Adult; Anti-Bacterial Agents; Erythema; Female | 2013 |
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Cohort | 2002 |
Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Dyspep | 2002 |
Single-dose metronidazole versus 5-day multi-drug antibiotic regimen in excision of pilonidal sinuses with primary closure: a prospective randomised controlled double-blinded study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Cefurox | 2002 |
Clinical outcome observed in subjects with recurrent periodontal disease following local treatment with 25% metronidazole gel.
Topics: Adult; Anti-Infective Agents; Dental Plaque Index; Dental Scaling; Follow-Up Studies; Gels; Gingival | 2003 |
Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial.
Topics: Aged; Clostridioides difficile; Double-Blind Method; Enterocolitis, Pseudomembranous; Female; Humans | 2003 |
Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anus Diseases; Azathioprine; | 2003 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Topics: Adult; Ciprofloxacin; Drug Therapy, Combination; Feces; Female; Humans; Male; Metronidazole; Middle | 2004 |
Lactobacillus GG in inducing and maintaining remission of Crohn's disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Crohn Disease; Double-Blind Method; Drug Therapy, Combination; | 2004 |
A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Diarrhea; Double-Blind Method; Fe | 2004 |
Antibiotics ineffective for prevention of recurrent MI.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydophila pneumoniae; Humans; Metronidazole; Myocardial Inf | 2004 |
[Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment].
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, C | 2004 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired I | 2004 |
The microbial outcome observed with polymerase chain reaction in subjects with recurrent periodontal disease following local treatment with 25% metronidazole gel.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Anti-Infective Agents; Colony Count, Microbial; Female | 2004 |
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; H | 2004 |
Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes.
Topics: Acute Disease; Amoxicillin; Antigens, CD; Coronary Disease; Female; Helicobacter Infections; Helicob | 2004 |
Modified lay-open (incision, curettage, partial lateral wall excision and marsupialization) versus total excision with primary closure in the treatment of chronic sacrococcygeal pilonidal sinus: a prospective, randomized clinical trial with a complete two
Topics: Adolescent; Adult; Anti-Bacterial Agents; Cefazolin; Chronic Disease; Curettage; Female; Follow-Up S | 2005 |
The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Sc | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: experience in clinical practice.
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Combined Modality Therapy; Female; Follow-Up Studies; H | 2005 |
A pilot clinical trial comparing an acid-buffering formulation (ACIDFORM gel) with metronidazole gel for the treatment of symptomatic bacterial vaginosis.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Drug Administration Schedule; Epidemiolo | 2006 |
Interconceptional antibiotics to prevent spontaneous preterm birth: a randomized clinical trial.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Double-Blind Method; Female; Humans; Metronidazole; Prec | 2006 |
Metronidazole with Lactacyd vaginal gel in bacterial vaginosis.
Topics: Adult; Anti-Infective Agents; Drug Combinations; Female; Humans; Hydrogen-Ion Concentration; Immune | 2006 |
Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembr | 2007 |
Lactobacillus plantarum 299v enhances the concentrations of fecal short-chain fatty acids in patients with recurrent clostridium difficile-associated diarrhea.
Topics: Anti-Infective Agents; Biomarkers; Chromatography, Gas; Clostridioides difficile; Diarrhea; Enteroco | 2007 |
Topical use of a metronidazole gel in the treatment of sites with symptoms of recurring chronic inflammation.
Topics: Administration, Topical; Adult; Aged; Anti-Infective Agents; Chronic Disease; Delayed-Action Prepara | 2007 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.
Topics: Adolescent; Adult; Animals; Female; HIV Infections; Humans; Louisiana; Metronidazole; Parasitic Sens | 2008 |
A dose-duration study of metronidazole for the treatment of nonspecific vaginosis.
Topics: Adolescent; Adult; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Resistance, Micr | 1983 |
Infection and the use of antibiotics in Crohn's disease.
Topics: Abscess; Anus Diseases; Bacterial Infections; Clinical Trials as Topic; Crohn Disease; Drug Combinat | 1984 |
Effect of combined systemic antimicrobial therapy and mechanical plaque control in patients with recurrent periodontal disease.
Topics: Adult; Aged; Bacteria; Combined Modality Therapy; Dental Plaque; Dental Prophylaxis; Female; Humans; | 1984 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
Extraperitonealization for sigmoid volvulus: a reappraisal.
Topics: Adolescent; Adult; Aged; Ampicillin; Colectomy; Drug Therapy, Combination; Elective Surgical Procedu | 1995 |
Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therap | 1995 |
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Comb | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
[Importance of anaerobic bacteria in recurrent childhood non-streptococcal tonsillitis].
Topics: Bacteria, Anaerobic; Bacterial Infections; beta-Lactamases; Child; Child, Preschool; Drug Therapy, C | 1995 |
Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Fo | 1995 |
Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection.
Topics: Adult; Crohn Disease; Double-Blind Method; Follow-Up Studies; Humans; Ileum; Metronidazole; Middle A | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Antacids; Bismuth; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug | 1994 |
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1994 |
Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; Drug Ther | 1995 |
Eradication of Helicobacter pylori infection and the recurrence of duodenal ulcers.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helic | 1993 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Selection of patients for treatment of duodenal ulcer infected with Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Cimetidine; Drug Therapy, Combination; Duodenal Ulcer; Fe | 1994 |
[H. pylori and chronic duodenal ulcer: eradication therapy with ranitidine-antibiotic combination and follow-up of ulcer disease].
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Heli | 1994 |
Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate.
Topics: Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastr | 1994 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicoba | 1994 |
Effect of lactic acid suppositories compared with oral metronidazole and placebo in bacterial vaginosis: a randomised clinical trial.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Lactates; Metronidazole; Middle Aged; Recur | 1993 |
[The effect of the eradication of H. pylori on the intractable ulcer].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacte | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Hel | 1993 |
Outcome at three to five years of primary closure of perianal and pilonidal abscess. A randomised, double-blind clinical trial with a complete three-year followup of one compared with four days' treatment with ampicillin and metronidazole.
Topics: Abscess; Ampicillin; Anus Diseases; Chi-Square Distribution; Combined Modality Therapy; Double-Blind | 1993 |
One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studi | 1994 |
Erythromycin versus metronidazole in the treatment of bacterial vaginosis.
Topics: Administration, Oral; Adolescent; Adult; Erythromycin; Female; Follow-Up Studies; Humans; Male; Metr | 1993 |
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; F | 1993 |
Patient factors affecting Helicobacter pylori eradication with triple therapy.
Topics: Adult; Age Factors; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1993 |
Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.
Topics: Administration, Intravaginal; Adult; Bacteroides Infections; Double-Blind Method; Female; Gardnerell | 1993 |
Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Colloids; Drug Therapy, Combina | 1993 |
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; | 1996 |
Effect of the eradication of Helicobacter pylori on duodenal ulcer healing and ulcer relapse: randomized controlled study in Japan.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedu | 1996 |
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocoliti | 1996 |
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocoliti | 1996 |
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocoliti | 1996 |
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocoliti | 1996 |
Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Refractory duodenal ulcer healing and relapse: comparison of omeprazole with Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Duod | 1996 |
Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastroscopy; Helic | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Recurrent bacterial vaginosis--an old approach to a new problem.
Topics: Administration, Intravaginal; Anti-Infective Agents, Local; Antitrichomonal Agents; Female; Humans; | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Diarrhea; Doub | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 1997 |
Helicobacter pylori-positive duodenal ulcer: a long-term double-blind randomized study in patients healed with H2-receptor antagonists.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Disease-Free Survival; Double-Blind Method; Doxycycline; D | 1996 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow- | 1997 |
Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1997 |
One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicob | 1997 |
Topical metronidazole maintains remissions of rosacea.
Topics: Administration, Cutaneous; Adult; Aged; Anti-Bacterial Agents; Dermatologic Agents; Double-Blind Met | 1998 |
Treatment of bacterial vaginosis with oral or vaginal ornidazole, secnidazole and metronidazole.
Topics: Administration, Intravaginal; Administration, Oral; Anti-Infective Agents; Drug Therapy, Combination | 1998 |
Recurrent Clostridium difficile disease: epidemiology and clinical characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Enteroc | 1999 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; China; Cimetidine; Cost-Be | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ul | 1999 |
Predictors of failure of Helicobacter pylori eradication and predictors of ulcer recurrence: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; D | 1999 |
Repeated local metronidazole-therapy as adjunct to scaling and root planing in maintenance patients.
Topics: Administration, Topical; Aggregatibacter actinomycetemcomitans; Anti-Bacterial Agents; Colony Count, | 1999 |
Behaviour of Saccharomyces boulardii in recurrent Clostridium difficile disease patients.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cells, Cultured; Clostridium Infections; Feces; Humans | 1999 |
Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis.
Topics: Abdominal Pain; Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2000 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer | 2001 |
Treatment of Helicobacter pylori in children with recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Coho | 2001 |
The nonsurgical treatment of patients with periodontal disease: results after five years.
Topics: Age Factors; Alveolar Bone Loss; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; D | 2002 |
Aggressive periodontitis: 5-year follow-up of treatment.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial Agents; Dental Plaque; Den | 2002 |
Failure of thiabendazole and metronidazole in the treatment and suppression of guinea worm disease.
Topics: Adolescent; Adult; Africa, Western; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dracunc | 1975 |
Efficacy of metronidazole in dracunculiasis. A clinical trial.
Topics: Dracunculiasis; Drug Evaluation; Humans; Metronidazole; Recurrence | 1979 |
[Treatment of duodenal peptic ulcer with metronidazole].
Topics: Adolescent; Adult; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Duodenal Ul | 1977 |
Giardiasis in infancy and childhood: a prospective study of 160 cases with comparison of quinacrine (Atabrine) and metronidazole (Flagyl).
Topics: Adolescent; Child; Child, Preschool; Feces; Female; Follow-Up Studies; Giardiasis; Humans; Infant; I | 1979 |
Comparison of four dosage schedules in the treatment of giardiasis with metronidazole.
Topics: Adolescent; Adult; Drug Administration Schedule; Feces; Female; Giardiasis; Humans; Male; Metronidaz | 1978 |
Two-day treatment of trichomoniasis in the female. Comparison of metronidazole and nimorazole.
Topics: Adolescent; Adult; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Metronidazole; Middl | 1976 |
Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; Humans; Metronidazole; Omep | 1992 |
Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Bismuth; Duodenal Ulcer; Endoscopy, Digestive System | 1992 |
[Treatment of acute salpingitis with tetracycline/metronidazole with or without additional balneotherapy, Augmentin or ciprofloxacin/metronidazole: a second-look laparoscopy study].
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Balneology; Clavulanic Acids; Com | 1992 |
Serial doxycycline and metronidazole in prevention of recurrent periodontitis in high-risk patients.
Topics: Bacteria; Dental Plaque Index; Dental Scaling; Doxycycline; Drug Therapy, Combination; Female; Human | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Duodenal ulcer recurrence and Helicobacter pylori.
Topics: Amoxicillin; Duodenal Ulcer; Follow-Up Studies; Helicobacter pylori; Humans; Metronidazole; Recurren | 1991 |
Cure of duodenal ulcer associated with eradication of Helicobacter pylori.
Topics: Administration, Oral; Amoxicillin; Anti-Ulcer Agents; Campylobacter; Campylobacter Infections; Drug | 1990 |
Duodenal ulcer disease--to heal or to cure?
Topics: Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter In | 1991 |
Efficacy of combined metronidazole and triple tetracycline therapy in the treatment of non-gonococcal urethritis.
Topics: Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Metronidazole; Recu | 1990 |
The effectiveness of single-dose metronidazole therapy for patients and their partners with bacterial vaginosis.
Topics: Adult; Bacterial Infections; Clinical Trials as Topic; Double-Blind Method; Drug Administration Sche | 1989 |
Should male consorts of women with bacterial vaginosis be treated?
Topics: Adolescent; Adult; Bacterial Infections; Double-Blind Method; Female; Gardnerella vaginalis; Haemoph | 1989 |
Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.
Topics: Administration, Oral; Adult; Aged; Campylobacter Infections; Clinical Trials as Topic; Drug Administ | 1989 |
Comparison of 2 g single dose of metronidazole, nimorazole and tinidazole in the treatment of vaginitis associated with Gardnerella vaginalis.
Topics: Female; Gardnerella vaginalis; Haemophilus Infections; Humans; Male; Metronidazole; Nimorazole; Nitr | 1987 |
Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study.
Topics: Adult; Aged; Clinical Trials as Topic; Crohn Disease; Double-Blind Method; Drug Combinations; Drug T | 1985 |
A controlled field trial of the treatment of dracontiasis with metronidazole and niridazole.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dracunculiasis; Gastrointestinal Diseases; Humans; | 1974 |
Treatment of trichomonal vaginitis with a single oral dose of metronidazole.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Contraceptives, Oral; Female; Gonorrhea; Huma | 1972 |
Clinical trials of benzoyl metronidazole suspension in amoebic dysentery and amoebic liver abscess.
Topics: Adult; Child; Child, Preschool; Dysentery, Amebic; Follow-Up Studies; Humans; Liver Abscess, Amebic; | 1974 |
Trichomonal vaginitis treated with one dose of metronidazole.
Topics: Chloramphenicol; Clinical Trials as Topic; Female; Humans; Metronidazole; Recurrence; Trichomonas Va | 1971 |
286 other studies available for metronidazole and Recrudescence
| Article | Year |
|---|---|
Recurrent bacterial vaginosis following metronidazole treatment is associated with microbiota richness at diagnosis.
Topics: Adult; Anti-Bacterial Agents; Female; Humans; Lactobacillus; Longitudinal Studies; Metronidazole; Mi | 2022 |
Non-inferiority of metronidazole to vancomycin in the treatment of first episode non-severe Clostridioides difficile infection: a single center retrospective cohort study.
Topics: Adult; Aftercare; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Hospital | 2022 |
Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients.
Topics: Anti-Bacterial Agents; Child; Clostridioides difficile; Clostridium Infections; Hematopoietic Stem C | 2022 |
Risk factors for Recurrent Clostridioides Difficile Infection in Children.
Topics: Anti-Bacterial Agents; Child; Chronic Disease; Clostridioides difficile; Clostridium Infections; Fem | 2023 |
Risk factors and treatment outcomes of severe Clostridioides difficile infection in Singapore.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridium Infections; Diarrh | 2019 |
Predominantly Antibiotic-resistant Intestinal Microbiome Persists in Patients With Pouchitis Who Respond to Antibiotic Therapy.
Topics: Adult; Anti-Bacterial Agents; Bacteria; Ciprofloxacin; Cytokines; Drug Resistance, Bacterial; Feces; | 2020 |
Risk Factors for Recurrent Community-associated Clostridiodes Difficile Infection in Children.
Topics: Adolescent; California; Child; Child, Preschool; Clostridioides difficile; Clostridium Infections; C | 2019 |
Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Fe | 2020 |
Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cr | 2020 |
Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Topics: Aged; Anti-Bacterial Agents; Clinical Trials, Phase III as Topic; Clostridioides difficile; Clostrid | 2020 |
Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.
Topics: Aged; Anti-Bacterial Agents; Clostridioides; Clostridium Infections; Comorbidity; Diagnostic Errors; | 2020 |
Factors Associated With the Recurrence, Persistence, and Clearance of Asymptomatic Bacterial Vaginosis Among Young African American Women: A Repeated-Measures Latent Class Analysis.
Topics: Adult; Asymptomatic Infections; Black or African American; Female; Humans; Incidence; Latent Class A | 2020 |
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
Topics: Female; Humans; Metronidazole; Recurrence; Vaginosis, Bacterial | 2020 |
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis. Reply.
Topics: Female; Humans; Metronidazole; Recurrence; Vaginosis, Bacterial | 2020 |
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis.
Topics: Female; Humans; Metronidazole; Recurrence; Vaginosis, Bacterial | 2020 |
Recurrent Facial Rash.
Topics: Administration, Cutaneous; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; De | 2020 |
Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; | 2021 |
A rare case of metronidazole induced recurrent pancreatitis.
Topics: Adult; Anti-Infective Agents; Female; Humans; Metronidazole; Pancreatitis; Recurrence | 2021 |
Efficacy and safety of a novel vaginal medical device in recurrent bacterial vaginosis: a multicenter clinical trial.
Topics: Administration, Intravaginal; Adolescent; Female; Humans; Lactobacillus; Metronidazole; Recurrence; | 2020 |
Outcomes associated with recent guideline recommendations removing metronidazole for treatment of non-severe Clostridioides difficile infection: a retrospective, observational, nationwide cohort study.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drug Utilization; Fem | 2021 |
An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clos | 2017 |
A Case of Recurrent Pneumoperitoneum and Pneumatosis Intestinalis After Bilateral Lung Transplant.
Topics: Anti-Bacterial Agents; Conservative Treatment; Humans; Lung Transplantation; Male; Metronidazole; Mi | 2019 |
Defining treatment success in rosacea as 'clear' may provide multiple patient benefits: results of a pooled analysis.
Topics: Adult; Aged; Dermatologic Agents; Female; Humans; Ivermectin; Male; Metronidazole; Middle Aged; Qual | 2017 |
Vancomycin vs Metronidazole for Clostridium difficile infection: focus on recurrence and mortality.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Feces; Female; Humans | 2017 |
Post-hospitalization Treatment Regimen and Readmission for C. difficile Colitis in Medicare Beneficiaries.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Co | 2018 |
Treating Clostridium difficile infection in patients presenting with hematological malignancies: Are current guidelines applicable?
Topics: Adult; Clostridioides difficile; Clostridium Infections; Cross Infection; Disease Management; Female | 2017 |
Recurrent bacteremia and liver abscess caused by Clostridium difficile: A case report.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Translocation; Carcinoma, Hepatocellular; Chemoem | 2017 |
Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cohort Studies | 2019 |
Comparison of outcomes with vancomycin or metronidazole for mild-to-moderate Clostridium difficile associated diarrhea among solid organ transplant recipients: A retrospective cohort study.
Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cohort Studies; Diar | 2018 |
The 'ins and outs' of faecal microbiota transplant for recurrent Clostridium difficile diarrhoea at Wits Donald Gordon Medical Centre, Johannesburg, South Africa.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cross Infectio | 2018 |
Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium I | 2019 |
Retrospective analysis of the use of quadruple therapy with bismuth (Pylera
Topics: Adult; Aged; Breath Tests; Cross-Sectional Studies; Drug Evaluation; Drug Therapy, Combination; Fema | 2018 |
A case report of fixed drug eruption caused by several drugs because of cross-reactivity and co-sensitization.
Topics: Aged; Anti-Bacterial Agents; Cross Reactions; Drug Eruptions; Esomeprazole; Humans; Levofloxacin; Ma | 2019 |
Stump Appendicitis Management.
Topics: Administration, Oral; Anti-Bacterial Agents; Appendectomy; Appendicitis; Ciprofloxacin; Female; Huma | 2018 |
Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study.
Topics: Adult; Anastomosis, Surgical; Anti-Bacterial Agents; Case-Control Studies; Crohn Disease; Female; Hu | 2019 |
Prognostic Indicators of Recurrence of Bacterial Vaginosis.
Topics: Adult; Anti-Bacterial Agents; Cross-Over Studies; DNA, Bacterial; Female; Humans; Metronidazole; Mid | 2019 |
Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Clostridioides difficile; Clos | 2019 |
Clostridium difficile: A Frequent Infection in Children After Intestinal Transplantation.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Clostridioides difficile; Clostridium In | 2020 |
Association Analysis on Recurrence of Bacterial Vaginosis Revealed Microbes and Clinical Variables Important for Treatment Outcome.
Topics: Adolescent; Adult; Bacteria; Biodiversity; Cohort Studies; DNA, Bacterial; Female; Humans; Lactobaci | 2019 |
Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco).
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Developing | 2013 |
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider.
Topics: Adolescent; Anti-Bacterial Agents; Arkansas; Ceftriaxone; Centers for Disease Control and Prevention | 2013 |
Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates.
Topics: Adolescent; Anti-Bacterial Agents; Belgium; Biopsy; Chi-Square Distribution; Child; Child, Preschool | 2014 |
Statin use and infections in Veterans with cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides difficile; Enterocolitis, Pseu | 2013 |
Recurrent lung infection due to chronic peri-odontitis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Diagnos | 2013 |
[Clostridium difficile infection (CDI) in the course of time - an issue only for the internist?].
Topics: Aminoglycosides; Clostridioides difficile; Colectomy; Colostomy; Cross-Sectional Studies; Drug Resis | 2014 |
Role of probiotics in the management of pouchitis.
Topics: Animals; Anti-Bacterial Agents; Ciprofloxacin; Colitis, Ulcerative; Humans; Intestines; Metronidazol | 2014 |
Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides diffi | 2013 |
Antibiotic therapy for appendicitis in patients aged ≥80 years.
Topics: Acute Disease; Aged, 80 and over; Anti-Bacterial Agents; Appendectomy; Appendicitis; Cephalosporins; | 2014 |
[Epidemiology of Clostridium difficile-associated disease (CDAD) in Salamanca].
Topics: Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Antineoplastic Agents; Clostridioides diff | 2014 |
Clostridium difficile infection after allogeneic hematopoietic stem cell transplant: strain diversity and outcomes associated with NAP1/027.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Child; Child, Preschool; Clostridioides difficile; C | 2014 |
Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Cr | 2014 |
Association between specific mucosa-associated microbiota in Crohn's disease at the time of resection and subsequent disease recurrence: a pilot study.
Topics: Adalimumab; Adult; Aged; Biopsy; Cecum; Colonoscopy; Crohn Disease; Cross-Sectional Studies; Drug Th | 2015 |
Long-term results of nonoperative treatment for uncomplicated acute appendicitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Append | 2014 |
Long-term results of nonoperative treatment for uncomplicated acute appendicitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Append | 2014 |
Long-term results of nonoperative treatment for uncomplicated acute appendicitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Append | 2014 |
Long-term results of nonoperative treatment for uncomplicated acute appendicitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Anti-Bacterial Agents; Append | 2014 |
Emphysematous cystitis due to recurrent Clostridium difficile infection.
Topics: Aged; Anti-Infective Agents; Clostridioides difficile; Clostridium Infections; Cystitis; Emphysema; | 2014 |
Refractory giardiasis in renal transplantation: a case report.
Topics: Adult; Antiprotozoal Agents; Doxycycline; Drug Therapy, Combination; Giardiasis; Humans; Kidney Tran | 2015 |
[Dientamoeba fragilis infection as cause of severe abdominal discomfort and flatulence].
Topics: Adolescent; Dientamoeba; Dientamoebiasis; Feces; Flatulence; Humans; Male; Metronidazole; Recurrence | 2015 |
Frozen encapsulated stool in recurrent Clostridium difficile: exploring the role of pills in the treatment hierarchy of fecal microbiota transplant nonresponders.
Topics: Abdominal Pain; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Biological Therapy; | 2015 |
Vulvovaginitis: screening for and management of trichomoniasis, vulvovaginal candidiasis, and bacterial vaginosis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Canada; Candidiasis, Vulvovaginal; Clindamycin; Female | 2015 |
Adynamic ileus and diarrhoea: a rare adverse effect of antidepressants.
Topics: Aged; Anti-Bacterial Agents; Antidepressive Agents; Colonoscopy; Diarrhea; Female; Humans; Iatrogeni | 2015 |
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Anti-Infective Agents; Case-Contr | 2016 |
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Anti-Infective Agents; Case-Contr | 2016 |
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Anti-Infective Agents; Case-Contr | 2016 |
Restoring vaginal microbiota: biological control of bacterial vaginosis. A prospective case-control study using Lactobacillus rhamnosus BMX 54 as adjuvant treatment against bacterial vaginosis.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Adult; Aged; Anti-Infective Agents; Case-Contr | 2016 |
Diarrhea With Clostridium difficile-Positive Stool-Trick or Treat: A Teachable Moment.
Topics: Aged; Anti-Bacterial Agents; Axitinib; Carcinoma, Renal Cell; Clostridioides difficile; Costs and Co | 2015 |
Gardnerella vaginalis: An overlooked pathogen in male patients?
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacteremia; Ceftriaxone; Ciprofloxacin; Drug Resistance, | 2015 |
Evaluation of a bedside scoring system for predicting clinical cure and recurrence of Clostridium difficile infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Female; Humans | 2015 |
Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
Topics: Anti-Bacterial Agents; Canada; Clostridioides difficile; Cohort Studies; Cost of Illness; Enterocoli | 2016 |
Self-Administered Home Series Fecal "Minitransplants" for Recurrent Clostridium difficile Infection on a Rectal Remnant.
Topics: Aged; Anti-Infective Agents; Clostridioides difficile; Colectomy; Enterocolitis, Pseudomembranous; F | 2015 |
Clostridium difficile Associated Diarrhea.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocolitis, Pseudomembranous; Fecal Mi | 2016 |
[Antibiotic treatment of clostridial colitis].
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Drug Resistance, Bacterial; Entero | 2016 |
Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Clostridioides difficile; Clostridium Infect | 2016 |
Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; C | 2016 |
Clostridium difficile infection in children: epidemiology and risk of recurrence in a low-prevalence country.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Clostridioides difficile; Clostridium In | 2017 |
Recurrent amebic liver abscesses over a 16-year period: a case report.
Topics: Adult; Furans; Humans; Liver Abscess, Amebic; Male; Metronidazole; Middle Aged; Recurrence; Young Ad | 2016 |
An institutional comparison of total abdominal colectomy and diverting loop ileostomy and colonic lavage in the treatment of severe, complicated Clostridium difficile infections.
Topics: Aged; Anti-Bacterial Agents; Clostridium Infections; Colectomy; Colon; Female; Humans; Ileostomy; Ma | 2017 |
Bacterial vaginosis.
Topics: Adult; Anti-Infective Agents; Bacterial Infections; Child; Female; Humans; Metronidazole; Mucous Mem | 2008 |
[A recurrent diarrhea].
Topics: Administration, Oral; Aged; Anti-Infective Agents; Clostridioides difficile; Colonoscopy; Diarrhea; | 2009 |
Summaries for patients. Factors related to bacterial vaginosis that persists or occurs again after treatment in women who have sex with women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Female; Homosexuality, Femal | 2008 |
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Clostridium; Female; Homosex | 2008 |
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Clostridium; Female; Homosex | 2008 |
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Clostridium; Female; Homosex | 2008 |
Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women.
Topics: Administration, Intravaginal; Adolescent; Adult; Anti-Infective Agents; Clostridium; Female; Homosex | 2008 |
Frequency of Giardia lamblia infection in children with recurrent abdominal pain.
Topics: Abdominal Pain; Animals; Antiprotozoal Agents; Causality; Child; Child, Preschool; Comorbidity; Fema | 2008 |
Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area.
Topics: Adolescent; Adult; Aged; Animals; Antiprotozoal Agents; Child, Preschool; Cohort Studies; Disease Ou | 2009 |
Is Porphyromonas gingivalis cell invasion required for atherogenesis? Pharmacotherapeutic implications.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bacteroidaceae Infections; Cell Line; Cholesterol; Diet | 2009 |
[The approach to recurrent infections with Clostridium difficile].
Topics: Anti-Bacterial Agents; Brachytherapy; Clostridioides difficile; Combined Modality Therapy; Complemen | 2008 |
An unusual case of chronic relapsing tetanus associated with mandibular osteomyelitis.
Topics: Anti-Bacterial Agents; Chronic Disease; Gallium Radioisotopes; Head and Neck Neoplasms; Humans; Lymp | 2009 |
The efficacy of retreatment with the same medication for early treatment failure of bacterial vaginosis.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Clindamycin; Cohort Studies; Drug Administrat | 2009 |
Recurrent cytomegalovirus infection in ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Ciprofloxacin; Colitis, Ulcerative; Colonic Pouches; Cytomegalovirus Infections; Dietary Supplements | 2010 |
Blastocystis sp. subtype 2 detection during recurrence of gastrointestinal and urticarial symptoms.
Topics: Adult; Animals; Anti-Infective Agents; Blastocystis; Blastocystis Infections; Chronic Disease; Gastr | 2010 |
Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis.
Topics: Female; Gardnerella vaginalis; Humans; Lactobacillus; Menstrual Cycle; Metronidazole; Polymerase Cha | 2010 |
Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease.
Topics: Adolescent; Ambulatory Care; Anti-Bacterial Agents; Child; Child, Preschool; Clostridioides difficil | 2010 |
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Enterocol | 2010 |
Clostridium difficile colitis: a call for aggressive management.
Topics: Algorithms; Anti-Infective Agents; Clostridioides difficile; Drug Therapy, Computer-Assisted; Entero | 2010 |
Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa.
Topics: Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Aza Compounds; Drug Therapy, Combination; | 2011 |
The severity, extent and recurrence of necrotizing periodontal disease in relation to HIV status and CD4+ T cell count.
Topics: Adolescent; Adult; Anti-Infective Agents; Anti-Infective Agents, Local; CD4 Lymphocyte Count; Child; | 2010 |
Maintenance after a complex orthoperio treatment in a case of generalized aggressive periodontitis: 7-year result.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Aggressive Periodontitis; Amoxicillin; Amoxicillin-Pot | 2010 |
Relapse of intestinal and hepatic amebiasis after treatment.
Topics: Amebicides; Antidiarrheals; Colonoscopy; Drug Therapy, Combination; Dysentery, Amebic; Humans; Iodoq | 2011 |
Studies of distribution and recurrence of Helicobacter spp. gastric mucosa of dogs after triple therapy.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Gastric | 2011 |
Relapse of posttraumatic osteomyelitis due to Clostridium celerecrescens.
Topics: Administration, Oral; Anti-Bacterial Agents; Cefuroxime; Chronic Disease; Clindamycin; Clostridium; | 2011 |
Day case stapled anopexy for the treatment of haemorrhoids and rectal mucosal prolapse.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Anti-Infective Agents; Antib | 2012 |
[Results of one-stage reconstruction of anal sphincter in surgical treatment of fistulas-in-ano combined with fecal incontinence].
Topics: Adult; Anal Canal; Antibiotic Prophylaxis; Ceftriaxone; Fecal Incontinence; Female; Follow-Up Studie | 2011 |
Antimicrobial use and risk for recurrent Clostridium difficile infection.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Bacterial Agents; Dose-Response Relationship, Dr | 2011 |
Relapse of polymicrobial endocarditis in an intravenous drug user.
Topics: Adult; Ceftriaxone; Coinfection; Eikenella corrodens; Endocarditis, Bacterial; Gram-Negative Bacteri | 2011 |
Recognizing metronidazole resistant C. difficile.
Topics: Anti-Infective Agents; Clostridioides difficile; Cross Infection; Drug Resistance, Bacterial; Drug T | 2011 |
Epidemiology and clinical characteristics of Clostridium difficile infection in a Korean tertiary hospital.
Topics: Aged; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Diarrh | 2011 |
Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Diarrhea; Drug Resistance, | 2012 |
The long-term clinical course of pouchitis after total proctocolectomy and IPAA for ulcerative colitis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Colonic Pou | 2012 |
A 5-year retrospective review of experience with Clostridium difficile-associated diarrhea.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Cross Infection; Diarrhea; Enterocolitis, Pseudomem | 2012 |
Successful use of nitazoxanide in the treatment of recurrent Clostridium difficile infection.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Humans; Male; Metroni | 2011 |
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study.
Topics: Adult; Anti-Infective Agents; Cohort Studies; DNA, Bacterial; Female; Humans; Lactobacillus; Metroni | 2012 |
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study.
Topics: Adult; Anti-Infective Agents; Cohort Studies; DNA, Bacterial; Female; Humans; Lactobacillus; Metroni | 2012 |
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study.
Topics: Adult; Anti-Infective Agents; Cohort Studies; DNA, Bacterial; Female; Humans; Lactobacillus; Metroni | 2012 |
Behavioral predictors of colonization with Lactobacillus crispatus or Lactobacillus jensenii after treatment for bacterial vaginosis: a cohort study.
Topics: Adult; Anti-Infective Agents; Cohort Studies; DNA, Bacterial; Female; Humans; Lactobacillus; Metroni | 2012 |
Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides difficile; Clostridium Infecti | 2013 |
A woman with community-acquired Clostridium difficile infection.
Topics: Aged; Anti-Infective Agents; Clostridioides difficile; Community-Acquired Infections; Enterocolitis, | 2012 |
Recurrent amebic liver abscess.
Topics: Antiprotozoal Agents; Combined Modality Therapy; Drainage; Drug Administration Schedule; Entamoeba h | 2012 |
Outcomes of conservative treatment of 134 cases of umbilical pilonidal sinus.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Combined Modality Therapy; Drainage; Drug The | 2013 |
Rifaximin in the treatment of recurrent Clostridium difficile infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clostridioides difficile; Clostridium Infecti | 2013 |
Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Bacteroides; Cecum; Clostridioides difficile; Clost | 2013 |
Recurrent bacterial vaginosis in a virgin adolescent: a new method of treatment.
Topics: Adolescent; Female; Humans; Metronidazole; Recurrence; Therapeutic Irrigation; Vagina; Vaginosis, Ba | 2002 |
[Follow up of Crohn's disease under therapy with hydro-MRI].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Azathiopri | 2003 |
[Antibiotic-associated diarrhea].
Topics: Anti-Bacterial Agents; Diarrhea; Enterocolitis, Pseudomembranous; Fluid Therapy; Humans; Metronidazo | 2003 |
Late recurrence of resistant Trichomonas vaginalis vaginitis: relapse or re-infection?
Topics: Adult; Antitrichomonal Agents; Drug Resistance, Bacterial; Female; Humans; Metronidazole; Recurrence | 2003 |
Trichomoniasis. Clinical trial of metronidazole (Flagyl).
Topics: Death; Exhalation; Female; Fetal Development; Humans; Imidazoles; Metronidazole; Pregnancy; Recurren | 1963 |
Fecundity and morbidity following acute pelvic inflammatory disease treated with doxycycline and metronidazole.
Topics: Abortion, Induced; Abortion, Spontaneous; Adolescent; Adult; Anti-Infective Agents; Bacteroides; Bio | 2003 |
Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis.
Topics: Acinonyx; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; | 2004 |
Incidence and therapeutic outcome of pouchitis for ulcerative colitis in Japanese patients.
Topics: Adenomatous Polyposis Coli; Adult; Anti-Infective Agents; Ciprofloxacin; Colitis, Ulcerative; Female | 2004 |
Probiotics in relapsing and chronic diarrhea.
Topics: Anti-Infective Agents; Bone Marrow Transplantation; Child, Preschool; Chronic Disease; Clostridioide | 2004 |
Treatment and follow-up of persistent granulomatous cheilitis with intralesional steroid and metronidazole.
Topics: Drug Therapy, Combination; Female; Glucocorticoids; Humans; Injections, Intralesional; Lip; Melkerss | 2004 |
Treatment of recurrent bacterial vaginosis with tinidazole.
Topics: Adult; Antiprotozoal Agents; Antitrichomonal Agents; Female; Humans; Metronidazole; Recurrence; Tini | 2004 |
Clostridium difficile-associated diarrhea: risk factors, diagnostic methods, and treatment.
Topics: Anti-Bacterial Agents; Diarrhea; Endoscopy, Gastrointestinal; Enterocolitis, Pseudomembranous; Feces | 2004 |
Recurrence of Helicobacter pylori infection 1 year after successful treatment: prospective cohort study in the Republic of Yemen.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2004 |
Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Estonia; Female; Follow-Up Studies; Helicobac | 2004 |
Gram stain as a relapse predictor of bacterial vaginosis after metronidazole treatment.
Topics: Anti-Infective Agents; Bacteria; Female; Gentian Violet; Gram-Negative Bacteria; Gram-Positive Cocci | 2005 |
Metronidazole for Clostridium difficile-associated disease: is it okay for Mom?
Topics: Anti-Bacterial Agents; Enterocolitis, Pseudomembranous; Humans; Metronidazole; Recurrence; Vancomyci | 2005 |
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Enterocolitis, Pseudomembra | 2005 |
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Enterocolitis, Pseudomembra | 2005 |
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Enterocolitis, Pseudomembra | 2005 |
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Enterocolitis, Pseudomembra | 2005 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Inf | 2005 |
Recurrent fixed drug eruption due to metronidazole elicited by patch test with tinidazole.
Topics: Adult; Antiprotozoal Agents; Antitrichomonal Agents; Cross Reactions; Drug Eruptions; Female; Humans | 2005 |
Remission of delayed pressure urticaria after eradication of Blastocystis hominis.
Topics: Adult; Animals; Antiprotozoal Agents; Blastocystis hominis; Blastocystis Infections; Diagnosis, Diff | 2005 |
Nonsurgical treatment of abdominal or pelvic abscess in consecutive patients with Crohn's disease.
Topics: Abdominal Abscess; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Bacterial Agents; Cephalos | 2006 |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence.
Topics: Adult; Contraceptives, Oral, Hormonal; Female; Humans; Incidence; Metronidazole; Middle Aged; Multiv | 2006 |
[Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromyc | 2006 |
Studies on periodontitis and analyses of individuals at risk for periodontal diseases.
Topics: Adult; Anti-Infective Agents; Chronic Disease; Diabetes Mellitus, Type 2; Female; Genetic Predisposi | 2006 |
The association of Atopobium vaginae and Gardnerella vaginalis with bacterial vaginosis and recurrence after oral metronidazole therapy.
Topics: Actinobacteria; Administration, Oral; Adult; Anti-Infective Agents; Cohort Studies; Cross-Sectional | 2006 |
Serial transverse enteroplasty for management of refractory D-lactic acidosis in short-bowel syndrome.
Topics: Acidosis, Lactic; Adolescent; Anti-Bacterial Agents; Bacteria; Digestive System Surgical Procedures; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Recurrence of symptomatic bacterial vaginosis 12 months after oral metronidazole therapy in HIV-positive and -negative women.
Topics: Administration, Oral; Adult; Aged; Anti-Infective Agents; Female; Follow-Up Studies; HIV Infections; | 2006 |
Bacterial vaginosis: resistance, recurrence, and/or reinfection?
Topics: Anti-Bacterial Agents; Azithromycin; Bacteria; Drug Resistance, Bacterial; Female; Humans; Metronida | 2007 |
A case of successful management of recurrent bacterial vaginosis of neovagina after male to female gender reassignment surgery.
Topics: Adult; Anti-Infective Agents; Female; Humans; Male; Metronidazole; Recurrence; Therapeutic Irrigatio | 2007 |
Metronidazole-induced aseptic meningitis during Helicobacter pylori eradication therapy.
Topics: Adult; Anti-Infective Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Meningitis | 2007 |
[Clostridium difficile associated diarrhea in the elderly patient].
Topics: Age Factors; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clostridioides difficile; Cross Inf | 2007 |
Early symptomatic recurrence after intestinal resection in Crohn's disease is unpredictable.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Comorbidity; Crohn Disease; Femal | 2007 |
A case of recurrent Clostridium difficile diarrhea.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Clostridioides difficile; Cross Infection; Diarrhea; Enter | 2007 |
Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis.
Topics: Acute Disease; Adult; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Male; Metronidazole; Pan | 2007 |
Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.
Topics: Aged; Anti-Bacterial Agents; Chi-Square Distribution; Clostridioides difficile; Enterocolitis, Pseud | 2007 |
The changing face of Clostridium difficile: what treatment options remain?
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Huma | 2007 |
[Mycobacterium ulcerans infection treated by Rifater, pyrazynamide, Myambutol, and surgery: a case report with a 6-year follow-up].
Topics: Anti-Bacterial Agents; Buruli Ulcer; Child; Chloramines; Combined Modality Therapy; Drug Combination | 2008 |
Electronic clinical challenges and images in GI. Ileal diverticulitis.
Topics: Aged, 80 and over; Anti-Infective Agents; Ciprofloxacin; Digestive System Surgical Procedures; Diver | 2008 |
Medical therapy of inflammatory bowel disease.
Topics: Acute Disease; Adjuvants, Immunologic; Anus Diseases; Azathioprine; Colitis, Ulcerative; Crohn Disea | 1980 |
[Crohn disease and ulcerative colitis - current status: internal medicine aspects].
Topics: Adrenal Cortex Hormones; Azathioprine; Colitis, Ulcerative; Crohn Disease; Diagnosis, Differential; | 1981 |
The relapse rate for rosacea after treatment with either oral tetracycline or metronidazole cream.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Male; Metronidazole; Middle Aged; Recurrence; Rosace | 1983 |
[Treatment of rosacea with metronidazole internally and externally].
Topics: Administration, Oral; Administration, Topical; Adult; Drug Administration Schedule; Female; Humans; | 1984 |
Intermittent therapy with metronidazole for relapse of pseudomembranous colitis.
Topics: Enterocolitis, Pseudomembranous; Humans; Male; Metronidazole; Recurrence | 1984 |
Metronidazole therapy for Crohn's disease and associated fistulae.
Topics: Adult; Crohn Disease; Female; Follow-Up Studies; Humans; Intestinal Fistula; Male; Metronidazole; Mi | 1984 |
[Clinical experience using solco trichovac in the treatment of trichomonad infections in women].
Topics: Adult; Bacterial Vaccines; Female; Humans; Lactobacillus acidophilus; Methods; Metronidazole; Middle | 1982 |
Metronidazole in the treatment of surgical infections.
Topics: Clindamycin; Drug Resistance, Microbial; Gentamicins; Humans; Metronidazole; Peritonitis; Premedicat | 1983 |
[Problems of amebic liver abscesses].
Topics: Humans; Immunologic Techniques; Liver Abscess, Amebic; Metronidazole; Pleural Effusion; Recurrence; | 1981 |
Use of oral metronidazole HCl (Flagyl) for posturethritis syndrome.
Topics: Adult; Drug Administration Schedule; Humans; Male; Metronidazole; Middle Aged; Recurrence; Urethriti | 1982 |
Metronidazole therapy for perineal Crohn's disease: a follow-up study.
Topics: Adult; Aged; Chromosome Aberrations; Crohn Disease; Drug Evaluation; Female; Follow-Up Studies; Huma | 1982 |
[Ulcerative colitis and Crohn disease. Conservative therapy].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Humans; Metro | 1982 |
[Repeated recurrences of hepatic amoebiasis with failure of metronidazole treatment].
Topics: Adult; Drug Resistance, Microbial; Humans; Liver Abscess, Amebic; Male; Metronidazole; Recurrence | 1982 |
Recurrent Candida vulvovaginitis.
Topics: Candidiasis, Vulvovaginal; Female; Humans; Metronidazole; Recurrence | 1982 |
Recurrence of antibiotic-associated pseudomembranous colitis after parenteral metronidazole therapy and cure by oral vancomycin: case report.
Topics: Administration, Oral; Aged; Enterocolitis, Pseudomembranous; Humans; Injections, Intravenous; Male; | 1981 |
Failure of conventional treatment to prevent relapse of hepatic amoebiasis.
Topics: Adolescent; Amebicides; Female; Humans; Liver Abscess, Amebic; Male; Metronidazole; Middle Aged; Rec | 1981 |
The management of vaginal discharges.
Topics: Bacterial Infections; Candidiasis, Vulvovaginal; Female; Humans; Metronidazole; Miconazole; Nystatin | 1980 |
Pseudomembranous colitis: multiple relapses after treatment with metronidazole.
Topics: Aged; Cholestyramine Resin; Diarrhea; Enterocolitis, Pseudomembranous; Feces; Female; Humans; Metron | 1981 |
Possible role of the anaerobe in tonsillitis.
Topics: Acute Disease; Adolescent; Anaerobiosis; Bacteria; Bacterial Infections; Child; Child, Preschool; Hu | 1981 |
[Delayed relapses of hepatic amoebiasis initially cured by metronidazole: 2 cases (author's transl)].
Topics: Adult; Digestive System; Humans; Liver Abscess, Amebic; Male; Metronidazole; Recurrence | 1980 |
Eczema responsive to treatment for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Eczema; Gastroenteritis; Helicobacter Inf | 1995 |
Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Antibodies, Bacterial; Bismuth; Child; Child, Preschool; Du | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Breath Tests; Drug Administration Schedule; Drug Resistance, Microbial; Drug Ther | 1995 |
"Cure" of Helicobacter pylori and "cure" of peptic ulcer: do they mean the same thing?
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helico | 1995 |
[Non-puerperal mastitis. Clinical study of 30 patients].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Diagnosis, Differential; Erythromycin; Female; Humans | 1995 |
Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting.
Topics: Adult; Anti-Ulcer Agents; Base Sequence; DNA Fingerprinting; DNA, Bacterial; Drug Therapy, Combinati | 1995 |
Helicobacter pylori infection in children with recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Anti-Ulcer Agents; Biopsy; Child; Child, Preschool; Endoscopy, Gastroint | 1994 |
[The effect of "triple therapy" on the eradicating of H. pylori and the healing of a duodenal ulcer. The initial study and 6 months later].
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Female; | 1995 |
[Surgical revision of the pilonidal sinus with single shot antibiosis].
Topics: Abscess; Adult; Bacterial Infections; Drug Therapy, Combination; Humans; Infusions, Intravenous; Mal | 1995 |
[Long-term damage to duodenal mucosa in malabsorption syndrome as a sequela of Giardia lamblia infection].
Topics: Adult; Animals; Antiprotozoal Agents; Atrophy; Dose-Response Relationship, Drug; Drug Administration | 1995 |
Kinetics of spiramycin/metronidazole (Rodogyl) in human gingival crevicular fluid, saliva and blood.
Topics: Adult; Alveolar Bone Loss; Anti-Bacterial Agents; Bacteria; Drug Combinations; Female; Gingival Crev | 1994 |
A combination of sulphadiazine, trimethoprim and metronidazole or tinidazole in kala-azar.
Topics: Adult; Animals; Drug Therapy, Combination; Female; Humans; Leishmania donovani; Leishmaniasis, Visce | 1994 |
Nd-YAG laser therapy for palliation of obstructed colorectal carcinomas.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Fema | 1994 |
[Pneumatosis intestinalis: a rare and difficult problem].
Topics: Aged; Combined Modality Therapy; Fatal Outcome; Female; Humans; Metronidazole; Oxygen Inhalation The | 1994 |
Metronidazole therapy for visceral leishmaniasis.
Topics: Adult; Animals; Antibodies, Protozoan; Bone Marrow; Hodgkin Disease; Humans; Leishmania donovani; Le | 1994 |
Management and control of a large outbreak of diarrhoea due to Clostridium difficile.
Topics: Aged; Bacterial Proteins; Bacterial Toxins; Clostridioides difficile; Clostridium Infections; Cross | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer.
Topics: Anti-Ulcer Agents; Antibodies, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Enzyme-Linked I | 1994 |
[Eradication of Helicobacter pylori. Effectiveness of a combination of ranitidine and metronidazole/roxithromycin].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal | 1994 |
Nasal dermoid sinus cysts: an unusual presentation, computed tomographic scan findings, and surgical results.
Topics: Bone Transplantation; Cellulitis; Child, Preschool; Cloxacillin; Combined Modality Therapy; Coronary | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
Metronidazole hypersensitivity.
Topics: Adult; Biological Availability; Candidiasis, Vulvovaginal; Drug Hypersensitivity; Drug Therapy, Comb | 1994 |
Empirical use of metronidazole for treatment of diarrhea in laboratory rhesus macaques: an evaluation.
Topics: Animals; Diarrhea; Drug Evaluation; Macaca mulatta; Metronidazole; Monkey Diseases; Recurrence | 1993 |
Antibiotic therapy alone eradicates Helicobacter pylori and prevents duodenal ulcer recurrence.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter pylori; | 1993 |
Eradication of Helicobacter pylori in recurrent duodenal ulcer.
Topics: Amoxicillin; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Re | 1993 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobac | 1993 |
Long-term Helicobacter pylori recurrence after successful eradication with triple therapy.
Topics: Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; H | 1993 |
Metronidazole resistant Trichomonas vaginalis in Brisbane.
Topics: Animals; Drug Resistance; Female; Humans; Metronidazole; Middle Aged; Recurrence; Tinidazole; Tricho | 1993 |
Treatment of peptic ulcers caused by Helicobacter pylori.
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metron | 1993 |
Collagenous colitis: are bacterial cytotoxins responsible?
Topics: Aged; Bacterial Toxins; Cholestyramine Resin; Colitis; Colon; Feces; Female; Humans; Intestinal Muco | 1993 |
Perianal group A streptococcal infection.
Topics: Anus Diseases; Child; Child, Preschool; Erythromycin Ethylsuccinate; Family Health; Humans; Male; Me | 1993 |
Cheilitis granulomatosa treated with metronidazole.
Topics: Adult; Anti-Inflammatory Agents; Connective Tissue; Female; Granuloma; Humans; Lip; Melkersson-Rosen | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; C | 1995 |
Metronidazole treatment in a patient with AIDS and visceral leishmaniasis.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Humans; Leishmania | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
The clinical spectrum of Clostridium difficile colitis in immunocompromised patients.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Humans; I | 1996 |
[Hepatic echinococcosis].
Topics: Administration, Oral; Anti-Infective Agents; Echinococcosis, Hepatic; Humans; Metronidazole; Recurre | 1995 |
Helicobacter pylori reinfection after apparent eradication--the Ipswich experience.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Case-Control Studies; Drug T | 1996 |
[The validation and effect of the prophylactic (antirelapse) treatment of peptic ulcer patients with chlorozil and metronidazole].
Topics: Adult; Anti-Ulcer Agents; Choline; Drug Evaluation; Duodenal Ulcer; Female; Follow-Up Studies; Human | 1996 |
Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; | 1997 |
Ranitidine in a twice daily triple therapy regimen for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Antitrichomonal Agents; Drug Administration Schedule; Drug Therapy, Combination; Duoden | 1997 |
Chronic amebiasis--treat couples.
Topics: Amebiasis; Amebicides; Chronic Disease; Family Health; Humans; Metronidazole; Recurrence; Spouses | 1995 |
Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets.
Topics: Amoxicillin; Animals; Antacids; Bacterial Proteins; Biopsy; Bismuth; DNA, Bacterial; Drug Therapy, C | 1996 |
[Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-U | 1998 |
Clostridium difficile colitis: factors influencing treatment failure and relapse--a prospective evaluation.
Topics: Aged; Anti-Bacterial Agents; Case-Control Studies; Enterocolitis, Pseudomembranous; Female; Follow-U | 1998 |
[Triple treatment for the eradication of Helicobacter pylori infection].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1998 |
Recalcitrant vaginal trichomoniasis.
Topics: Anti-Infective Agents; Drug Resistance; Female; Humans; Metronidazole; Recurrence; Trichomonas Vagin | 1999 |
[Conservative therapy of fistulas of the anorectal area in Crohn disease].
Topics: Crohn Disease; Humans; Immunosuppressive Agents; Metronidazole; Postoperative Complications; Prognos | 1999 |
Clostridium difficile-associated diarrhea in the elderly.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anti-Bacterial Agents; Child; Clostridioides diff | 1999 |
Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1999 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
[Joint manifestations related to Clostridium difficile].
Topics: Adult; Aged; Amikacin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-In | 2000 |
Actinobacillus actinomycetemcomitans in destructive periodontal disease. Three-year follow-up results.
Topics: Actinobacillus Infections; Adult; Aggregatibacter actinomycetemcomitans; Amoxicillin; Anti-Bacterial | 2000 |
[Recurrent Clostridium difficile enterocolitis].
Topics: Aged; Aged, 80 and over; Clostridioides difficile; Drug Therapy, Combination; Enterocolitis, Pseudom | 2000 |
[Delorme procedure for rectal prolapse].
Topics: Age Factors; Aged; Anti-Infective Agents; Frail Elderly; Humans; Metronidazole; Postoperative Care; | 2000 |
The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2000 |
Liver abscess caused by Clostridium difficile.
Topics: Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Drainage; Female; Hum | 2001 |
Efficacy and safety of 'hot' tonsillectomy.
Topics: Acute Disease; Adolescent; Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Biopsy, Needl | 2001 |
Beneficial effect of Helicobacter pylori eradication in dermatologic diseases.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Blotting, Western; Clarithromycin; D | 2001 |
The effect of systemic antibiotics in the treatment of patients with recurrent periodontitis.
Topics: Adult; Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Amoxicillin; Anti-Bacterial Agents | 2001 |
Vaginal candidiasis and other types of vaginitis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; CD4 Lymphocyte Count; Clinical Trials as Topic; Female | 1995 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease.
Topics: Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Follow- | 2001 |
[A comparative study of various evaluation methods of the antibiotic sensitivity of strict anaerobic bacteria of the subgingival flora].
Topics: Adult; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Bacteria, Anaerobic; Campylobacter; Chronic D | 2001 |
Severe antibiotic-associated colitis in a patient with cystic fibrosis and colonic wall thickening.
Topics: Adult; Anti-Bacterial Agents; Clostridioides difficile; Colon; Cystic Fibrosis; Diagnosis, Different | 2002 |
[What measures are necessary in the demonstration of Clostridium difficile toxin?].
Topics: Adolescent; Aged; Anti-Bacterial Agents; Bacterial Toxins; Child; Clostridioides difficile; Enteroco | 2002 |
Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Child; Child, Preschool; Clarithromycin; D | 2002 |
Inflammatory bowel diseases 1977.
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Cromolyn Sodium; Diet; Eye Diseases; Humans; Joint | 1977 |
Anaerobic subareolar breast abscess.
Topics: Abscess; Adult; Ampicillin; Bacteroides; Bacteroides Infections; Drainage; Female; Humans; Mastitis; | 1979 |
Metronidazole and tinidazole in a single large dose for treating urogenital infections with Trichomonas vaginalis in men.
Topics: Drug Combinations; Female; Humans; Male; Metronidazole; Nitroimidazoles; Recurrence; Tinidazole; Tri | 1978 |
Failure of chloroquine in human babesiosis (Babesia microti): case report and chemotherapeutic trials in hamsters.
Topics: Animals; Babesiosis; Benzamidines; Chloroquine; Cricetinae; Drug Resistance; Humans; Male; Metronida | 1978 |
[Recurrent Quincke's edema caused by trichopal].
Topics: Adult; Angioedema; Humans; Male; Metronidazole; Recurrence | 1978 |
The treatment of amebiasis. A recurrent agony.
Topics: Amebiasis; Amebicides; Chloroquine; Drug Therapy, Combination; Dysentery, Amebic; Emetine; Humans; I | 1976 |
Single-dose metronidazole for trichomonal vaginitis. Patient and consort.
Topics: Coitus; Female; Follow-Up Studies; Humans; Male; Methods; Metronidazole; Patient Compliance; Recurre | 1975 |
Microbiological and clinical results of metronidazole plus amoxicillin therapy in Actinobacillus actinomycetemcomitans-associated periodontitis.
Topics: Adult; Age Factors; Aggregatibacter actinomycetemcomitans; Alveolar Bone Loss; Amoxicillin; Bacteroi | 1992 |
Use of Klion suspension in paediatry and gynaecology.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Child; Drug Evaluation; Female; Human | 1992 |
Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter | 1992 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compoun | 1992 |
[Treatment of stomach ulcer with bismuth subnitrate, oxytetracycline and metronidazole].
Topics: Adult; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter pylori; Humans; Male | 1992 |
Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study.
Topics: Amoxicillin; Brazil; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; | 1992 |
Clinical, microbiological, and biochemical factors in recurrent bacterial vaginosis.
Topics: Adult; Bacteria; Fatty Acids; Female; Humans; Metronidazole; Middle Aged; Polyamines; Recurrence; Va | 1992 |
[Helicobacter pylori: from harmless commensal to clinically significant disease factor].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter | 1992 |
Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse.
Topics: Adult; Amoxicillin; Breath Tests; Carbon Radioisotopes; Drug Administration Schedule; Drug Therapy, | 1991 |
Blastocystis hominis may be a potential cause of intestinal disease.
Topics: Abdominal Pain; Adult; Animals; Diarrhea; Eukaryota; Feces; Female; Humans; Male; Metronidazole; Mid | 1991 |
Fibrin adhesive in the treatment of perineal fistulas.
Topics: Administration, Topical; Adult; Aged; Cefotaxime; Drug Therapy, Combination; Female; Fibrin Tissue A | 1991 |
Cure of duodenal ulcer after eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Ulcer Agents; Campylobacter Infections; Duodenal Ulcer; Duodenitis; Duodenum; Fema | 1990 |
Microbiological monitoring and results of treatment of extraradicular endodontic infection.
Topics: Apicoectomy; Calcium Hydroxide; Dental Fistula; Dental Pulp Cavity; Female; Humans; Incisor; Metroni | 1990 |
[The metronidazole treatment of vaginitis patients].
Topics: Adolescent; Adult; Aminocaproates; Anti-Bacterial Agents; Anti-Infective Agents, Local; Bacterial In | 1990 |
Perirectal abscess in Crohn's disease. Drainage and outcome.
Topics: Abscess; Adolescent; Adult; Catheters, Indwelling; Crohn Disease; Drainage; Female; Humans; Male; Me | 1990 |
Common variable hypogammaglobulinemia. A case report.
Topics: Agammaglobulinemia; Anemia, Pernicious; Female; Giardiasis; Humans; Immunization, Passive; Metronida | 1990 |
Metronidazole-induced pancreatitis.
Topics: Acute Disease; Adult; Amylases; Female; Humans; Lipase; Metronidazole; Pancreatitis; Recurrence | 1985 |
A mandibular fracture triggering trigeminal neuralgia.
Topics: Aged; Carbamazepine; Denture, Complete, Lower; Female; Fracture Fixation; Humans; Mandibular Fractur | 1989 |
Post-traumatic brain abscess with Clostridium perfringens.
Topics: Adolescent; Brain Abscess; Combined Modality Therapy; Frontal Bone; Gas Gangrene; Humans; Male; Metr | 1989 |
Healing of severe perineal and cutaneous Crohn's disease with hyperbaric oxygen.
Topics: Combined Modality Therapy; Crohn Disease; Female; Humans; Hyperbaric Oxygenation; Metronidazole; Mid | 1989 |
Cyclosporin A treatment in inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adult; Colitis, Ulcerative; Crohn Disease; Cyclosporins; Drug Therapy, Comb | 1989 |
Treatment of Clostridium difficile diarrhea.
Topics: Diarrhea; Enterocolitis, Pseudomembranous; Humans; Metronidazole; Recurrence; Vancomycin | 1989 |
Recurrence of hepatic amebiasis after successful treatment with metronidazole.
Topics: Adult; Drug Resistance; Humans; Intestinal Diseases, Parasitic; Liver Abscess, Amebic; Male; Metroni | 1988 |
Combined antibiotic (metronidazole) and mechanical treatment effects on the subgingival bacterial flora of sites with recurrent periodontal disease.
Topics: Adult; Bacteria; Dental Prophylaxis; Dental Scaling; Humans; Metronidazole; Middle Aged; Periodontal | 1988 |
Metronidazole-associated pancreatitis.
Topics: Adult; Contraceptives, Oral, Combined; Female; Gardnerella vaginalis; Haemophilus Infections; Humans | 1988 |
Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain.
Topics: Adult; Canada; Drug Resistance, Microbial; Female; Humans; Metronidazole; Recurrence; Trichomonas va | 1986 |
Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.
Topics: Aged; Aged, 80 and over; Clostridium; Diarrhea; Enterocolitis, Pseudomembranous; Female; Humans; Met | 1987 |
Changing epidemiology, diagnosis, and treatment of Clostridium difficile toxin-associated colitis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bacitracin; Bacterial Toxins; Child; Child, Preschoo | 1986 |
Use of an intravenous steroid regimen in the treatment of acute Crohn's disease.
Topics: Adolescent; Adult; Aged; Crohn Disease; Drug Therapy, Combination; Female; Humans; Hydrocortisone; I | 1986 |
Prophylactic use of antibiotics in combined abdominovaginal Marlex sling procedures for correction of recurrent urinary stress incontinence.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefazolin; Cefoxitin; Female; Humans; Metronidazole; Middle Aged | 1986 |
Vaginitis.
Topics: Anti-Bacterial Agents; Candidiasis, Vulvovaginal; Female; Gardnerella vaginalis; Haemophilus Infecti | 1985 |
Antibiotic-associated colitis: why do patients relapse?
Topics: Bacitracin; Colitis; Humans; Metronidazole; Recurrence; Vancomycin | 1986 |
Blastocystis hominis infection presenting as recurrent diarrhea.
Topics: Adult; Diarrhea; Eukaryota; Feces; Fungi; Humans; Male; Metronidazole; Protozoan Infections; Recurre | 1985 |
Antibiotic-associated colitis.
Topics: Adult; Anti-Bacterial Agents; Bacitracin; Clostridium; Clostridium Infections; Colitis; Feces; Human | 1985 |
The investigation and natural history of acute viral hepatitis.
Topics: Alanine Transaminase; Amebiasis; Antigens, Viral; Antistreptolysin; Aspartate Aminotransferases; Aut | 1973 |
Metronidazole and amebiasis.
Topics: Administration, Oral; Adolescent; Adult; Carrier State; Dysentery, Amebic; Entamoeba histolytica; Fe | 1974 |
Giardiasis and the adult traveler.
Topics: Adult; Diarrhea; Feces; Female; Giardia; Giardiasis; Humans; Metronidazole; Middle Aged; Quinacrine; | 1974 |
Metronidazole in the single-dose treatment of trichomoniasis in men and women.
Topics: Adolescent; Adult; Female; Follow-Up Studies; Humans; Male; Metronidazole; Middle Aged; Recurrence; | 1972 |
Metronidazole (Flagyl) for amebiasis.
Topics: Amebiasis; Dysentery, Amebic; Humans; Liver Abscess, Amebic; Meningoencephalitis; Metronidazole; Rec | 1972 |
Standard and single dosage regimens of "Flagyl" (metronidazole) in giardiasis in children.
Topics: Child; Child, Preschool; Female; Follow-Up Studies; Giardiasis; Humans; Infant; Male; Metronidazole; | 1972 |